# Patent

## Title
Benzazepine compound

## Abstract

Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. application Ser. No. 13/044,080 filed on Mar. 9, 2011, which claims the benefit of U.S. Provisional Application. No. 61/313,133 filed on Mar. 12, 2010. This application also is a continuation-in-part of U.S. application Ser. No. 13/583,410 filed on Sep. 7, 2012, which is a U.S. national-stage of International Application No. PCT/JP2011/055759 filed on Mar. 11, 2011, which claims the benefit of U.S. Provisional Application. No. 61/313,133 filed on Mar. 12, 2010. The entire disclosures of U.S. application Ser. No. 13/044,080 and U.S. application Ser. No. 13/583,410 are incorporated by reference herein.


TECHNICAL FIELD
The present invention relates to a benzazepine compound which is useful as an active ingredient of a pharmaceutical composition, particularly a pharmaceutical composition for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
BACKGROUND ART
A serotonin 2C (5-HT2C) receptor is one of the receptors for serotonin, a transmitter related to various physiological functions in the biological body. Its expression has been recognized mainly in the central nervous system (brain/spinal cord).
An anorectic action is known as a physiological function of the central 5-HT2C receptor, and the lowering action of various 5-HT2C receptor agonists on food intake has been reported in rats (Non-Patent Documents 1 and 2). Further, it has been confirmed that an anti-obesity action in humans is exhibited due to the anorectic action of the 5-HT2C receptor agonist (Non-Patent Document 3).
The central 5-HT2C receptor is involved in the control of peripheral nerve functions and it has been reported that the rat penile erection is induced by a 5-HT2C receptor agonist (Non-Patent Document 4) and that the time taken from insertion to ejaculation in the experiment for mating behavior of monkeys is prolonged (Non-Patent Document 5). Moreover, it has been reported that a 5-HT2C receptor agonist increases the urethral resistance when the abdominal pressure is increased in rats (Non-Patent Document 6). In addition, it has been reported that in disease models with neuropathic/inflammatory pain in rats, efficacy is exhibited by intraspinal administration of a 5-HT2C receptor agonist (Non-Patent Documents 7 and 8). Various clinical applications are considered for 5-HT2C receptor agonists, particularly as anti-obesity drugs, drugs for treating male erectile dysfunction, drugs for treating premature ejaculation, drugs for treating stress urinary incontinence, drugs for treating neuropathic/inflammatory pain, or the like.
As the 5-HT2C receptor agonist, a benzazepine derivative has been reported, and as a tricyclic benzazepine derivative, for example, Compound A (Patent Document 1) and Compound B (Patent Document 2) are known.




As other 5-HT2C receptor agonists, bicyclic benzazepine derivatives have been reported (Patent Document 3, Patent Document 4, and Patent Document 5).
As a 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline derivative or a 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine derivative, which is a tricyclic benzazepine derivative, a compound of the formula (AA) is known to be a Dopamine D3 modulator and be useful for central drug abuse and drug dependence (Patent Document 6).




In addition, in this document, the following compounds are disclosed as a synthetic intermediate for the formula (AA).




Furthermore, there is a report on the structure-activity relationship of a specific compound of the formula (AA) (Non-Patent Document 9), and in this report, it is described that the following compound was used in the preparation of the compound of the formula (AA).




Moreover, there is a report on a 5-HT6 receptor antagonist (Non-Patent Document 10), and it is disclosed that for the compound below, potency on the 5-HT6 receptor is lost by changing a ring condensed with benzazepine from a 5-membered ring to a 6-membered ring.




However, in the documents which disclose such tricyclic benzazepine derivatives, there is no disclosure on the 5-HT2C receptor agonist activity of the 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline derivative or the 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine derivative.
PRIOR ART DOCUMENT
Patent Document


    [Patent Document 1] WO 2002/074746
    [Patent Document 2] WO 2003/086306
    [Patent Document 3] WO 2005/042490
    [Patent Document 4] WO 2005/042491
    [Patent Document 5] WO 2005/003096
    [Patent Document 6] WO 2005/118549


Non-Patent Document


    [Non-Patent Document 1] Obesity, 2008, vol. 17, pp. 494-503
    [Non-Patent Document 2] Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, vol. 26, pp. 441-449
    [Non-Patent Document 3] Journal of Pharmacology and Experimental Therapeutics, 2008, vol. 325, pp. 577-587
    [Non-Patent Document 4] European Journal of Pharmacology, 2004, vol. 483, pp. 37-43
    [Non-Patent Document 5] Psychopharmacology, 1993, vol. 111, pp. 47-54
    [Non-Patent Document 6] American Journal of Physiology: Renal Physiology, 2009, vol. 297, pp. 1024-1031
    [Non-Patent Document 7] Pain, 2004, vol. 108, pp. 163-169
    [Non-Patent Document 8] Anesthesia and Analgesia, 2003, vol. 96, pp. 1072-1078
    [Non-Patent Document 9] Bioorganic & Medicinal Chemistry Letters, 2008, vol. 18, pp. 901-907
    [Non-Patent Document 10] Bioorganic & Medicinal Chemistry Letters, 2008, vol. 18, pp. 5698-5700


SUMMARY OF THE INVENTION
Problems to be Solved by the Invention
A benzazepine compound which is useful as an active ingredient for a pharmaceutical composition, particularly a pharmaceutical composition for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like is provided.
Means for Solving the Problem
The present inventors have extensively studied compounds having a 5-HT2C receptor agonist activity, and as a result, they have found that the benzazepine compound of the present invention has a 5-HT2C receptor agonist activity, thereby completing the present invention.
That is, the present invention relates to a pharmaceutical composition including the compound of the formula (I) or a salt thereof and a pharmaceutically acceptable excipient.




(wherein
R1a and R1b are the same or different and each represents or C1-6 alkyl, or are combined to form oxo,
R2a and R2b are the same or different and each represents —H or C1-6 alkyl which may be substituted with —O—C1-6 alkyl,
R3 represents —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or a hetero ring which may be substituted,
R4 represents —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,
R5 represents —H, halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, or an aromatic hetero ring,
R6 and R7 are the same or different and each represents —H or C1-6 alkyl,
X represents —C(RA)(RB)— or —O—, and
RA and RB are the same or different and each represents —H or C1-6 alkyl.)
Furthermore, the present invention relates to a compound of the formula (II) or a salt thereof.




(wherein
R11a and R11b are the same or different and each represents —H or C1-6 alkyl, or are combined to form oxo,
R21a and R21b are the same or different and each represents —H or C1-6 alkyl which may be substituted with —O—C1-6 alkyl,
R31 represents —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or a hetero ring which may be substituted,
R41 represents —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,
R51 represents —H, halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, or an aromatic hetero ring,
R61 and R71 are the same or different and each represents —H or C1-6 alkyl,
X1 represents —C(RA1)(RB1)— or —O—, and
RA1 and RB1 are the same or different and each represents —H or C1-6 alkyl, provided that
(i) in the case where R11a, R11b, R21a, R21b, R41, R51, R61, and R71 are respectively —H and X1 is —O—, R31 is a group other than —H, —CO-methyl, or —SO2-methyl, and
(ii) in the case where R11a and R11b are combined to form oxo, R21a, R21b, R41, R51, R61, and R71 are respectively —H, and X1 is —O—, R31 is a group other than —H or methyl.)
Furthermore, in the case where the symbols in any of the formulas in the present specification are also used in other formulas, the same symbols denote the same meanings, unless specifically described otherwise.
Furthermore, the present invention relates to a pharmaceutical composition for preventing or treating 5-HT2C receptor-related diseases, including the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof. In this connection, the pharmaceutical composition includes an agent for preventing or treating 5-HT2C receptor-related diseases, including the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof.
Moreover, the present invention relates to use of the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof for preparation of a pharmaceutical composition for preventing or treating 5-HT2C receptor-related diseases; the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof for prevention or treatment of 5-HT2C receptor-related diseases; and a method for preventing or treating 5-HT2C receptor-related diseases, including administering to a subject an effective amount of the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof. In addition, the “subject” is human or other animals in need of the prevention or treatment, and in a certain embodiment, human in need of the prevention or treatment.
In addition, the compound of the formula (II) or a salt thereof is included in the compound of the formula (I) or a salt thereof. Accordingly, in the present specification, the explanation of the compound of the formula (I) includes that of the compound of the formula (II).
Effects of the Invention
The compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof has a 5-HT2C receptor agonist activity and can be used as an agent for preventing or treating 5-HT2C receptor-related diseases.
Here, examples of the 5-HT2C receptor-related diseases include incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
EMBODIMENTS FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described in detail.
In the present specification, the “alkyl” includes straight alkyl and branched alkyl. Accordingly, the “C1-6 alkyl” is a straight or branched alkyl having 1 to 6 carbon atoms, and specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, and the like, in another embodiment, methyl, ethyl, propyl, isopropyl, in a further embodiment, methyl, ethyl, in a still further embodiment, methyl, and in a still further embodiment, ethyl.
The “alkylene” is a divalent group formed by the removal of any one hydrogen atom of the “alkyl” above. Accordingly, the “C1-6 alkylene” is straight or branched alkylene having 1 to 6 carbon atoms, and specific examples thereof include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, dimethylmethylene, ethylmethylene, methylethylene, dimethylethylene, ethylethylene, and the like, in another embodiment, methylene, ethylene, and in a further embodiment methylene.
The “aryl” is a monocyclic to tricyclic aromatic hydrocarbon ring group having 6 to 14 carbon atoms. Specific examples thereof include phenyl and naphthyl, in another embodiment, phenyl, and in a further embodiment, naphthyl.
The “cycloalkyl” is a saturated hydrocarbon ring group, the cycloalkyl may have a bridge and may be condensed with a benzene ring, and a part of the bonds may be unsaturated. Accordingly, specific examples of the “C3-8 cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclooctadienyl, norbornyl, bicyclo[2.2.2]octyl, indanyl, indenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and the like.
The “hetero ring” is a monovalent group of a 3- to 15-membered, in another embodiment, a 5- to 10-membered, monocyclic to tricyclic heterocyclic group containing 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen, and includes a saturated ring, an aromatic ring, and a partially hydrogenated ring group thereof. The ring atom, sulfur or nitrogen, may be oxidized to form an oxide or a dioxide. Specific examples thereof include monocyclic aromatic hetero rings such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like, bicyclic aromatic hetero rings such as indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl, benzothiadiazolyl, and the like, tricyclic aromatic hetero rings such as carbazolyl, dibenzo[b,d]furanyl, dibenzo[b,d]thienyl, and the like, monocyclic non-aromatic hetero rings such as azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, tetrahydropyridinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, tetrahydrothiopyranyl, and the like, bicyclic non-aromatic hetero rings such as indolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzimidazolyl, tetrahydrobenzimidazolyl, tetrahydroquinoxalinyl, dihydroquinoxalinyl, dihydrobenzoxazolyl, dihydrobenzoxazinyl, dihydrobenzofuryl, chromanyl, chromenyl, methylenedioxyphenyl, ethylenedioxyphenyl, and the like, bridged hetero rings such as quinuclidinyl and the like, in another embodiment, a 5- to 10-membered monocyclic to bicyclic hetero ring, in a further embodiment, a 5- to 6-membered monocyclic hetero ring, and in a still further embodiment, a 5- to 6-membered mono cyclic aromatic hetero ring.
The “aromatic hetero ring” is a 5- to 10-membered monocyclic to bicyclic aromatic hetero ring among the “hetero rings” above, and specific examples thereof include pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl, and the like, and in another embodiment, furyl, thienyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, and pyrazyl.
The “cyclic amino” is a 5- to 7-membered non-aromatic hetero ring having a binding position at a nitrogen atom among the “hetero rings” above, and specific examples thereof include pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, morpholinyl, and thiomorpholinyl.
The “oxygen-containing hetero ring” is a monovalent group of a non-aromatic 5- to 6-membered ring which may be condensed with a benzene ring having one or two oxygen atoms as ring-constituting atoms. Specific examples thereof include tetrahydropyranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, dihydrobenzofuranyl, dihydrochromenyl, benzodioxolyl, benzodioxinyl, dihydrodioxinyl, dihydrobenzodioxinyl, dihydropyranyl, dioxinyl, chromenyl, and benzodioxinyl.
The “halogen” means —F, —Cl, —Br, or —I, and in another embodiment, —F, —Cl, or —Br.
The “halogeno-C1-6 alkyl” is C1-6 alkyl substituted with one or more halogen atoms, and specific examples thereof include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, fluoroethyl, chloroethyl, bromoethyl, fluoropropyl, dichloropropyl, fluorochloropropyl, and the like, and in another embodiment, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoro ethyl, and fluoropropyl.
In the present specification, the expression “which may be substituted” means unsubstituted or substituted with 1 to 5 substituents. Further, if it has a plurality of substituents, the substituents may be the same as or different from each other.
Specific examples of the substituent for the “C1-6 alkyl which may be substituted”, “C1-6 alkylene which may be substituted”, “(C3-8)cycloalkyl which may be substituted”, “aryl which may be substituted”, or “hetero ring which may be substituted” of R3 and R4 include amino, nitro, cyano, halogen, C1-6 alkyl, halogeno-C1-6 alkyl, —OH, —C1-6 alkylene-OH, —O—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —C1-6 alkylene-cycloalkyl, —C1-6 alkylene-aryl, —C1-6 alkylene-hetero ring, —CO—C1-6 alkyl, —CO—C1-6 alkylene-O—C1-6 alkyl, —CO-cycloalkyl, —CO-aryl, —CO—NR8R9, —CO—O—C1-6 alkyl, —CO—O—C1-6 alkylene-aryl, —SO2—C1-6 alkyl, aryl, a hetero ring, and the like.
Here, R8 and R9 are the same or different and each represents —H or C1-6 alkyl.
In another embodiment, examples of the substituent for “C1-6 alkyl which may be substituted” in R3 include:
(1) halogen,
(2) oxo, —OH, and —O—RZ,
(3) —O-(phenyl which may be substituted with one or more groups selected from the group consisting of RZ, —O—RZ, halogen, and cyano),
(4) —O-aromatic hetero ring,
(5) amino which may be substituted with one or two RZ,
(6) phenyl which may be substituted with one or more groups selected from the group consisting of RZ, —O—RZ, halogen, and cyano,
(7) C3-4 cycloalkyl which may be substituted with RZ,
(8) an oxygen-containing hetero ring which may be substituted with halogen,
(9) a cyclic amino which may be substituted with RZ, and
(10) an aromatic hetero ring,
in which the C1-6 alkyl may be substituted with one or more substituents.
Furthermore, RZ herein represents C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of halogen, —O—C1-6 alkyl, C3-4 cycloalkyl, and phenyl (in which the phenyl may be substituted with one or more groups selected from the group consisting of halogen and —O—C1-6 alkyl).
In another embodiment, examples of the substituent for the “aryl which may be substituted” in R3 include halogen, and the aryl may be substituted with one or more substituents.
In a further embodiment, examples of the substituent for the “C1-6 alkyl which may be substituted” in R4 include halogen and aryl, and the C1-6 alkyl may be substituted with one or more substituents.
In a still further embodiment, examples of the substituent of the “aryl which may be substituted” in R4 include halogen, C1-6 alkyl, and —O—C1-6 alkyl, and the aryl may be substituted with one or more substituents.
Some embodiments of the compound of the formula (I) or a salt thereof are presented below.
(1) The compound or a salt thereof, wherein R1a and R1b are the same or different and each represents —H or methyl. In another embodiment, the compound or a salt thereof, wherein R1a and R1b are respectively —H. In a further embodiment, the compound or a salt thereof, wherein R1a is —H and R1b is methyl. In a still further embodiment, the compound or a salt thereof, wherein R1a and R1b are combined to form oxo.
(2) The compound or a salt thereof, wherein R2a is —H and R2b is —H or C1-6 alkyl. In another embodiment, the compound or a salt thereof, wherein R2a is —H and R2b is —H or methyl. In a further embodiment, the compound or a salt thereof, wherein R2a and R2b are respectively —H.
(3) The compound or a salt thereof, wherein R3 is C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (a) to (e) below:
(a) halogen, (b) —O—C1-6 alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C1-6 alkyl which may be substituted with —O—C1-5 alkyl, halogen, and —O—C1-6 alkyl.
In another embodiment, the compound or a salt thereof, wherein R3 is C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (f) to (j) below:
(f) fluoro, (g) methoxy, ethoxy, (h) phenoxy which may be substituted with one or more groups selected from the group consisting of fluoro and cyano, (i) tetrahydrofuranyl, tetrahydropyranyl, or dihydrobenzodioxinyl, and (j) phenyl which may be substituted with one or more groups selected from the group consisting of fluoro, chloro, methyl, and methoxymethyl.
In another embodiment, the compound or a salt thereof, wherein R3 is isobutyl. In another embodiment, the compound or a salt thereof, wherein R3 is ethyl or propyl, which respectively is substituted with one or more groups selected from the group consisting of fluoro, methoxy, and ethoxy. In a further embodiment, the compound or a salt thereof, wherein R3 is ethyl substituted with phenoxy which may be substituted with one or more groups selected from the group consisting of fluoro and cyano. In a still further embodiment, the compound or a salt thereof, wherein R3 is methyl substituted with a group selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl and dihydrobenzodioxinyl. In a still further embodiment, the compound or a salt thereof, wherein R3 is methyl substituted with phenyl which may be substituted with one or more groups selected from the group consisting of fluoro, chloro, methyl, and methoxymethyl.
(4) The compound or a salt thereof, wherein R4 is —H, halogen, or C3-8 cycloalkyl. In another embodiment, the compound or a salt thereof, wherein R4 is —H, bromo, or cyclopropyl. In a further embodiment, the compound or a salt thereof, wherein R4 is —H. In a further embodiment, the compound or a salt thereof, wherein R4 is bromo. In a still further embodiment, the compound or a salt thereof, wherein R4 is cyclopropyl.
(5) The compound or a salt thereof, wherein R5 is —H or C1-6 alkyl. In another embodiment, the compound or a salt thereof, wherein R5 is —H or methyl. In a further embodiment, the compound or a salt thereof, wherein R5 is —H.
(6) The compound or a salt thereof, wherein R6 and R7 are the same or different and each represents —H or methyl. In another embodiment, the compound or a salt thereof, wherein R6 is methyl and R7 is —H. In a further embodiment, the compound or a salt thereof, wherein R6 is —H and R7 is methyl. In a still further embodiment, the compound or a salt thereof, wherein R6 and R7 are respectively —H.
(7) The compound or a salt thereof, wherein X is —C2— or —O—. In another embodiment, the compound or a salt thereof, wherein X is —CH2—. In a further embodiment, the compound or a salt thereof, wherein X is —O—.
(8) The compound or a salt thereof, which is a combination of two or more of (1) to (7) as described above.
The compound or a salt thereof as described above in (8), which is a combination of two or more of (1) to (7) as described above, is included in the present invention, and the following embodiments including the specific examples thereof can be exemplified as below.
(9) The compound or a salt thereof, wherein R3 is —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or an oxygen-containing hetero ring, and R4 is —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-4 cycloalkyl, an aromatic hetero ring, or an oxygen-containing hetero ring.
(10) The compound or a salt thereof as described in (9), wherein R3 is a group other than —H, methyl, —CO-methyl, or —SO2— methyl.
(11) The compound or a salt thereof as described in (10), wherein R1a is —H or methyl, and R1b, R2a, R2b, R5, R6, and R7 are respectively —H.
(12) The compound or a salt thereof as described in (11), wherein R4 is —H, halogen, or C3-4 cycloalkyl.
(13) The compound or a salt thereof as described in (12), wherein R4 is cyclopropyl.
(14) The compound or a salt thereof as described in (13), wherein R3 is C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (a) halogen, (b) —O—C1-6 alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C1-6 alkyl which may be substituted with —O—C1-6 alkyl, halogen, and —O—C1-6 alkyl.
(15) The compound or a salt thereof as described in any one of (1) to (14), wherein
X is —CH2— or —O—. In another embodiment, the compound or a salt thereof as described in any one of (1) to (14), wherein X is —O—. In a still further embodiment, the compound or a salt thereof as described in any one of (1) to (14), wherein X is —CH2—.
Examples of the specific compounds included in the compound of the formula (I) or a salt thereof include:

    11-cyclopropyl-1-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline,
    4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(2-ethoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(3-fluoropropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline,
    5-bromo-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-[(2S)-tetrahydrofuran-2-ylmethyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-[(2R)-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(2-fluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-[(2S)-3-fluoro-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    4-(3-chlorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(tetrahydro-2H-pyran-3-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(2-phenoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(2-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(3-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(2,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-[3-(methoxymethyl)benzyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    4-(5-chloro-2-fluorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    (3S)-5-cyclopropyl-4-(2-methoxyethyl)-3-methyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    4-[2-(5-cyclopropyl-2,3,7,8,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepin-4(6H)-yl)ethoxy]-3,5-difluorobenzonitrile,
    5-cyclopropyl-4-(3-methoxybenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    5-cyclopropyl-4-(3,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, and
    5-cyclopropyl-4-[(2R)-2-ethoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, and salts thereof.


The compound of the formula (I) may exist in the form of tautomers or geometrical isomers depending on the kind of substituents. In the present specification, the compound of the formula (I) shall be described in only one form of isomer, yet the present invention includes other isomer, such as an isolated forms of the isomers, or a mixture thereof.
In addition, the compound of the formula (I) may have asymmetric carbon atoms or axial asymmetry in some cases, and correspondingly, it may exist in the form of optical isomers. The present invention includes both an isolated form of the optical isomers of the compound of the formula (I) or a mixture thereof.
Moreover, the present invention also includes a pharmaceutically acceptable prodrug of the compound of the formula (I). The pharmaceutically acceptable prodrug is a compound having a group that can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like through solvolysis or under physiological conditions. Examples of the group forming the prodrug include the groups described in Prog. Med., 5, 2157-2161 (1985) and Pharmaceutical Research and Development, Drug Design, Hirokawa Publishing Company (1990), vol. 7, 163-198.
Moreover, the salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I) and may form an acid addition salt or a salt with a base depending on the kind of substituents. Specific examples thereof include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid, and the like, and salts with inorganic bases such as sodium, potassium, magnesium, calcium, aluminum, and the like or organic bases such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and the like, salts with various amino acids or amino acid derivatives such as acetylleucine and the like, ammonium salts, etc.
In addition, the present invention also includes various hydrates or solvates, and polymorphic crystal substances of the compound of the formula (I) and a salt thereof. In addition, the present invention also includes compounds labeled with various radioactive or non-radioactive isotopes.
(Preparation Methods)
The compound of the formula (I) and a salt thereof can be prepared using the characteristics based on the basic structure or the type of substituents thereof and by applying various known synthesis methods. During the preparation, replacing the relevant functional group with a suitable protective group (a group that can be easily converted into the functional group) at the stage from starting material to an intermediate may be effective depending on the type of the functional group in production technology in some cases. The protective group for such a functional group may include, for example, the protective groups described in “Greene's Protective Groups in Organic Synthesis (4th Ed., 2006)” written by P. G. M. Wuts and T. W. Greene, and one of these may be selected and used as necessary depending on the reaction conditions. In this kind of method, a desired compound can be obtained by introducing the protective group, by carrying out the reaction and by eliminating the protective group as necessary.
In addition, the prodrug of the compound of the formula (I) can be produced by introducing a specific group or by carrying out the reaction using the obtained compound of the formula (I) at the stage from a starting material to an intermediate, just as in the case of the above-mentioned protective group. The reaction can be carried out using methods known to those skilled in the art, such as ordinary esterification, amidation, dehydration, and the like.
Hereinbelow, the representative preparation methods for the compound of the formula (I) will be described. Each of the production processes may also be carried out with reference to the References appended in the present description. Further, the preparation methods of the present invention are not limited to the examples as shown below.




The compound of the formula (I) can be obtained by removing P which is a protective group for an amino group. The protective group for P may be any protective group for an amino group which is usually used by a person skilled in the art, and carbonyl such as trifluoroacetyl and the like; oxycarbonyl such as t-butoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, and the like; or sulfonyl such as methanesulfonyl, p-toluenesulfonyl, trifluoromethanesulfonyl, p-nitrophenylsulfonyl, 2,4-dinitrophenylsulfonyl, and the like is suitably used.
For the deprotection in the present step, the conditions for deprotection usually used by a person skilled in the art can be employed. For example, preparation can be performed by acid treatment, hydrolysis, hydrogenolysis, or the like. For acid treatment, for example, trifluoroacetic acid, hydrochloric acid, sulfuric acid, or the like can be used. In the case of alkali hydrolysis, inorganic bases (for example NaOH, KOH, NaHCO3, Cs2CO3, and the like) can be used. In the case of acid hydrolysis, hydrochloric acid and the like can be used. For any reaction temperature, the reaction can be performed under the condition from under ice-cooling to under refluxing and under the condition which does not allow the substrate to be decomposed. As the solvent, dioxane, tetrahydrofuran, dichloromethane, chloroform, ethyl acetate, alcohols (MeOH, EtOH, and the like), N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), water, or a mixed solvent thereof, and the like may be used, but are not limited thereto. In the case of hydrogenolysis, the reaction can usually be performed under a hydrogen atmosphere in the presence of a palladium catalyst. Usually, the reaction can be performed under the condition of from room temperature to under refluxing and under the condition which does not allow the substrate to be decomposed. As the solvent, DMF or alcohols (MeOH, EtOH, and the like) may be used, but are not limited thereto. Further, the conditions for the de-carboxamide reaction, the de-carbamate reaction, the de-sulfonamide reaction described in “Greene's Protective Groups in Organic Synthesis (4th Ed., 2006)” above can be employed.
Various substituents defined as the groups in the compound of the formula (I), R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 can be easily converted to other functional groups by using the compound of the formula (I) as a starting material or using the synthetic intermediate of the compound of the formula (I) as a starting material by means of the reaction described in Examples as described later, the reaction apparent to a person skilled in the art, or modified methods thereof. For example, the step that can be usually employed by a person skilled in the art, such as O-alkylation, N-alkylation, reduction, hydrolysis, amidation, and the like can be arbitrarily combined and performed.
(Preparation of Starting Compound)
The starting compound in the preparation method above can be prepared by, for example, the following method, the method described in Preparation Examples as described later, known methods, or modified methods thereof.
(Starting Material Synthesis 1)




A compound represented by the general formula (1) which is a starting material for synthesizing a compound of the general formula (2) is commercially available or prepared by a means known to a person skilled in the art. Then, the compound of the general formula (2) can be prepared by nitrating the compound of the general formula (1). For example, a number of known nitration reactions can be used, examples of which include a method using nitric acid, fumed nitric acid, potassium nitrate, or the like in an acid solvent, a method using nitronium tetrafluoroborate, and the like. Then, the compound of the general formula (3) can be prepared by reducing a nitro group of the compound of the general formula (2) to an amino group. For example, a number of known reduction methods can be used, examples of which include a method using metal hydrides such as lithium aluminum hydride and the like, a method using reduced iron or the like, and the like. Further, catalytic hydrogenation using noble metal catalysts such as Raney nickel, palladium, ruthenium, rhodium, platinum, and the like can also be used.
(Starting Material Synthesis 2)




(wherein RXa is C1-6 alkyl).
A compound of the general formula (4) can be prepared by halogenating the compound of the general formula (3). For example, a number of known halogenation reactions can be used, examples of which include a method using N-bromosuccinimide or N-chlorosuccinimide, and the like. Then, the compound of the general formula (5) can be prepared from the compound of the general formula (4) by a coupling reaction using a transition metal catalyst. Examples of the coupling reaction include a Heck reaction. The reaction conditions for the Heck reaction vary depending on the starting materials, solvents, and transition metal catalysts used, and techniques known to a person skilled in the art can be used. Examples of the preferred solvent include acetonitrile, tetrahydrofuran, 1,4-dioxane or DMF, and the like, but are not limited thereto. The transition metal catalyst is preferably a palladium complex, and more preferably known palladium complexes such as palladium(II) acetate, dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), and the like. Further, for the present reaction, a phosphorous ligand (preferably, triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine, 2-(di-tert-butylphosphino)biphenyl, or the like) may be added in order to obtain excellent results. Also, the present reaction can yield preferable results in the presence of a base, and the base used herein is not particularly limited as long as it is used for the coupling reaction of the present reaction, but it is preferably triethylamine, N,N-diisopropylethylamine, or the like.
(Starting Material Synthesis 3)




The compound of the general formula (IIIa) can be obtained by allowing an intramolecular amide condensation cyclization reaction to proceed by carrying out a hydrogenation reaction of the double bond of the α,β-unsaturated esters of the compound of the general formula (5). In this reaction, the compound of the general formula (5) is stirred in the presence of a metal catalyst, usually for 1 hour to 5 days, in a solvent inert to the reaction, under a hydrogen atmosphere. This reaction is usually carried out in the range from cooling to heating, preferably at room temperature. Examples of the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, 2-propanol, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, water, ethyl acetate, DMF, DMSO and a mixture thereof. As the metal catalyst, palladium catalysts such as palladium on carbon, palladium black, palladium hydroxide, and the like, platinum catalysts such as a platinum plate, platinum oxide, and the like, nickel catalysts such as reduced nickel, Raney nickel, and the like, rhodium catalysts such as tetrakistriphenylphosphine chlororhodium, and the like, iron catalysts such as reduced iron and the like, etc. are preferably used. Instead of hydrogen gas, formic acid or ammonium formate in an equivalent amount or in an excess amount to the compound of the general formula (5) can be used as a hydrogen source.
Furthermore, for the compound in which R2b is other than —H, an R2b group other than —H can be introduced to a desired position by using an electrophilic substitution reaction to the α-position of carbonyl by the use of a base or by a method which can be usually employed by a person skilled in the art for the compound (Ma).
REFERENCES


    “Reductions in Organic Chemistry, 2nd Ed. (ACS Monograph: 188)” written by M. Hudlicky, ACS, 1996


(Starting Material Synthesis 4)




A compound of the general formula (IIIb) can be obtained by carrying out reduction of a carbonyl group of the compound of the general formula (IIIa). This reaction is usually carried out in the presence of a reducing agent in a solvent. Examples of the solvent used herein are not particularly limited, but include ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, and aromatic hydrocarbons such as benzene, toluene, xylene, and the like. Examples of the reducing agent include aluminum hydride compounds such as lithium aluminum hydride, sodium bis(2-methoxyethoxy)aluminum hydride, and the like, and borohydride compounds such as sodium borohydride, diborane, a borane-tetrahydrofuran complex, and the like.
(Starting Material Synthesis 5)




(wherein R4a represents C1-6 alkyl, halogeno-C1-6 alkyl, cycloalkyl which may be substituted, or aryl which may be substituted, and Hal represents halogen).
A compound of the general formula (IIId) can be obtained by a coupling reaction of a compound of the general formula (IIIc). For example, the Suzuki coupling described in the following references, the Heck reaction described for the Starting Material Synthesis 2 above, or the like can be employed.
REFERENCES


    Chemical Reviews, vol. 95, No. 7, p. 2457 (1995), Journal of American Chemical Society, vol. 127, p. 4685 (2005), Synlett, No. 13, p. 2327 (2004), Tetrahedron letters, No. 41, p. 4363 (2000), or Tetrahedron letters, No. 43, p. 2695 (2002)


The compound of the general formula (IIId) can also be obtained by the method described in Examples as described later.
(Starting Material Synthesis 6)




(wherein R3a represents a group other than —H among the groups defined as R3).
A compound of the general formula (IIIe) can be obtained by alkylation, acylation, or the like of the compound of the general formula (IIIb). For the specific reaction conditions, the conditions described in the following references can be employed.
REFERENCES


    “Organic Functional Group Preparations” written by S. R. Sandler and W. Karo, 2nd Ed., vol. 1, Academic Press Inc., 1991
    “Courses in Experimental Chemistry (5th Ed.)”, edited by The Chemical Society of Japan, vol. 14 (2005) (Maruzen)


The compound of the general formula (IIIe) can also be obtained by the method described in the Examples as described later and the method described for the Starting Material Synthesis 4 above.
(Starting Material Synthesis 7)




A compound of the general formula (8) can be obtained by the reaction of a compound of the general formula (6) with a compound of the general formula (7). In this regard, examples of the leaving group of L1 include halogen, methanesulfonyloxy, p-toluenesulfonyloxy groups, and the like.
In this reaction, the compound of the general formula (6) and the compound of the general formula (7) are used in equivalent amounts, or with either one of them in an excess amount, and a mixture thereof is stirred under a temperature condition from cooling to heating and refluxing, preferably at 0° C. to 80° C., usually for 0.1 hours to 5 days, in a solvent inert to the reaction in the presence of a base. Examples of the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene, xylene, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, and the like, DMF, DMSO, ethyl acetate, acetonitrile, and a mixture thereof. Examples of the base include organic bases such as triethylamine, N,N-diisopropylethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, n-butyllithium, and the like, and inorganic bases such as sodium carbonate, potassium carbonate, sodium hydride, potassium tert-butoxide, and the like. It may be advantageous to carry out a reaction in the presence of a phase transfer catalyst such as tetra-n-butylammonium chloride and the like in some cases.
A compound of the general formula (IIIf) can be obtained by the method described in the Starting Material Synthesis 3 above and a compound of the general formula (IIIg) can be obtained by the method described in the Starting Material Synthesis 4 above.
REFERENCES


    “Organic Functional Group Preparations” written by S. R. Sandler and W. Karo, 2nd Ed., vol. 1, Academic Press Inc., 1991


“Courses in Experimental Chemistry (5th Ed.)” edited by The Chemical Society of Japan, vol. 14 (2005) (Maruzen)
(Starting Material Synthesis 8)




(wherein R3b represents C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, or a hetero ring which may be substituted, among the groups defined as R3. Further, among the C1-6 alkyl which may be substituted, one having oxo substituted on a carbon atom directly bonded to a nitrogen atom connected with R3b is excluded).
The compound of the general formula (10) can be obtained by using the compound of the general formula (9) and a suitable aldehyde or ketone compound in equivalent amounts, and stirring a mixture thereof under a temperature condition from −45° C. to heating and refluxing, preferably at 0° C. to room temperature, usually for 0.1 hours to 5 days, in a solvent inert to the reaction in the presence of a reducing agent. Examples of the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, and a mixture thereof. Examples of the reducing agent include sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, and the like. It is preferable in some cases to carry out the reaction in the presence of a dehydrating agent such as molecular sieves, and the like or an acid such as acetic acid, hydrochloric acid, a titanium(IV) isopropoxide complex, and the like. Further, the reaction can be carried out in a solvent such as methanol, ethanol, ethyl acetate, and the like, in the presence or absence of an acid such as acetic acid, hydrochloric acid, and the like, using a reduction catalyst (for example, palladium on carbon, Raney nickel, and the like), instead of treatment with the reducing agent. In this case, it is preferable to carry out the reaction under a hydrogen atmosphere from normal pressure to 50 atmospheres under a temperature condition ranging from cooling to heating.
A compound of the general formula (IIIh) can be obtained by using the compound of the general formula (10) and a suitable halogenocarboxylic ester and reacting them in the presence of a base.
The compound of the general formula (IIIi) can be obtained by using the method described in the Starting Material Synthesis 4 above and carrying out reduction of a carbonyl group of the compound of the general formula (IIIh).
REFERENCES


    “Comprehensive Organic Functional Group Transformations II” written by A. R. Katritzky and R. J. K. Taylor, vol. 2, Elsevier Pergamon, 2005
    “Courses in Experimental Chemistry (5th Ed.)”, edited by The Chemical Society of Japan, vol. 14 (2005) (Maruzen)


The compounds of the formula (I) can be isolated and purified as their free compounds, salts, hydrates, solvates, or polymorphic crystal substances thereof. The salts of the compound of the formula (I) can be prepared by carrying out the treatment of a conventional salt forming reaction.
Isolation and purification are carried out by employing ordinary chemical operations such as extraction, fractional crystallization, various types of fractional chromatography, and the like.
Various isomers can be prepared by selecting an appropriate starting compound or separated by using the difference in the physicochemical properties between the isomers. For example, the optical isomers can be obtained by means of a general method for designing optical resolution of racemic products (for example, fractional crystallization for inducing diastereomer salts with optically active bases or acids, chromatography using a chiral column or the like, and others), and further, the isomers can also be prepared from an appropriate optically active starting material.
The pharmacological activity of the compound of the formula (I) was confirmed by the tests shown below.
Test Example 1
Evaluation of 5-HT2C Receptor Agonist Activity
The agonist activity of the compound of the formula (I) on the 5-HT2C receptor was confirmed by the method shown below.
The human 5-HT2C receptor agonist activity was evaluated by measuring the increase of the ligand-dependent intracellular calcium concentration. CHO cells which stably expressing a human 5-HT2C receptor were used. The receptor-expressing cells were prepared by transfecting the genes of the human 5-HT2C receptor (Accession numbers: AF498983 (5-HT2C)) into CHO cells (dihydrofolic acid-deficient strain, DS Pharma Biomedical Co., Ltd.)) using a pEF-BOS vector (Nucleic Acids Research, vol. 18, No. 17). After transcription, the 5-HT2C is known to be subjected to RNA editing to cause differences in three kinds of amino acids, resulting in fourteen receptor isoforms. Among them, cells stably expressing an INI type of 5-HT2C receptor which had not been subjected to editing were used. Cells used for evaluation were cultured in a 10% fetal bovine serum (FBS)-containing medium (trade name: α-MEM, Invitrogen) at 37° C. and 5% carbon dioxide. On the day before the evaluation, the cells were suspended in a serum-free medium (trade name: CD-CHO, Invitrogen) containing 8 mM L-glutamine (trade name: L-glutamine 200 mM, Invitrogen, added to the medium at a final concentration of 8 mM) and dispensed into a 96-well poly-D-lysine-coated plate (trade name: Biocoat PDL96W Black/Clear, Japan Becton, Dickinson and Company)) at 4×104 cells/well and cultured at 37° C. and 5% carbon dioxide overnight. A solution including a washing solution (mixture of Hank's Balanced Salt Solution (HBSS)-sodium hydroxide (NaOH), 20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES)-sodium hydroxide (NaOH), 2.5 mM probenecid, and 0.1% bovine serum albumin (BSA)), and a 4 μM fluorescent reagent (trade name: Fluo-4-AM, Dojindo Co., Ltd.) was used as a loading buffer and the medium of the 96-well plate which had been cultured overnight was replaced with a loading buffer. After leaving to stand (with light-shielding) at room temperature for 3 hours, the cells were washed with a plate washer (trade name: ELx405, BioTek Instruments, Inc.) in which a washing solution had been set up. The plates of the washed cells were set up in a system for measuring a calcium (Ca) concentration in a cell (trade name: FLIPR, Molecular Devices, Inc.). In this device, a test compound that had been dissolved in dimethyl sulfoxide and diluted in the washing solution at a predetermined concentration was added and set up to measure a change in the Ca concentrations in a cell. The difference between a maximum value and a minimum value in the change of the intracellular Ca concentration was determined and kept as measurement data.
Taking the maximum reaction of the 5-HT (agonist action with addition of 5-HT 10 μM) as 100% and the reaction of a solvent alone as 0%, the efficacy (Emax (%)) and potency (EC50 (nM)) of the present invention compound to the maximum reaction of the 5-HT were calculated with a logistic regression method.
The results of several compounds are shown in Table 1. In the Table, Ex represents Example Compound No. below.










TABLE 1









5-HT2C agonist activity










Ex
EC50 (nM)
Emax (%)












2
0.64
99


16
1.5
109


21
0.81
101


33
32.9
94


35
0.42
100


36
12
97


38
2.1
94


42
1.9
97


45
3.9
107


50
68
98


56
3.2
112


58
4.0
117


59
7.1
108


76
1.9
116


78
36
98


81
0.84
114


88
1.1
105


90
8.3
113


92
79
84


98
4.4
107


104
1.1
107


105
8.0
111


106
1.1
112


108
5.9
106


135
2.9
112


141
0.36
100


215
1.0
96


243
0.53
96


258
1.9
97


263
2.8
96


265
1.3
97


267
0.51
99


268
0.92
99


276
6.4
104


277
2.3
95


283
1.7
90


287
1.0
97


288
0.64
90


290
3.8
93


291
1.2
93


292
0.65
93


297
0.71
96


299
1.0
98


313
4.2
97


315
2.8
108









Test Example 2
Measurement of External Urethral Sphincter Electromyography
The activating action of the compound of the formula (I) on the urethral sphincter electromyography was confirmed with the method shown below.
Hartley female guinea pigs with a body weight of 250 to 350 g were anesthetized with urethane (Sigma). The guinea pigs were fixed in a supine position and catheters (PE-50; Clay Adams) for administration of test compounds were inserted into the jugular vein. Further, a catheters (PE-160; Clay Adams), for an infusion of physiological saline into bladder and measurement of the intravesical pressure, were inserted through an incision into the dome of the bladder. Further, in order to measure the external urethral sphincter electromyography, two electrodes were inserted into both the left and right sides of the urethral opening to the urethral sphincter. The electrodes for measuring base voltages were placed under the skin of the hind part. The bladder catheter was branched over a three-way stopcock, and one was connected with a 50 mL syringe (Terumo) fixed to an infusion pump (Terumo). The other was connected to a pressure transducer (DX-100; Nihon Kohden Corporation) to transfer the signal of the transducer through an amplifier (AP-630G; Nihon Kohden Corporation) and a data acquisition system (PowerLab; AD Instruments) to a computer and record on a hard disk. The electrodes for electromyography measurement were connected to a control unit (JB-101J; Nihon Kohden Corporation) to transfer the signal through an amplifier (AP-651J; Nihon Kohden Corporation) and a data acquisition system (PowerLab; AD Instruments) to a computer and record on a hard disk. Further, the data were analyzed on the computer using a software (Chart; AD Instruments). Physiological saline was continuously injected into the bladder using an infusion pump at a rate of 18 mL/hour and it was confirmed that a micturition reflexes were stably induced. The electromyography activity was analyzed by taking the lowest potential amplitude as a standard during the stabilization period and using the firing frequency over the standard amplitude as an indicator. At intervals between the respective urinations (urine filling phase), the activity of the urethral sphincter electromyography was analyzed and its average value was calculated. After the stabilization period, the solvent and the test compound were administered at an increased dose at an interval of 40 minutes through the catheter placed into the jugular vein. The urethral sphincter electromyography activity after the administration of the solvent was taken as 100% and the urethral sphincter electromyography activity after the administration of the test compound was denoted as a percentage (%) of the electromyography activity after the administration of the solvent.
As a result, the compounds of Example 81, Example 59, Example 88, Example 104, Example 106, Example 141, Example 38, Example 135, Example 215, Example 243, Example 265, Example 287, Example 258, Example 263, Example 267, Example 268, Example 276, Example 277, Example 283, Example 288, Example 290, Example 291, Example 292, Example 297, Example 299, Example 313, and Example 315 as shown later showed an external urethral sphincter electromyography activity of 200% or more with intravenous administration at 3 mg/kg.
As a result of each test above, it was confirmed that the compound of the formula (I) has a 5-HT2C receptor agonist activity, and the compound of the formula (I) can be used for treatment or prevention of 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like as a pharmaceutical.
According to the results obtained by the tests above, it is considered that the compound has a 5-HT2C receptor agonist activity and thus has substantially the same or a higher activity value than Lorcaserin under development as an anti-obesity drug (The Journal of Pharmacology and Experimental Therapeutics vol. 325, No. 2 p. 577-587 (2008)).
A pharmaceutical composition containing one or two or more kinds of the compound of the formula (I) or a salt thereof as an active ingredient can be prepared using excipients that are usually used in the art, that is, excipients for pharmaceutical preparation, carriers for pharmaceutical preparation, and the like according to the methods usually used.
Administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, and the like, or parenteral administration injections, such as intraarticular, intravenous, or intramuscular injections, and the like, suppositories, ophthalmic solutions, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalations, and the like.
The solid composition for oral administration is used in the form of tablets, powders, granules, or the like. In such a solid composition, one or more active ingredient(s) are mixed with at least one inactive excipient. According to a usual method, the composition may contain inactive additives, such as lubricants, disintegrating agents, stabilizing agents, and solubilization assisting agents. If necessary, tablets or pills may be coated with sugar or a film of a gastric or enteric coating substance.
The liquid composition for oral administration contains pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, or the like, and also contains generally used inert diluents, for example, purified water or ethanol. In addition to the inert diluent, the liquid composition may also contain auxiliary agents, such as a solubilization assisting agent, a moistening agent, and a suspending agent, as well as sweeteners, flavors, aromatics, and antiseptics.
The injections for parenteral administration contain sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of the aqueous solvent include distilled water for injection use and physiological saline. Examples of the non-aqueous solvent include alcohols such as ethanol. Such a composition may further contain a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, and a solubilization assisting agent. These are sterilized by filtration through a bacteria retaining filter, blending of a germicide, or irradiation. Furthermore, they may also be prepared in the form of sterile solid compositions and dissolved or suspended in sterile water or a sterile solvent for injecting prior to their use.
Examples of the formulation for external use include ointments, plasters, creams, jellies, patches, sprays, lotions, eye-drops, eye ointments, and the like. The drug contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like.
Transmucosal agents such as inhalers, transnasal agents, and the like are used in the form of solids, liquids, or semisolids and can be prepared according to conventional known methods. For example, known excipients, and further, pH adjusters, antiseptics, surfactants, lubricants, stabilizing agents, thickeners, or the like may also be added where appropriate. For administration, suitable devices for inhalation or insufflation can be used. For example, using known devices and sprayers such as a metered dose inhaler, the compound can be administered independently or in the form of prescribed mixture powders. Furthermore, the compound combined with pharmaceutically acceptable carriers can also be administered in the form of solutions or suspensions. Dry powder inhalers and the like may be devices for single or multiple administrations, and dry powders or capsules containing powders can also be used. Still further, the devices may be in the form of a pressure aerosol spray or the like that use suitable ejection agents, for example, chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide and the like.
Usually, in the case of oral administration, the daily dose is suitably from 0.001 to 100 mg/kg per body weight, preferably from 0.1 to 30 mg/kg, and more preferably from 0.1 to 10 mg/kg, and this is administered in one portion or dividing it into 2 to 4 portions. In the case of intravenous administration, the daily dose is suitably from about 0.0001 to 10 mg/kg per body weight, and this is administered once a day or two or more times a day. In addition, a transmucosal agent is administered at a dose from about 0.001 to 100 mg/kg per body weight, and this is administered once a day or two or more times a day. The dose is appropriately decided in response to an individual case by taking the symptoms, the age, the gender, and the like into consideration.
Although varying depending on administration routes, dosage forms, administration sites, or the types of excipients and additives, the pharmaceutical composition of the present invention contains 0.01 to 100% by weight, and in a certain embodiment, 0.01 to 50% by weight of one or more kinds of the compound of the formula (I) or a salt thereof, which is an active ingredient.
The compound of the formula (I) can be used in combination with various agents for treating or preventing the diseases, in which the compound of the formula (I) is considered effective, as described above. The combined preparation may be administered simultaneously or separately and continuously, or at a desired time interval. The preparations to be co-administered may be prepared individually or may be a pharmaceutical composition including various agents for treating or preventing the diseases, in which the compound of the formula (I) is considered effective, as described above, and the compound of the formula (I).


EXAMPLES
Hereinbelow, the preparation methods for the compound of the formula (I) and the starting compounds thereof will be described in more detail with reference to Examples. The present invention is not limited to the compounds described in the Examples described below. Furthermore, the production processes for the starting compounds will be described in Preparation Examples. The preparation methods for the compound of the formula (I) are not limited to the preparation methods of the specific Examples as below, but the compound of the formula (I) can be prepared by any combination of the preparation methods or the methods that are apparent to a person skilled in the art.
Furthermore, the following abbreviations may be used in some cases in the Preparation Examples, Examples, and Tables below.
PEx: Preparation Example No., Ex: Example No., PSyn: Preparation Example No. prepared by the same method, Syn: Example No. prepared by the same method, No: Compound No., Str: Structural formula, Dat: Physicochemical Data, EI: m/z values in mass spectroscopy (Ionization EI, representing (M)+ unless otherwise specified), ESI+: m/z values in mass spectroscopy (Ionization ESI, representing (M+H)+ unless otherwise specified), ESI−: m/z values in mass spectroscopy (Ionization ESI, representing (M−H)− unless otherwise specified), FAB+: m/z values in mass spectroscopy (Ionization FAB, representing (M+H)+ unless otherwise specified), FAB−: m/z values in mass spectroscopy (Ionization FAB, representing (M−H)− unless otherwise specified), APCI+: m/z values in mass spectroscopy (Ionization APCI, representing (M+H)+ unless otherwise specified), NMR: δ (ppm) in 1H NMR in DMSO-d6, NMR-A: δ (ppm) in 1H NMR in DMSO-d6 (with addition of trifluoroacetic acid), NMR-C: δ (ppm) in 1H NMR in CDCl3, s: singlet (spectrum), d: doublet (spectrum), t: triplet (spectrum), q: quartet (spectrum), br: broad line (spectrum) (e.g.: br-s), mp: melting point (° C.).
Me: methyl, Et: ethyl, nPr: normal propyl, iPr: isopropyl, nBu: normal butyl, iBu: isobutyl, t-Bu: tert-butyl, cPr: cyclopropyl, cBu: cyclobutyl, cPen: cyclopentyl, cHex: cyclohexyl, Bz: benzyl, Boc: t-butoxycarbonyl, MeOH: methanol, EtOH: ethanol, EtOAc: ethyl acetate, HEX: n-hexane, DMF: N,N-dimethylformamide, TFA: trifluoroacetic acid, THF: tetrahydrofuran, DPPA: diphenylphosphorylazide, HOBt: 1-hydroxybenzotriazole.
HCl in the structural formula indicates that the Example compound is isolated as a hydrochloride. Further, a case where the structural formula of fumaric acid is described together in the structural formula indicates that the Example compound is isolated as fumarate. Also, a case where the structural formula of oxalic acid is described together in the structural formula indicates that the Example compound is isolated as an oxalate. In addition, a case where the structural formula of succinic acid is described together in the structural formula indicates that the Example compound is isolated as a succinate.
Furthermore, in the case where a numeral is prefixed to HCl, the numeral means a molar ratio of the compound to hydrochloric acid. For example, 2HCl represents dihydrochloride. Further, in the Example Compounds in which the structural formula of fumaric acid is described together in the structural formula, “M” described under the Example No. indicates that the Example Compound is isolated as monofumarate, “H” described as such indicates that the Example Compound is isolated as hemifumarate, and “S” described as such indicates that the Example Compound is isolated as sesquifumarate. Also, “T” of Example 267 indicates that the compound is isolated as 0.75 fumarate. Further, description of these “M”, “H”, and “S” has the same meanings in the Example Compound in which the structural formula of oxalic acid is described together in the structural formula and the Example Compound in which where the structural formula of succinic acid is described together in the structural formula.
Furthermore, for the sake of convenience, a concentration mol/l is expressed as M. For example, a 1 M aqueous sodium hydroxide solution means a 1 mol/l aqueous sodium hydroxide solution.
Preparation Example 1
To a solution of 27.11 g of 3-chloro-o-xylene in 300 ml of carbon tetrachloride were added 75 g of N-bromosuccinimide and 0.81 g of 2,2′-azobis(isobutyronitrile), followed by heating and refluxing for 2 hours. The reaction mixture was washed with water and saturated sodium hydrogen carbonate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 63.297 g of 1,2-bis(bromomethyl)-3-chlorobenzene as a reddish orange oily substance.
Preparation Example 2
To a solution of 20.5 g of sodium cyanide in 120 ml of water was added a solution of 57.533 g of 1,2-bis(bromomethyl)-3-chlorobenzene in 120 ml of EtOH, followed by heating and refluxing for 30 minutes. The reaction mixture was poured into ice, followed by stirring, and the precipitated solid was collected by filtration to obtain 32.941 g of 2,2′-(3-chloro-1,2-phenylene)diacetonitrile as a yellowish brown solid.
Preparation Example 3
To a suspension of 32.94 g of 2,2′-(3-chloro-1,2-phenylene)diacetonitrile in 100 ml of acetic acid was added dropwise 100 ml of a 33% hydrogen bromide-acetic acid solution over 1.5 hours while keeping the inner temperature at 20° C. or lower. The reaction mixture was stirred at room temperature for 3 hours, and then to the reaction mixture were added diethylether and acetone. The resulting candy-like dark brown solid substance and the suspension were separated, the suspension was concentrated under reduced pressure, and the candy-like substance was pulverized in acetone to obtain a suspension. The concentrated residue and the acetone suspension were combined and concentrated under reduced pressure, and to the residue was added EtOAc, followed by stirring. The solid was collected by filtration. The resulting solid was suspended in 400 ml of water which had been heated to 80° C., and 31.2 g of sodium acetate was added thereto, followed by stirring at 90° C. for 3 hours. The reaction mixture was cooled to room temperature and then the solid was collected by filtration to obtain 22.506 g of 6-chloro-1H-3-benzazepine-2,4(3H,5H)-dione as a brown solid.
Preparation Example 4
To a solution of 22.5 g of 6-chloro-1H-3-benzazepine-2,4(3H,5H)-dione in 200 ml of THF were added dropwise 38 ml of a 10 M borane-dimethyl sulfide complex at 0° C. for 20 minutes, followed by stirring for 2.5 hours. The reaction mixture was heated and refluxed, and further stirred. To the reaction mixture was added dropwise 30 ml of MeOH under ice-cooling, followed by stirring, and then 30 ml of 4 M hydrochloric acid was added dropwise thereto, followed by heating and refluxing for 1 hour after generation of bubbles substantially settled. The mixture was alkalified by the addition of aqueous ammonia and a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered. The filtrate was concentrated under reduced pressure, the residue was dissolved in EtOH, and activated carbon was added thereto, followed by heating and refluxing, and then filtering on amino silica gel, and the filtrate was concentrated under reduced pressure. To a solution of 18.7 g of the resulting residue in 180 ml of dichloromethane was added 17 ml of pyridine, followed by ice-cooling, and 13 ml of ethyl chlorocarbonate was added dropwise thereto, followed by stirring for 1.5 hours. The reaction mixture was concentrated under reduced pressure, the residue was diluted with EtOAc, then washed with 1 M hydrochloric acid and water, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 9.653 g of ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish brown oily substance.
Preparation Example 5
A solution of 11.86 g of ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 30 ml of chloroform was ice-cooled, and while maintaining the inner temperature at 10° C. or lower, 60 ml of concentrated sulfuric acid was added thereto. Then, 3.2 ml of concentrated nitric acid was added dropwise thereto, followed by stirring for 30 minutes. The reaction mixture was poured into ice, followed by extraction with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 6.442 g of ethyl 6-chloro-7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish orange viscous substance and 5.201 g of ethyl 6-chloro-9-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow solid.
Preparation Example 6
To 6.431 g of ethyl 6-chloro-7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was added 120 ml of EtOH, followed by stirring at 60° C. for dissolution, and 12.15 g of reduced iron and 60 ml of 1 M hydrochloric acid were added thereto, followed by heating and refluxing for 1 hour. The reaction mixture was alkalified by the addition of a 1 M aqueous sodium hydroxide solution and then filtered through celite, and then the organic solvent was evaporated under reduced pressure. The residue was extracted with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 5.743 g of ethyl 7-amino-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish orange viscous substance.
Preparation Example 7
To a solution of 5.74 g of ethyl 7-amino-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 100 ml of dichloromethane was added portionwise 3.9 g of N-bromosuccinimide under ice-cooling, followed by stirring for 40 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 5.769 g of ethyl 7-amino-8-bromo-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a brown solid.
Preparation Example 8
To a solution of 4.37 g of ethyl 7-amino-8-bromo-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 40 ml of DMF were added 2.1 ml of ethyl acrylate, 230 mg of tris-o-tolylphosphine, 85 mg of palladium(II) acetate, and 3.6 ml of triethylamine, followed by stirring at 120° C. for 3 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The resulting yellow solid was stirred and washed in diisopropylether to obtain 3.125 g of ethyl 7-amino-6-chloro-8-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow solid.
Preparation Example 9
To a solution of 2.12 g of ethyl 7-amino-6-chloro-8-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 20 ml of chloroform and 20 ml of MeOH was added 65 mg of platinum(IV) oxide, followed by stirring for 20 hours at 1 atm under a hydrogen atmosphere. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 2.256 g of ethyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a milky white solid.
Preparation Example 10
To a suspension of 1.403 g of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one in 15 ml of dioxane were added 1.2 ml of triethylamine and 1.5 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.779 g of t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a milky white solid.
Preparation Example 11
To a solution of 1.772 g of t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 10 ml of THF was added 10.1 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by elevating to room temperature and stirring for 3 hours. To the reaction mixture was added dropwise 10 ml of EtOH, and subsequently 10 ml of a 1 M aqueous sodium hydroxide solution was added dropwise thereto, followed by stirring. The mixed solution was diluted with water, followed by extraction with EtOAc. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 2.007 g of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.
Preparation Example 12
To a solution of 205 mg of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 3 ml of acetonitrile were added 0.077 ml of 36% formalin, 58 mg of sodium cyanoborohydride, and 0.5 ml of acetic acid, followed by stirring at room temperature. To the reaction mixture was added water, followed by extraction with EtOAc, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 96 mg of t-butyl 11-chloro-1-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as an orange viscous substance.
Preparation Example 13
To a solution of 193 mg of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of toluene was added 0.121 ml of isobutyric chloride, followed by stirring at 60° C. The reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 80 mg of t-butyl 11-chloro-1-isobutyryl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless solid.
Preparation Example 14
To a solution of 1.75 g of 2,3,4,5-tetrahydro-1H-3-benzazepine in 20 ml of dichloromethane was added 2.884 ml of pyridine. The reaction mixture was ice-cooled, and 1.705 ml of ethyl chloroformate which had been dissolved in 5 ml of dichloromethane was added dropwise thereto, followed by stirring overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 2.15 g of ethyl 1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow oily substance.
Preparation Example 15
287 mg of ethyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was dissolved in 5 ml of DMF, and 65 mg of 60% sodium hydride was added thereto in an ice-bath, followed by stirring for 1 hour. 0.3 ml of methyl iodide was added thereto, followed by stirring at room temperature for 3 hours. Then, a saturated aqueous sodium hydrogen carbonate solution was added thereto, followed by extraction with chloroform. The solvent was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 94 mg of ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless solid.
Preparation Example 71
To 5 g of ethyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 40 ml of ethylene glycol and 28 ml of a 4 M aqueous sodium hydroxide solution, followed by stirring at 150° C. After stirring overnight, the reaction mixture was ice-cooled, then acidified by the addition of concentrated hydrochloric acid, and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and then the residue was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The solvent was concentrated under reduced pressure and then the resulting dark brown residue was dissolved in dichloromethane, followed by addition of 4 g of di-t-butyl dicarbonate and 3.5 ml of triethylamine. The reaction mixture was stirred at room temperature overnight and concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH) to obtain 3.39 g of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
Preparation Example 17
To a solution of 250 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2.5 ml of dichloroethane were added 0.175 ml of isobutyryl chloride and 0.4 ml of triethylamine, followed by elevating the temperature to 60° C. and stirring for 30 minutes. The reaction mixture was diluted with EtOAc and washed with 1 M hydrochloric acid, water, a 1 M aqueous sodium hydroxide solution, and saturated brine, and the solvent was concentrated. To the resulting residue was added 2 ml of THF and 3.5 ml of a 1 M solution of a borane-THF complex in THF was added thereto in an ice-bath, followed by stirring at room temperature overnight. The reaction mixture was ice-cooled, and EtOH was added thereto, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 213 mg of t-butyl 1-isobutyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
Preparation Example 18
To a solution of 460 mg of t-butyl 11-bromo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 9 ml of dioxane were added 1.6 ml of a 2 M aqueous potassium carbonate solution under an argon atmosphere, and subsequently 449 mg of trimethylboroxine and 70 mg of tetrakistriphenylphosphine palladium, followed by stirring at 90° C. for 13 hours. The reaction mixture was allowed to cool, filtered, and then concentrated under reduced pressure, the resulting residue was diluted with EtOAc, and the organic layer was washed with water and saturated brine. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 380 mg of t-butyl 11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
Preparation Example 19
To a solution of 670 mg of t-butyl 11-isopropenyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 10 ml of MeOH was added 200 mg of palladium on carbon, followed by stirring at room temperature for 3.5 hours at normal pressure under a hydrogen atmosphere. Further, after stirring overnight at 4.5 atm under a hydrogen atmosphere, the reaction mixture was filtered through celite, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 512 mg of t-butyl 11-isopropyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
Preparation Example 20
To a solution of 140 mg of t-butyl 11-ethyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 1.86 ml of acetonitrile was added 0.12 ml of glycidylmethylether, followed by substitution with argon. In an ice-bath, 9 mg of ytterbium(III) trifluoromethanesulfonate was added thereto, followed by stirring at room temperature for 2 hours, then elevating the temperature to 50° C., and stirring overnight. To the reaction mixture were added EtOAc and aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 147 mg of t-butyl 11-ethyl-1-(2-hydroxy-3-methoxypropyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
Preparation Example 21
To a solution of 215 mg of t-butyl 7-hydroxy-8-(tetrahydro-2H-pyran-4-ylamino)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 4 ml of DMF were added 98 mg of potassium carbonate and 0.062 ml of methyl bromoacetate, followed by stirring at room temperature for 6 hours. To the reaction mixture was added water, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine three times, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. To a solution of 259 mg of the resulting residue in 7 ml of EtOH was added 1.2 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at 50° C. overnight. Further, 1.2 ml of a 1 M aqueous hydrochloric acid solution was added thereto under ice-cooling, followed by extraction with chloroform twice, and the combined organic layer was dried over anhydrous sodium sulfate and then filtered. The solvent was evaporated under reduced pressure. To a solution of 239 mg of the resulting residue in 4 ml of DMF were added 120 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 84 mg of HOBt at room temperature, followed by stirring at room temperature overnight. Water was added thereto, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 153 mg of t-butyl 3-oxo-4-(tetrahydro-2H-pyran-4-yl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white solid.
Preparation Example 22
To a solution of 828 mg of t-butyl 7-hydroxy-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 25 ml of DMF were added 0.268 ml of methyl bromoacetate and 390 mg of potassium carbonate, followed by stirring at 55° C. for 13 hours. The reaction mixture was allowed to cool, and water added, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.076 g of t-butyl 7-(2-methoxy-2-oxoethoxy)-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a yellowish white solid.
Preparation Example 23
To a mixture of 967 mg of t-butyl 7-(2-methoxy-2-oxoethoxy)-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 25 ml of EtOH was added 97 mg of 10% palladium on carbon under an argon atmosphere, followed by stirring for 2 hours at normal pressure under a hydrogen atmosphere. To the reaction mixture was added 200 ml of THF, then the catalyst was removed using celite, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 629 mg of t-butyl 11-methyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white solid.
Preparation Example 24
To a solution of 120 mg of t-butyl 2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of DMF were added 0.026 ml of methyl iodide and 104 mg of potassium carbonate at room temperature, followed by stirring for 13 hours. To the reaction mixture were added 0.012 ml of methyl iodide and 26 mg of potassium carbonate, followed by further stirring for 3 hours. To the reaction mixture was added water, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 55 mg of t-butyl 2,4-dimethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a brown solid.
Preparation Example 25
To a solution of 120 mg of t-butyl 2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of DMF were added 0.113 ml of isopropyl iodide and 0.197 ml of diisopropylethylamine, followed by stirring at 100° C. for 6.5 hours. Further, to the reaction mixture were added 0.113 ml of isopropyl iodide and 0.197 ml of diisopropylethylamine, followed by stirring at 100° C. for 4 hours. Further, to the reaction mixture were added 0.226 ml of isopropyl iodide and 0.394 ml of diisopropylethylamine, followed by stirring at 100° C. for 19 hours. The reaction mixture was cooled to room temperature, and water added, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 90 mg of t-butyl 4-isopropyl-2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(211)-carboxylate as a pale brown solid.
Preparation Example 26
To a solution of 130 mg of t-butyl 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of dichloromethane were added 0.036 ml of methanesulfonyl chloride and 0.089 ml of diisopropylethylamine under ice-cooling, followed by stirring at room temperature for 16 hours. To the reaction mixture were added 0.036 ml of methanesulfonyl chloride and 0.089 ml of diisopropylethylamine, followed by stirring at room temperature for additional 9 hours. To the reaction mixture was added water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 152 mg of t-butyl 4-(methylsulfonyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a colorless solid.
Preparation Example 27
To a mixture of 5 g of sodium borohydride and 30 ml of anhydrous THF was added a solution of 10.27 g of 2-methyl-3-nitrophenylacetic acid in 60 ml of anhydrous THF under ice-cooling, and then a solution of 3.5 ml of methanesulfonic acid in 10 ml of anhydrous THF was added dropwise thereto. The reaction mixture was heated to 70° C. and then stirred for 30 minutes, and 80 ml of 3 M hydrochloric acid was then added thereto under ice-cooling, followed by stirring. The mixed liquid was extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 9.701 g of an orange viscous substance. To a solution of 9.53 g of the resulting substance in 100 ml of dichloromethane were added dropwise 22 ml of diisopropylethylamine and 4.75 ml of chloromethylmethylether under ice-cooling, followed by stirring for 24 hours. 1.0 ml of chloromethylmethylether was added thereto, followed by further stirring for 24 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 11.26 g of a yellow oily substance. To a solution of 11.26 g of the resulting substance in 200 ml of EtOH was added 340 mg of platinum(IV) dioxide, followed by stirring at room temperature for 1 hour under a hydrogen atmosphere of 4 atm. The reaction mixture was removed using celite and the filtrate was concentrated under reduced pressure to obtain 9.21 g of an orange viscous substance. To a solution of the residue in 200 ml of dichloromethane and 40 ml of MeOH were added 14.2 g of calcium carbonate and 36.5 g of benzyl trimethylammonium dichloroiodate, followed by stirring at room temperature for 13 hours. The insoluble materials were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 15.93 g of 4,6-diiodo-3-[2-(methoxymethoxy)ethyl]-2-methylaniline as a dark red viscous substance.
Preparation Example 28
To a mixed liquid of 400 mg of palladium(II) acetate, 934 mg of triphenylphosphine, 9.91 g of tetrabutylammonium chloride, and 7 g of potassium acetate in 150 ml of DMF was added a solution of 15.93 g of 4,6-diiodo-3-[2-(methoxymethoxy)ethyl]-2-methylaniline in 150 ml of DMF, and 16 ml of ethyl acrylate was added thereto, followed by stirring at 80° C. for 3 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 12.11 g of a yellow solid. To a solution of 12.11 g of the resulting substance in 250 ml of EtOH and 250 ml of THF was added 701 mg of platinum(IV) oxide, followed by stirring at room temperature for 4 hours under a hydrogen atmosphere of 4 atm. The reaction mixture was removed using celite and the filtrate was concentrated-under reduced pressure to obtain 11.39 g of ethyl 3-{7-[2-(methoxymethoxy)ethyl]-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}propanoate as a milky white solid.
Preparation Example 29
To a solution of 10.81 g of ethyl 3-{7-[2-(methoxymethoxy)ethyl]-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}propanoate in 100 ml of EtOH and 100 ml of THF was added 100 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 1 hour. The reaction mixture was neutralized by the addition of hydrochloric acid and then concentrated under reduced pressure to one third of the liquid amount, and the residue was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To a solution of the resulting residue in 300 ml of t-butanol were added 9.0 ml of triethylamine and 7.0 ml of DPPA, followed by heating and refluxing for 24 hours. The reaction mixture was concentrated under reduced pressure, the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and then the resulting solid was washed with HEX to obtain 8.006 g of t-butyl (2-{7-[2-(methoxymethoxy)ethyl]-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}ethyl)carbamate as a milky white solid.
Preparation Example 30
To a suspension of 1.01 g of t-butyl (2-{7-[2-(methoxymethoxy)ethyl]-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}ethyl)carbamate in 10 ml of THF was added 10 ml of 6 M hydrochloric acid, followed by stirring at 50° C. for 1 hour. The reaction mixture was alkalified by the addition of sodium hydroxide and then 675 mg of di-t-butyl dicarbonate was added thereto, followed by stirring at room temperature for 15 hours. The reaction mixture was extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 1.105 g of t-butyl {2-[7-(2-hydroxyethyl)-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]ethyl}carbamate as a white foamed substance.
Preparation Example 31
To a solution of 1.793 g of t-butyl {2-[7-(2-hydroxyethyl)-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]ethyl}carbamate in 30 ml of THF were added 0.48 ml of methanesulfonyl chloride and 1.5 ml of triethylamine under ice-cooling, followed by stirring for 30 minutes. To the reaction mixture was added portionwise 1.8 g of potassium t-butoxide under ice-cooling, followed by stirring for 1.5 hours. To the reaction mixture was added a saturated aqueous ammonium chloride solution, followed by extraction with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.06 g of t-butyl 11-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white foamed substance.
Preparation Example 32
To a solution of 167 mg of t-butyl 11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of dichloromethane were added 0.221 ml of triethylamine and 0.062 ml of ethyl isocyanate, followed by stirring at room temperature for 15 hours. To the reaction mixture were added 3 ml of toluene and 0.062 ml of ethyl isocyanate, followed by heating to 60° C. and stirring for 15 hours. Then, the reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 200 mg of t-butyl 1-(ethylcarbamoyl)-11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.
Preparation Example 33
To a solution of 201 mg of t-butyl 11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of pyridine was added 0.1 ml of ethyl chloroformate, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 261 mg of 8-t-butyl 1-ethyl 11-methyl-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-dicarboxylate as a colorless viscous substance.
Preparation Example 34
To a suspension of 2 g of 3-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propionic acid in 40 ml of t-butanol were added 2.1 ml of DPPA and 2.6 ml of triethylamine, followed by heating and refluxing at 100° C. for 18 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH) to obtain 1.832 g of t-butyl[2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as an orange solid.
Preparation Example 35
To a mixed solution of 770 mg of t-butyl[2-(1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate in 15 ml of dichloromethane and 3 ml of MeOH were added 420 mg of calcium carbonate and 970 mg of benzyltrimethylammonium dichloroiodate, followed by stirring at room temperature for 2 hours. The insoluble materials were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 595 mg of t-butyl [2-(6-iodo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a reddish brown viscous substance.
Preparation Example 36
To a solution of 595 mg of t-butyl[2-(6-iodo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate in 3 ml of dichloromethane were added 3 ml of water and 376 mg of sodium hydrogen carbonate, and a solution of 0.273 ml of benzyl chloroformate in 3 ml of dichloromethane wad added dropwise under ice-cooling while stirring, followed by stirring for additional 5 hours. The reaction mixture was extracted with EtOAc, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 877 mg of benzyl 7-{2-[(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate as a reddish orange solid.
Preparation Example 37
To a solution of 793 mg of benzyl 7-{2-[(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate in 10 ml of THF was added dropwise 1.8 ml of a 1 M solution of sodium bistrimethylsilylamide in THF under ice-cooling, followed by stirring for 5 minutes. Then, 0.166 ml of allyl bromide was added thereto, followed by stirring for 18 hours while slowly elevating the temperature to room temperature. To the reaction mixture were added a saturated aqueous ammonium chloride solution and water, followed by extraction with EtOAc, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 788 mg of benzyl 7-{2-[allyl(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate.
Preparation Example 38
To a mixture of 403 mg of potassium acetate, 441 mg of tetrabutylammonium bromide, 9 mg of triphenylphosphine, and 4 mg of palladium(II) acetate was added a solution of 788 mg of benzyl 7-{2-[allyl(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate in 25 ml of DMF, followed by substitution with argon and stirring at 80° C. for 4 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, and concentrated under reduced pressure. To 25 ml of a solution of the resulting residue in MeOH was added 36 mg of platinum(IV) oxide, followed by stirring at room temperature overnight under a hydrogen atmosphere of 4 atm. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 570 mg of 1-benzyl 8-t-butyl 6-methyl-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-dicarboxylate as an orange foamed substance.
Preparation Example 39
To a mixed liquid of 9.3 g of aluminum chloride in 30 ml of dichloromethane was added dropwise 1.6 ml of acetyl chloride under ice-cooling, followed by stirring. Then, a solution of 5 g of 7-methoxy-1-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine in 70 ml of dichloromethane was added thereto, followed by stirring for 13 hours while slowly elevating the temperature to room temperature. The reaction mixture was ice-cooled, and 30 ml of 1 M hydrochloric acid was added dropwise thereto, followed by addition of water and extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (elution solvent: HEX-EtOAc) to obtain 5.137 g of 1-[8-hydroxy-5-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]ethanone as a pale brown solid.
Preparation Example 40
To a suspension of 5.13 g of 1-[8-hydroxy-5-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]ethanone in 50 ml of MeOH was added 50 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure to a half of the amount, and to the residue were added 50 ml of dioxane and 4.27 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 30 minutes. The reaction mixture was neutralized by the addition of 1 M hydrochloric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 4.385 g of t-butyl 8-acetyl-7-hydroxy-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a yellow viscous substance.
Preparation Example 41
To a solution of 1.715 g of t-butyl 8-acetyl-7-(2-ethoxy-2-oxoethoxy)-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 20 ml of EtOH was added 325 mg of hydroxylamine hydrochloride, followed by heating and refluxing for 3 hours. 500 mg of hydroxylamine hydrochloride was added thereto, followed by further heating and refluxing for 2 hours. The reaction mixture was concentrated under reduced pressure, and to the residue was added water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To 10 ml of a solution of the resulting residue in acetonitrile were added 24 mg of cyanuric chloride and 33 mg of zinc(II) chloride, followed by heating and refluxing for 12 hours. The reaction mixture was concentrated under reduced pressure. To the resulting residue were added 10 ml of dioxane, 10 ml of a 1 M aqueous sodium hydroxide solution and 1.2 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure to a half of the amount, made weakly acidic by the addition of 1 M hydrochloric acid, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To the resulting residue was added 60 ml of a 17% aqueous sulfuric acid solution, followed by stirring at 100° C. for 1 hour. The reaction mixture was ice-cooled and alkalified by the addition of 15 g of sodium hydroxide, and 50 ml of dioxane and 1.21 g of di-t-butyl dicarbonate were added thereto, followed by stirring at room temperature for 3 hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 735 mg of t-butyl 6-methyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2′-1)-carboxylate as a pale yellow solid.
Preparation Example 42
To a solution of 704 mg of t-butyl 6-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 15 ml of dichloromethane was added portionwise 438 mg of N-bromosuccinimide under ice-cooling, followed by stirring for 30 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 446 mg of a pale yellow foamed substance. To a mixture of 445 mg of the resulting compound, 144 mg of cyclopropylboric acid, 724 mg of potassium phosphate, 65 mg of tricyclohexylphosphine, and 28 mg of palladium(II) acetate were added 10 ml of toluene and 0.5 ml of water, followed by stirring at 110° C. for 12 hours. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 379 mg of t-butyl 5-cyclopropyl-6-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a pale brown foamed substance.
Preparation Example 334
To a solution of 500 mg of t-butyl 3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 10 ml of DMF were added 250 μl of 1-(bromomethyl)-3-fluorobenzene and 800 mg of cesium carbonate, followed by stirring at 50° C. for 16 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, and water added, followed by extraction with ethyl acetate twice. The combined organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. The solvent was evaporated and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 609 mg of t-butyl 4-(3-fluorobenzyl)-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.
Preparation Example 339
To a solution of 600 mg of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 9 ml DMF were added 426 mg of potassium t-butoxide and 451 μl of benzyl bromide in an ice-bath, followed by stirring at room temperature for 3 hours. Water and ethyl acetate were added thereto, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 644 mg of t-butyl 1-benzyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a pale yellow solid.
Preparation Example 344
To a solution of 3.83 g of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 40 ml of dichloromethane were added 1.3 ml of pyridine and 1.29 g of triphosgene under ice-cooling, followed by stirring for 3 hours. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, washed with water and an aqueous ammonium chloride solution, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. To the residue was added hexane, followed by stirring, and the solid was collected by filtration and dried to obtain 3.07 g of t-butyl 1-(chlorocarbonyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white solid.
Preparation Example 345
To a solution of 200 mg of t-butyl 1-(chlorocarbonyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of pyridine was added 140 μl of phenethyl alcohol, followed by stirring at 100° C. for 5.5 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 68 mg of 8-t-butyl 1-(2-phenylethyl) 3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-dicarboxylate as a yellow viscous substance.
Preparation Example 349
To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate and 318 mg of 2-(2-methoxyphenyl)ethyl 4-nitrophenylcarbonate in 5 ml of dichloroethane was added 0.11 ml of pyridine, followed by stirring at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and basic silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 243 mg of 8-t-butyl 1-[2-(methoxyphenyl)ethyl]-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-carboxylate as a pale yellow viscous substance.
Preparation Example 367
To a solution of 150 mg of t-butyl 11-chloro-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-caxboxylate in 3 ml of tetrahydrofuran was added 1.5 ml of a 1 M aqueous sodium hydrogen carbonate solution, followed by ice-cooling, and 64 μl of ethyl chloroformate was added dropwise thereto followed by stirring. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 149 mg of 8-t-butyl 4-ethyl-1′-chloro-2,3,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-4,8-dicarboxylate as a colorless foamed substance.
Preparation Example 375
To 500 mg of t-butyl 11-bromo-1-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate, 350 mg of potassium carbonate, 290 mg of copper iodide, 173 mg of 1H-pyrazole, and 313 mg of N,N-dimethylglycine was added 6.25 ml of dimethylsulfoxide under argon, followed by stirring at 135° C. for 36 hours. To the reaction mixture were added water and ethyl acetate, followed by stirring, and then the solid was separated by filtration. The organic layer was washed with aqueous sodium bicarbonate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 43 mg of t-butyl 1-methyl-1′-(1H-pyrazol-1-yl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous liquid.
Preparation Example 376
A solution of 200 mg of t-butyl 11-bromo-1-(2-methoxyethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate, 34 mg of zinc cyanide, 13 mg of bis(tri-t-butylphosphine)palladium, and 10 mg of zinc powder in 4 ml of N,N-dimethylacetamide was substituted with argon and then stirred at 100° C. for 15 hours. The reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 132 mg of t-butyl 11-cyano-1-(2-methoxyethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.
Preparation Example 377
1.1946 g of 1-[11-bromo-1-(2-methoxyethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-yl]-2,2,2-trifluoroethanone, 2.2395 g of sodium trifluoroacetate, and 1.568 g of copper iodide were added to 24 ml of N-methylpyrrolidone under an argon atmosphere, followed by stirring at 170° C. for 18 hours. To the reaction mixture were added water and ethyl acetate, and filtered through celite was performed. The filtrate was subjected to liquid separation, the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 239 mg of 2,2,2-trifluoro-1-[1-(2-methoxyethyl)-11-(trifluoromethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-yl]ethanone as a pale yellow solid.
Preparation Example 379
To 7.87 g of 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoic acid were added 200 ml of t-butanol, 7 ml of triethylamine, and 5 ml of diphenylphosphoryl azide, followed by heating and refluxing for 70 hours. The reaction mixture was cooled to room temperature, then diluted by the addition of water, and stirred, and the solid was collected by filtration and dried to obtain 9.49 g of t-butyl[2-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a pale brown solid. Further, the solid precipitated from the filtrate was collected by filtration to obtain 665 mg of t-butyl[2-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a white solid.
Preparation Example 380
670 mg of t-butyl 1-[(benzyloxy)methyl]-6-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was stirred at room temperature for 3.5 hours in a 48% aqueous hydrobromic acid solution. The reaction mixture was extracted with hexane and a side-product, benzyl bromide, was removed. Then, the aqueous layer was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, and 20 ml of tetrahydrofuran was added thereto. To the mixed liquid was added 500 mg of di-t-butyl dicarbonate, followed by stirring at room temperature for 2 hours. The reaction mixture was extracted with ethyl acetate and the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure to obtain 513 mg of t-butyl 6-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless foamed substance.
Preparation Example 381
Under an argon atmosphere, to a solution of 1.7 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 30 ml of DMF was added 283 mg of sodium hydride under ice-cooling, followed by stirring at the same temperature for 10 minutes. Then, 1.54 g of t-butyl (4R)-4-methyl-2,2-dioxo-[1,2,3]oxathiazolidine-3-carboxylate was added thereto, followed by stirring at room temperature for 18 hours. To the reaction mixture was added water and 1 M aqueous hydrochloric acid sequentially, followed by stirring, and the precipitated solid was collected by filtration. To 20 ml of a suspension of the resulting solid in ethanol was added 10 ml of a 4 M hydrogen chloride-ethyl acetate solution under ice-cooling, followed by stirring at 60° C. for 1 hour. The reaction mixture was evaporated under reduced pressure, and to the residue were added chloroform and saturated aqueous sodium bicarbonate. After extraction with chloroform, the combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain 2.26 g of ethyl 7-{[(2R)-2-aminopropyl]oxy}-8-bromo-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as an opaque cream-colored oily substance.
Preparation Example 383
Under an argon atmosphere, to a solution of 1.64 g of ethyl 7-{[(2R)-2-aminopropyl]oxy}-8-bromo-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 41 ml of toluene were added 509 mg of sodium t-butoxide, 275 mg of 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and 202 mg of tris(dibenzylideneacetone)dipalladium (0) in this order, followed by heating at 100° C. for 24 hours. Further, 509 mg of sodium t-butoxide, 275 mg of 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and 202 mg of tris(dibenzylideneacetone)dipalladium (0) were added thereto, followed by stirring at 100° C. for additional 24 hours. The reaction mixture was returned to room temperature, then filtered through celite, and washed with ethyl acetate, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 610 mg of ethyl (3R)-3-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.
Preparation Example 385
Under an argon atmosphere, to a solution of 1.032 g of ethyl 7-[(3-methylbut-2-enoyl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 10.5 ml of dichloromethane was added 870 mg of aluminum chloride at room temperature, followed by stirring at room temperature for 3 hours. Further, 435 mg of aluminum chloride was added thereto, followed by stirring at room temperature for 2 hours. The reaction mixture was poured into ice-water, followed by extraction with chloroform. The combined organic layer was washed with water, a saturated aqueous sodium hydrogen carbonate solution, water, and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 431 mg of ethyl 4,4-dimethyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white solid.
Preparation Example 386
Under an argon atmosphere, to a solution of 1 g of ethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate and 539 mg of 1,1-dimethylprop-2-in-1-yl acetate in 10 ml of tetrahydrofuran was added 43 mg of copper chloride, followed by heating at 90° C. for 5 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate added, and washed with a saturated aqueous ammonium chloride solution, and saturated brine. The aqueous layer was extracted with ethyl acetate twice, the combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography to obtain 272 mg of ethyl 2,2-dimethyl-1,2,6,7,9,10-hexahydro-8H-azepine[4,5-g]quinoline-8-carboxylate.
Preparation Example 387
To ethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was added a 5% aqueous sulfuric acid solution, followed by stirring under ice-cooling. An aqueous solution (30 ml) of 10.22 g of sodium nitrite was added dropwise in portions thereto, and followed by stirring at the same temperature for 0.5 hours and then stirring at 60° C. for 3 hours. The reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain a crude purified product having ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a main component. The crude purified product was recrystallized from ethyl acetate twice to obtain 15.66 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate.
Preparation Example 388
To a solution of 30 g of ethyl 7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 300 ml of ethanol was added 3 g of 10% palladium on carbon, followed by stirring at room temperature for 16 hours under a hydrogen atmosphere of 4 atm. The reaction mixture was filtered through celite, and the filtrate was ice-cooled and then 21.6 ml of anhydrous acetic acid was added dropwise thereto, followed by stirring for 16 hours. The reaction mixture was concentrated under reduced pressure and to the residue was added diethylether to wash the solid, thereby obtaining 26.45 g of ethyl 7-acetamide-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a white solid.
Preparation Example 389
The mixed liquid of 12 g of ethyl 7-acetamide-8-bromo-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate, 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline, and 33.12 g of cesium carbonate in 240 ml of dioxane was substituted with argon, followed by stirring at 100° C. for 18 hours. The reaction mixture was diluted with ethyl acetate, the insoluble materials were removed using celite, and the filtrate was concentrated under reduced pressure to obtain a milky white solid. The resulting residue was suspended in 240 ml of dioxane, and 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline, and 33.1 g of cesium carbonate were added thereto, followed by stirring at 100° C. for 3 days. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and filtered through celite to remove the solid, and the filtrate was concentrated under reduced pressure to obtain 9.245 g of ethyl 2-methyl-5,6,8,9-tetrahydro-7H-[1,3]oxazolo[4,5-h][3]benzazepine-7-carboxylate as a milky white solid.
Preparation Example 390
To a solution of 7 g of ethyl 2-methyl-5,6,8,9-tetrahydro-7H-[1,3]oxazolo[4,5-h][3]benzazepine-7-carboxylate in 130 ml of ethanol was added 130 ml of 1 M aqueous hydrochloric acid, followed by stirring for 16 hours. Ethanol was evaporated under reduced pressure, dried, dissolved in chloroform, and washed with water. The organic layer was dried over anhydrous sodium sulfate and then the solvent was evaporated under reduced pressure to obtain 6.84 g of ethyl 7-acetamide-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a brownish white solid.
Preparation Example 408
To a solution of 860 mg of t-butyl 4-ethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 25 ml of dichloroethane was added 1.1 g of sodium hydrogen carbonate, and further, a solution of 200 μl of bromine in 5 ml of dichloroethane was added dropwise thereto over about 30 minutes, followed by stirring at room temperature. To the reaction mixture was slowly added a 3% aqueous sodium thiosulfate solution, followed by stirring vigorously and extracting with chloroform twice. The combined organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. The solvent was evaporated and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 490 mg of t-butyl 5-bromo-4-ethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.
Preparation Example 409
Under an argon atmosphere, to a mixed solution of 5.0 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 100 ml of dichloromethane and 20 ml of methanol was added portionwise 8.05 g of N,N,N-trimethylanilinium tribromide under ice-cooling, followed by stirring at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, the residue was extracted by the addition of ethyl acetate and water, and the organic layer was washed with 1 M aqueous hydrochloric acid and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure to obtain 6.67 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a beige solid.
Preparation Example 411
To a solution of 150 mg of t-butyl 1-(3-methoxypropyl)-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 4.2 ml of acetonitrile were added 107 mg of N-bromosuccinimide and 3.7 mg of ammonium nitrate, followed by stirring at room temperature for 3.5 hours. The reaction mixture was concentrated to about 1⁄4, and ethyl acetate, an aqueous sodium thiosulfate solution, and aqueous sodium bicarbonate was added thereto. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated to obtain 198 mg of t-butyl 11-bromo-1-(3-methoxypropyl)-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
Preparation Example 426
To a solution of 16.23 g of ethyl 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoate in 200 ml of ethanol was added 150 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 2 hours. The reaction mixture was made weakly acidic by the addition dropwise of concentrated hydrochloric acid and diluted by the addition of water. The precipitated solid was collected by filtration and dried to obtain 8.88 g of 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoic acid as a pale brown solid.
Preparation Example 427
To 3.421 g of ethyl 8-acetamide-6-bromo-7-(2-ethoxy-2-oxoethoxy)-1,2,4,5-tetrahydro-3H-benzazepine-3-carboxylate were added 30 ml of acetic acid and 30 ml of 8 M hydrochloric acid, followed by stirring at 150° C. for 16 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in 35 ml of THF, and alkalified by the addition of 35 ml of a 1 M aqueous sodium hydroxide solution. 2 g of di-t-butyl dicarbonate was added thereto, followed by stirring at room temperature for 1 hour. The reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 1.373 g of t-butyl 11-bromo-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.
Preparation Example 495
To a solution of 590 mg of t-butyl 4-benzyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 10 ml of tetrahydrofuran was added 3.5 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by stirring at room temperature for 14 hours. The reaction mixture was cooled, and MeOH and a 1 M aqueous sodium hydroxide solution were added thereto, followed by stirring at room temperature for 3 hours. The reaction mixture was concentrated, to the residue were added ethyl acetate and water, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated, and to a solution of 578 mg of the resulting residue in 10 ml of dichloromethane was added 620 mg of sodium hydrogen carbonate. Further, a solution of 280 mg of bromine in 5 ml of dichloromethane was added dropwise thereto over about 30 minutes, followed by stirring at room temperature. To the reaction mixture was slowly added a 3% aqueous sodium thiosulfate solution, followed by stirring vigorously and extracting with chloroform twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 518 mg of t-butyl 4-benzyl-5-bromo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.
Preparation Example 540
To a solution of 210 mg of 2,4,5-trifluorobenzonitrile and 500 mg of t-butyl 5-cyclopropyl-4-(2-hydroxyethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 15 ml of THF was added portionwise 150 mg of potassium t-butoxide, followed by stirring at −30° C. for 2 hours. Further, to the reaction mixture was added 0.15 ml of MeOH and then 150 mg of potassium t-butoxide was added portionwise thereto, followed by elevating the temperature to −10° C. and stirring for 15 hours. Further, to the reaction mixture were added 0.15 ml of MeOH, and then 150 mg of potassium t-butoxide was added portionwise thereto, followed by elevating the temperature to 0° C. and stirring for additional 14 hours. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc)) to obtain 726 mg of t-butyl 4-[2-(4-cyano-2-fluoro-5-methoxyphenoxy)ethyl]-5-cyclopropyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a colorless viscous substance.
Preparation Example 543
To a solution of 270 mg of t-butyl 5-cyclopropyl-4-[2-(2,6-difluoro-4-formylphenoxy)ethyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 6 ml of MeOH was added 30 mg of sodium borohydride, followed by stirring at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc)) to obtain 220 mg of t-butyl 5-cyclopropyl-4-{2-[2,6-difluoro-4-(hydroxymethyl)phenoxy]ethyl}-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white solid.
Preparation Example 545
To a solution of 400 mg of t-butyl 5-cyclopropyl-4-(2-hydroxyethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of dichloromethane were added 217 mg of p-toluenesulfonyl chloride, 0.22 ml of triethylamine, and 125 μl of N-methylimidazole in this order, followed by stirring for 1 hour. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 541 mg of t-butyl 5-cyclopropyl-4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(211)-carboxylate as a white solid.
Preparation Example 549
To 400 mg of t-butyl 5-cyclopropyl-4-[(2R)-2-methoxy-3-{[(4-methylphenyl)sulfonyl]oxy}propyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate was added 7 ml of a 1 M solution of tetrabutylammonium fluoride in THF, followed by heating and stirring at 60° C. for 13 hours under an argon atmosphere. The reaction mixture was cooled to room temperature and a saturated aqueous sodium hydrogen carbonate solution was added thereto, followed by extraction with ethyl acetate twice. The combined organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 257 mg of t-butyl 5-cyclopropyl-4-[(2R)-3-fluoro-2-methoxypropyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white foamed solid.
Preparation Example 565
To a solution of 300 mg of t-butyl 5-cyclopropyl-4-(2-hydroxy-3-methoxypropyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 3 ml of toluene were added 0.1 ml of o-fluorophenol and 250 mg of cyanomethylenetributylphosphorane, followed by stirring at 80° C. for 20 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 277 mg of t-butyl 5-cyclopropyl-4-[2-(2-fluorophenoxy)-3-methoxypropyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a pale yellow viscous substance.
In the same manner as in the methods of Preparation Examples above, the compounds of Preparation Examples as shown in the Tables below were prepared. For the compounds of the Preparation Examples, the structures are shown in Tables 2 to 81 and the preparation methods and the physicochemical data are shown in Tables 82 to 96.
Example 1
To 1.865 g of ethyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 20 mL of ethylene glycol and 20 mL of a 40% aqueous potassium hydroxide solution, followed by heating to 120° C. for 18 hours. The reaction mixture was ice-cooled and adjusted to pH 1 by the addition of concentrated hydrochloric acid, followed by stirring for 1 hour. The reaction mixture was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 1.451 g of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one as a brown solid. To 60 mg of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one were added 1 ml of EtOAc and then EtOH, followed by dissolution under heating. The precipitated solid was collected by filtration to obtain 29.5 mg of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one as a white solid.
Example 2
To 47 mg of t-butyl 11-chloro-1-isobutyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was added 1 ml of a 4 M hydrogen chloride solution in EtOAc, followed by stirring at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by amino-silica gel chromatography (elution solvent: chloroform-MeOH). 26 mg of the resulting pale yellow viscous substance was dissolved in EtOH, followed by addition of 10.3 mg of fumaric acid and stirring. The precipitated solid was collected by filtration to obtain 23.2 mg of 11-chloro-1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate as a white solid.
Example 3
To a solution of 200 mg of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of THF was added 1.9 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by elevating the temperature to room temperature and stirring for 6 hours, and then elevating the temperature to 45° C. After stirring for 3 hours, 1.9 ml of a 1 M solution of a borane-THF complex in THF was added thereto in an ice-bath. After an additional 2 hours, MeOH was added dropwise thereto, followed by stirring for 20 minutes. The mixed solution was diluted with water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in 1.6 ml of dichloromethane, and 0.4 ml of trifluoroacetic acid was added thereto, followed by stirring at room temperature for 1 hour and then concentrating under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH— aqueous ammonia), and the resulting solid was dissolved in 0.25 ml of hot EtOH, followed by addition of 21 mg of fumaric acid. While stirring, the resultant was cooled to room temperature and the precipitated solid was filtered to obtain 36 mg of 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate as a pale yellow solid.
Example 4
To 150 mg of ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 4 ml of ethylene glycol and 2 ml of a 40% aqueous potassium hydroxide solution, followed by heating at 120° C. and stirring for 18 hours. The reaction mixture was ice-cooled and the liquid was made acidic by the addition of concentrated hydrochloric acid, followed by stirring for an additional 1 hour. The reaction mixture was neutralized with a 1 M aqueous sodium hydroxide solution and then extracted with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. Then, the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). To a solution of the resulting residue in 2 ml of EtOAc was added 0.2 ml of a 4 M hydrogen chloride solution in EtOAc, followed by stirring. The solvent was concentrated under reduced pressure and the resulting solid was dissolved in 2 ml of EtOH under heating, followed by stirring at room temperature. The precipitated solid was collected by filtration to obtain 43.7 mg of 1-methyl-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one monohydrochloride as a pale yellow solid.
Example 5
To a solution of 140 mg of t-butyl 11-cyclopropyl-1-(methoxyacetyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 1 ml of EtOH was added 2 ml of 4 M hydrogen chloride solution in EtOAc, followed by stirring at room temperature for 3 hours. The reaction mixture was poured into a 1 M aqueous sodium hydroxide solution, the aqueous layer was extracted with chloroform, and the organic layer was dried over sodium sulfate. The solvent was concentrated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH-aqueous ammonia) to obtain 102 mg of 11-cyclopropyl-1-(methoxyacetyl)-2,3,4,6,7,8,9,10-octahydro-8H-azepino[4,5-g]quinoline as a pale yellow oily substance.
Example 6
To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2.13 ml of dichloroethane were added 0.553 ml of triethylamine and 0.19 ml of ethyl chloroformate, followed by stirring at 60° C. for 2 hours. The reaction mixture was cooled to room temperature, and then the reaction mixture was diluted with EtOAc, washed with 1 M hydrochloric acid, water, a 1 M aqueous sodium hydroxide solution, and saturated brine, and concentrated, and the residue was purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in chloroform, followed by adding 0.05 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 76 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 79 mg of ethyl 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4.5-g]quinoline-1-carboxylate hemifumarate.
Example 7
To a solution of 300 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 5.26 ml of pyridine was added 0.455 ml of N,N-dimethylcarbamoyl chloride, followed by stirring at 80° C. for 3 hours. To the reaction mixture was added 1 M hydrochloric acid, followed by extraction with EtOAc. The organic layer was washed with saturated brine and the solvent was evaporated. The resulting residue was purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 6 ml of chloroform, followed by adding 3 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in 4.5 ml of EtOH and 115 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 120 mg of N,N-dimethyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline-1-carboxamide fumarate.
Example 8
To a solution of 300 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of toluene was added 1.16 ml of ethyl isocyanate, followed by stirring at 90° C. overnight. The reaction mixture was concentrated under reduced pressure and then purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 7.5 ml of chloroform, followed by adding 3 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 115 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 247 mg of N-ethyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline-1-carboxamide monofumarate.
Example 9
To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of dichloromethane were added 0.148 ml of triethylamine, 0.093 ml of ethanesulfonyl chloride, and 54 mg of 1-methylimidazole under ice-cooling, followed by stirring at room temperature overnight. To the reaction mixture were added EtOAc and saturated brine, and the organic layer was washed with saturated brine and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 4 ml of chloroform, followed by adding 2 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 76 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 61 mg of 1-(ethylsulfonyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate.
Example 112
To a solution of 283 mg of t-butyl 4-(3-chlorobenzyl)-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 1.8 ml of tetrahydrofuran was added 1.46 ml of a 1 M solution of a borane-THF complex in THF, followed by stirring at 50° C. for 4 hours. The reaction mixture was ice-cooled, and MeOH was added thereto, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and MeOH was added thereto, followed by concentration again. The residue was dissolved in 2.8 ml of EtOH, and 4 M hydrogen chloride-ethyl acetate solution was added thereto, followed by stirring overnight. After concentration under reduced pressure, the resultant was dissolved in EtOH, neutralized by the addition of triethylamine, and concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH). The resulting substance was dissolved in ethanol and fumaric acid was added thereto, followed by stirring for a while. The solid was generated, then dissolved by heating once, and stirred at room temperature for 3 hours. The resulting white solid was collected by filtration and dried to obtain 23 mg of 4-(3-chlorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine fumarate.
Example 282
To a solution of 606 mg of t-butyl 11-bromo-1-(2-methoxyethyl)-10-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of dichloromethane was added 3 ml of trifluoroacetic acid, followed by stirring at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and the residue was purified by basic silica gel chromatography (elution solvent: chloroform-MeOH). 150 mg of the resulting residue was collected by separation using DAICEL CHIRALPAK AD-H (2 cmφ×25 cm) to obtain 51 mg of a low-polarity material and 45 mg of a high-polarity material. Each was dissolved in ethanol and fumaric acid was added thereto to form a salt. The precipitated solid was recrystallized from ethanol to obtain 42 mg and 36 mg of enantiomers of 11-bromo-1-(2-methoxyethyl)-10-methyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline fumarate as white solids, respectively.
In this regard, while the products are shown with a single planar structure in the Tables below with respect to the compounds of Example 282, and Example 280 and Example 281 in which preparation was performed as in Example 282, each of two kinds of enantiomers was isolated and obtained similarly as described above but the stereochemistry identification was not carried out.
In the same manner as in the methods of Examples above, the compounds of Examples shown in the Tables below were prepared. The structure of the compounds of the Examples are shown in Tables 97 to 147 and the preparation methods and the physicochemical data are shown in Tables 148 to 181.
Furthermore, the structures of the other compounds of the present invention are shown in Tables 182 to 190. These can be easily synthesized by the methods described in the preparation methods and Examples above, methods apparent to a person skilled in the art, or modified methods thereof.










TABLE 2







PEx
Str









1







 



2







 



3







 



4







 



5







 



6







 



7







 



8
























TABLE 3







PEx
Str









 9







 



10







 



11







 



12







 



13







 



14







 



15







 



16







 



17
























TABLE 4







PEx
Str









18







 



19







 



20







 



21







 



22







 



23







 



24







 



25
























TABLE 5







PEx
Str









26







 



27







 



28







 



29







 



30







 



31







 



32







 



33
























TABLE 6







PEx
Str









34







 



35







 



36







 



37







 



38







 



39







 



40







 



41






















TABLE 7





PEx
Str







42






 


43






 


44






 


45






 


46






 


47






 


48






 


49






 


50






 


51





















TABLE 8





PEx
Str







52






 


53






 


54






 


55






 


56






 


57






 


58






 


59






 


60





















TABLE 9





PEx
Str







61






 


62






 


63






 


64






 


65






 


66






 


67






 


68






 


69





















TABLE 10





PEx
Str







70






 


71






 


72






 


73






 


74






 


75






 


76






 


77






 


78





















TABLE 11





PEx
Str







79






 


80






 


81






 


82






 


83






 


84






 


85






 


86





















TABLE 12





PEx
Str







87






 


88






 


89






 


90






 


91






 


92






 


93






 


94





















TABLE 13





PEx
Str
















95






 


96






 


97






 


98






 


99






 


100






 


101






 


102





















TABLE 14





PEx
Str







103






 


104






 


105






 


106






 


107






 


108






 


109





















TABLE 15





PEx
Str







110






 


111






 


112






 


113






 


114






 


115





















TABLE 16





PEx
Str







116






 


117






 


118






 


119






 


120






 


121





















TABLE 17





PEx
Str







122






 


123






 


124






 


125






 


126






 


127






 


128






 


129





















TABLE 18





PEx
Str







130






 


131






 


132






 


133






 


134






 


135






 


136





















TABLE 19





PEx
Str







137






 


138






 


139






 


140






 


143





















TABLE 20





PEx
Str







144






 


145






 


146






 


149






 


150






 


151





















TABLE 21





PEx
Str







152






 


153






 


154






 


155






 


156






 


157






 


158























TABLE 22







PEx
Str









159







 



160







 



161







 



162







 



163







 



164







 



165
























TABLE 23







PEx
Str









166







 



167







 



168







 



169







 



170







 



171







 



172







 



173
























TABLE 24







PEx
Str









175







 



176







 



177







 



178







 



179







 



180







 



181
























TABLE 25







PEx
Str









182







 



183







 



184







 



185







 



186







 



187







 



188







 



189
























TABLE 26







PEx
Str









190







 



192







 



193







 



195







 



196







 



197
























TABLE 27







PEx
Str









198







 



199







 



200







 



201







 



202







 



203







 



204
























TABLE 28







PEx
Str









205







 



206







 



207







 



208







 



209







 



210







 



211






















TABLE 29





PEx
Str







212






 


213






 


214






 


215






 


216






 


217





















TABLE 30





PEx
Str







218






 


219






 


220






 


221






 


222






 


223























TABLE 31







PEx
Str









224







 



225







 



226







 



227







 



228







 



229







 



230
























TABLE 32







PEx
Str









231







 



232







 



233







 



234







 



235







 



236







 



237
























TABLE 33







PEx
Str









238







 



239







 



240







 



241







 



242







 



243







 



244
























TABLE 34







PEx
Str









245







 



246







 



247







 



248







 



249







 



250






















TABLE 35





PEx
Str







251






 


252






 


253






 


254






 


255






 


256






 


257























TABLE 36







PEx
Str









258







 



259







 



260







 



261







 



262







 



263







 



264
























TABLE 37







PEx
Str









265







 



266







 



267







 



268







 



269







 



270







 



271






















TABLE 38





PEx
Str







272






 


273






 


274






 


275






 


276






 


277























TABLE 39







PEx
Str









278







 



279







 



280







 



281







 



282







 



283
























TABLE 40







PEx
Str









284







 



285







 



286







 



287







 



288







 



289
























TABLE 41







PEx
Str









290







 



291







 



292







 



293







 



294







 



295







 



296







 



297
























TABLE 42







PEx
Str









298







 



299







 



300







 



301







 



302







 



303
























TABLE 43







PEx
Str









304







 



305







 



306







 



307







 



308







 



309







 



310
























TABLE 44







PEx
Str









311







 



312







 



313







 



314







 



315







 



316
























TABLE 45







PEx
Str









317







 



318







 



319







 



320







 



321







 



322







 



323
























TABLE 46







PEx
Str









324







 



325







 



326







 



327







 



328







 



329







 



330
























TABLE 47







PEx
Str









331







 



332







 



333







 



334







 



335







 



336







 



337






















TABLE 48





PEx
Str







338






 


339






 


340






 


341






 


342






 


343






 


344






 


345





















TABLE 49





PEx
Str







346






 


347






 


348






 


349






 


350






 


351






 


352






 


353





















TABLE 50





PEx
Str







354






 


355






 


356






 


357






 


358






 


359






 


360






 


361





















TABLE 51





PEx
Str







362






 


363






 


364






 


365






 


366






 


367






 


368






 


369





















TABLE 52





PEx
Str







370






 


371






 


372






 


373






 


374






 


375






 


376






 


377





















TABLE 53





PEx
Str







378






 


379






 


380






 


381






 


382






 


383






 


384






 


385






 


386





















TABLE 54





PEx
Str







387






 


388






 


389






 


390






 


391






 


392






 


393





















TABLE 55





PEx
Str







394






 


395






 


396






 


397






 


398






 


399






 


400






 


401





















TABLE 56





PEx
Str







402






 


403






 


404






 


405






 


406






 


407






 


408





















TABLE 57





PEx
Str







409






 


410






 


411






 


412






 


413






 


414






 


415






 


416





















TABLE 58





PEx
Str







417






 


418






 


419






 


420






 


421






 


422






 


423





















TABLE 59





PEx
Str







424






 


425






 


426






 


427






 


428






 


429






 


430






 


431





















TABLE 60





PEx
Str







432






 


433






 


434






 


435






 


436






 


437






 


438






 


439





















TABLE 61





PEx
Str







440






 


441






 


442






 


443






 


444






 


445






 


446





















TABLE 62





PEx
Str







447






 


448






 


449






 


450






 


451






 


452






 


453





















TABLE 63





PEx
Str







454






 


455






 


456






 


457






 


458






 


459





















TABLE 64





PEx
Str







460






 


461






 


462






 


463






 


464






 


465






 


466






 


467





















TABLE 65





PEx
Str







468






 


469






 


470






 


471






 


472






 


473






 


474





















TABLE 66





PEx
Str







475






 


476






 


477






 


478






 


479






 


480






 


481





















TABLE 67





PEx
Str







482






 


483






 


484






 


485






 


486






 


487























TABLE 68







PEx
Str









488







 



489







 



490







 



491







 



492







 



493
























TABLE 69







PEx
Str









494







 



495







 



496







 



497







 



498







 



499
























TABLE 70







PEx
Str









500







 



501







 



502







 



503







 



504







 



505






















TABLE 71





PEx
Str







506






 


507






 


508






 


509






 


510






 


511






 


512






 


513























TABLE 72







PEx
Str









514







 



515







 



516







 



517







 



518







 



519







 



520







 



521
























TABLE 73







PEx
Str









522







 



523







 



524







 



525







 



526







 



527
























TABLE 74







PEx
Str









528







 



529







 



530







 



531







 



532







 



533






















TABLE 75





PEx
Str







534






 









535




.


 


536







 


537







 


538







 


539





















TABLE 76





PEx
Str







540






 


541






 


542






 


543






 


544























TABLE 77







PEx
Str









545







 



546







 



547







 



548







 



549







 



550
























TABLE 78







PEx
Str









551







 



552







 



553







 



554







 



555







 



556
























TABLE 79







PEx
Str









557







 



558







 



559







 



560







 



561







 



562






















TABLE 80





PEx
Str







563






 


564






 


565






 


566






 


567






 


568





















TABLE 81





PEx
Str







569






 


570






 


571






 


572






 


573






 


574
























TABLE 82







PEx
Psyn
Dat




















1
1
EI: 296, 298, 300



2
2
EI: 190, 192



3
3
EI: 209, 211



4
4
ESI+: 254, 256



5
5
FAB+: 299, 301



6
6
EI: 268, 270



7
7
EI: 346, 348, 350



8
8
ESI+: 367, 369



9
9
EI: 322, 324



10
10
ESI+: 351, 353



11
11
ESI+: 337, 339



12
12
ESI+: 351, 353



13
13
ESI+: 407



14
14
APCI+: 220



15
15
ESI+; 303



16
71
ESI+; 331



17
17
ESI+; 359



18
18
ESI+; 317



19
19
ESI+; 345



20
20
ESI+; 419



21
21
ESI+: 403



22
22
ESI+: 417([M + Na]+)



23
23
FAB−: 331



24
24
ESI+: 333



25
25
ESI+: 361



26
26
ESI+: 383, 405([M + Na]+)



27
27
ESI+: 448



28
28
ESI+: 350



29
29
ESI+: 393



30
30
ESI+: 349



31
31
ESI+: 331



32
32
ESI+: 388



33
33
ESI+: 389



34
34
ESI+: 291



35
35
ESI+: 403



36
36
FAB+: 537



37
37
ESI+: 577



38
38
ESI+: 473([M + Na]+)



39
39
EI: 315



40
40
FAB+: 320





















TABLE 83







PEx
Psyn
Dat




















41
41
FAB+: 333



42
42
ESI+: 359



43
27
EI: 181



44
4
ESI+: 182, 184



45
19
ESI+: 235



46
7
EI; 312



47
8
ESI+; 333



48
5
EI; 264



49
9
EI; 288



50
22
ESI+: 403([M + Na]+)



51
15
ESI+: 333



52
11
ESI+: 319



53
11
ESI+: 365, 367



54
11
ESI+: 305



55
13
ESI+: 393, 395



56
13
ESI+: 407, 409



57
13
ESI+: 409, 411



58
23
FAB−: 317



59
11
ESI+; 317



60
15
ESI+: 347, 369([M + Na]+)



61
11
ESI+: 379, 381



62
11
ESI+: 395, 397



63
11
ESI+: 393, 395



64
11
ESI+: 333



65
11
ESI+: 319



66
25
ESI+: 333



67
7
ESI+: 383, 385



68
18
ESI+: 319



69
25
ESI+: 347



70
24
APCI+: 333



71
71
ESI+; 317



72
11
ESI+; 303



73
7
ESI+: 381, 383



74
11
ESI+; 331



75
13
FAB+; 345



76
24
ESI+: 397, 399



77
13
ESI+; 373



78
18
ESI+: 345



79
13
ESI+: 405, 407



80
13
ESI+: 419, 421





















TABLE 84







PEx
Psyn
Dat




















81
11
ESI+: 391, 393



82
11
ESI+: 405, 407



83
13
ESI+: 433, 435



84
13
ESI+: 441, 443



85
18
ESI+; 379



86
15
ESI+; 331



87
11
ESI+: 419, 421



88
11
ESI+: 427, 429



89
13
ESI+: 447, 449



90
11
ESI+: 433, 435



91
22
ESI+: 431([M + Na]+)



92
23
FAB−: 331



93
11
ESI+: 319



94
24
ESI+: 363



95
24
ESI+: 359



96
13
ESI+: 375



97
24
ESI+: 361



98
15
ESI+: 391



99
11
ESI+: 377



100
15
ESI+: 431([M + Na]+)



101
15
ESI+: 375



102
17
ESI+: 437



103
11
ESI+: 395



104
11
ESI+: 361



105
15
ESI+: 391



106
11
ESI+: 377



107
15
ESI+: 417



108
11
ESI+: 403



109
7
ESI+: 361



110
18
ESI+: 381



111
17
ESI+; 361



112
18
ESI+; 409



113
18
ESI+; 447, 449



114
18
ESI+; 413, 415



115
17
ESI+; 471, 473



116
17
ESI+; 505, 507



117
18
ESI+; 397



118
17
ESI+; 465



119
12
ESI+: 363



120
13
ESI+: 403





















TABLE 85







PEx
Psyn
Dat









121
17
ESI+; 467



122
17
ESI+; 455



123
15
ESI+; 375



124
18
ESI+; 343



125
17
ESI+; 399



126
17
ESI+; 401



127
15
ESI+: 405



128
11
ESI+: 391



129
11
ESI+: 389



130
18
ESI+: 395



131
13
ESI+: 467



132
11
ESI+: 453



133
15
ESI+: 391



134
15
ESI+: 405



135
11
ESI+: 377



136
11
ESI+: 391



137
18
ESI+; 343



138
13
ESI+: 439([M + Na]+)



139
12
ESI+: 347



140
11
ESI+: 403



143
11
ESI+: 389



144
22
ESI+: 406



145
27
ESI+: 226



146
27
EI: 195



149
21
ESI+: 387



150
17
ESI+; 403



151
28
ESI+: 392



152
13
ESI+: 391



153
29
ESI+: 322



154
41
ESI+: 421



155
41
ESI+: 393



156
11
ESI+: 319



157
42
ESI+: 397, 399



158
11
ESI+: 373



159
18
ESI+: 395, 417([M + Na]+)



160
13
ESI+: 431



















TABLE 86





PEx
Psyn
Dat







161
13
ESI+: 389


162
13
ESI+: 417


163
11
ESI+: 417


164
11
ESI+: 377


165
11
ESI+: 381


166
12
ESI+: 351


167
18
ESI+: 331


168
18
ESI+: 345


169
19
ESI+: 333


170
11
ESI+: 375


171
11
ESI+: 361


172
18
ESI+: 329


173
19
ESI+; 331


175
13
ESI+: 405


176
21
ESI+: 391


177
17
ESI+; 389


178
18
ESI+; 359


179
11
ESI+: 391


180
11
ESI+: 377


181
19
ESI+: 347


182
13
FAB+: 419


183
11
ESI+: 277


184
11
ESI+: 405


185
15
FAB+: 379


186
11
ESI+: 365


187
13
ESI+: 453([M + Na]+)


188
11
ESI+: 417


189
13
ESI+: 457, 479([M + Na]+)


190
11
ESI+: 443


192
13
ESI+: 431, 453([M + Na]+)


193
11
ESI+: 417


195
22
NMR: 1.19(3H, t, J = 7.1 Hz), 1.38(9H, s),




1.54(6H, s), 2.80-2.93(4H, br), 3.39-3.51(4H, br),




4.20(2H, q, J = 7.1 Hz), 6.79(1H, s), 7.68(1H, s)


196
22
ESI+: 457, 459


197
22
ESI+: 413, 415


198
22
ESI+: 431([M + Na]+)


199
22
ESI+: 447([M + Na]+)


200
22
ESI+: 459([M + Na]+)




















TABLE 87







PEx
Psyn
Dat









201
18
ESI+: 439



202
18
ESI+: 435



203
18
ESI+: 399



204
18
ESI+: 405



205
18
ESI+: 345



206
18
ESI+: 417



207
18
ESI+: 359



208
18
ESI+: 457



209
18
ESI+: 417



210
18
ESI+: 465



211
18
ESI+: 403



212
18
ESI+: 439



213
18
ESI+: 445



214
18
ESI+: 445



215
18
ESI+: 427



216
18
ESI+: 493



217
18
ESI+: 453



218
18
ESI+: 383



219
18
ESI+: 493



220
18
ESI+: 529



221
18
ESI+: 535



222
18
ESI+: 385



223
18
ESI+: 427



224
18
ESI+: 417



225
18
ESI+: 403



226
18
ESI+: 429, 451([M + Na]+)



227
18
ESI+: 417



228
18
ESI+: 405, 427([M + Na]+)



229
18
ESI+: 401



230
18
ESI+: 395



231
18
ESI+: 345



232
18
ESI+: 359



233
18
ESI+: 383



234
18
ESI+: 415



235
18
ESI+: 415



236
18
ESI+: 429



237
18
ESI+: 405



238
18
ESI+: 431



239
18
ESI+: 347



240
18
ESI+: 391





















TABLE 88







PEx
Psyn
Dat









241
18
ESI+: 401



242
18
ESI+: 391



243
18
ESI+: 379



244
18
ESI+: 427



245
18
ESI+: 427



246
18
ESI+: 403



247
18
ESI+: 403



248
18
ESI+: 379



249
18
ESI+: 435



250
18
ESI+: 469, 471



251
18
ESI+: 469, 471



252
18
ESI+: 453



253
18
ESI+: 391



254
18
ESI+: 453



255
13
ESI+: 459, 481([M + Na]+)



256
13
ESI+: 317



257
13
ESI+: 401



258
13
ESI+: 403



259
13
ESI+: 427



260
13
ESI+: 391



261
13
ESI+: 391



262
13
ESI+: 445, 467([M + Na]+)



263
13
ESI+: 485, 507([M + Na]+)



264
13
ESI+: 459, 481([M + Na]+)



265
13
ESI+: 467([M + Na]+)



266
13
ESI+: 457



267
13
ESI+: 443



268
13
ESI+: 457, 479([M + Na]+)



269
13
ESI+: 457



270
13
ESI+: 415, 437([M + Na]+)



271
13
ESI+: 445, 467([M + Na]+)



272
13
ESI+: 507



273
13
ESI+: 419



274
13
ESI+: 479



275
13
ESI+: 493



276
13
ESI+: 323([M-Boc]+)



277
13
ESI+: 529



278
13
ESI+: 529



279
13
ESI+: 491



280
13
ESI+: 507





















TABLE 89







PEx
Psyn
Dat




















281
13
ESI+: 463



282
13
ESI+: 463



283
13
ESI+: 485



284
13
ESI+: 385([M-Boc]+)



285
13
ESI+: 501



286
13
ESI+: 491



287
13
ESI+: 493



288
13
ESI+: 485



289
13
ESI+: 501



290
13
ESI+: 507



291
17
ESI+: 389



292
17
ESI+: 387



293
17
ESI+: 373



294
15
ESI+: 537



295
15
ESI+: 361, 383([M + Na]+)



296
15
ESI+: 375



297
15
ESI+: 447



298
15
ESI+: 447



299
15
ESI+: 417



300
15
ESI+: 523



301
15
ESI+: 391



302
20
ESI+: 433, 455([M + Na]+)



303
20
ESI+: 433



304
20
ESI+: 403



305
20
ESI+: 509



306
334
ESI+: 377



307
334
ESI+: 389



308
334
ESI+: 373



309
334
ESI+: 439



310
334
ESI+: 443, 445



311
334
ESI+: 391



312
334
ESI+: 465([M + Na]+), 467([M + Na]+)



313
334
ESI+: 465([M + Na]+), 467([M + Na]+)



314
334
ESI+: 461([M + Na]+)



315
334
ESI+: 416



316
334
ESI+: 410



317
334
ESI+: 439



318
334
ESI+: 437



319
334
ESI+: 359



320
334
ESI+: 405, 427([M + Na]+)





















TABLE 90







PEx
Psyn
Dat









321
334
ESI+: 403



322
334
ESI+: 377



323
334
ESI+: 405



324
334
ESI+: 403, 425([M + Na]+)



325
334
ESI+: 391, 413([M + Na]+)



326
334
ESI+: 379, 401([M + Na]+)



327
334
ESI+: 403



328
334
ESI+: 379, 401([M + Na]+)



329
334
ESI+: 405.427([M + Na]+)



330
334
ESI+: 389



331
334
ESI+: 419



332
334
ESI+: 401



333
334
ESI+: 401



334
334
ESI+: 416



335
334
ESI+: 391, 413([M + Na]+)



336
334
ESI+: 427



337
339
ESI+: 345



338
339
ESI+: 359



339
339
ESI+: 407



340
339
ESI+: 361



341
339
ESI+: 389



342
339
ESI+: 411, 413



343
339
ESI+: 389



344
344
ESI+: 365, 367



345
345
ESI+: 451



346
345
ESI+: 485, 487



347
345
ESI+: 485, 487



348
349
ESI+: 485, 487



349
349
ESI+: 481



350
349
ESI+: 481



351
349
ESI+: 453



352
349
ESI+: 509([M + Na]+), 511([M + Na]+)



353
349
ESI+: 509([M + Na]+), 511([M + Na]+)



354
349
ESI+: 509([M + Na]+), 511([M + Na]+)



355
349
ESI+: 483



356
349
ESI+: 483



357
349
ESI+: 471



358
349
ESI+: 471



359
349
ESI+: 471



360
349
ESI+: 531, 533



















TABLE 91





PEx
Psyn
Dat

















361
349
ESI+: 467


362
349
ESI+: 467


363
367
ESI+: 437


364
367
ESI+: 403


365
367
ESI+: 389


366
367
ESI+: 375


367
367
ESI+: 411, 413


368
27
ESI+: 448


369
38
ESI+: 451


370
28
ESI+: 350


371
29
ESI+: 393


372
30
ESI+: 349


373
31
ESI+: 331


374
37
ESI+: 577


375
375
ESI+: 383


376
376
ESI+: 386


377
377
ESI+: 425


378
377
ESI+: 427


379
379
ESI+: 417


380
380
ESI+: 331


381
381
NMR-C: 1.19(3H, d, J = 6.6 Hz), 1.28(3H, t, J = 7.1 Hz),




2.75-2.89(4H, m), 3.34-3.44(1H, m), 3.51-3.65(4H, m),




3.69(1H, dd, J = 8.7, 7.6 Hz), 3.93(1H, dd, J = 8.7,




4.1 Hz), 4.18(2H, q, J = 7.1 Hz), 6.66(1H, s), 7.28(1H, s)


382
381
ESI+: 371, 373


383
383
ESI+: 291


384
383
ESI+: 291


385
385
ESI+: 317


386
386
ESI+: 301


387
387
ESI+: 236


388
388
ESI+: 277


389
389
ESI+: 275


390
390
ESI+: 293


391
545
ESI+: 587


392
7
ESI+: 374


393
7
ESI+: 371, 373


394
7
ESI+: 327, 329


395
408
ESI+: 441, 443


396
408
ESI+: 455


397
408
ESI+: 457


398
408
ESI+: 443, 445


399
408
ESI+: 455, 457


400
408
ESI+: 465; 467


















TABLE 92





PEx
Psyn
Dat

















401
408
ESI+: 491; 493


402
408
ESI+: 467, 469


403
408
ESI+: 455, 457


404
408
ESI+: 443, 445


405
408
ESI+: 467, 469


406
408
ESI+: 443, 445


407
408
ESI+: 469, 471


408
408
ESI+: 413


409
409
ESI+: 314, 316


410
411
ESI+: 453; 455


411
411
ESI+: 467; 469


412
411
ESI+: 355, 357


413
411
ESI+: 437; 439


414
411
ESI+: 455


415
411
ESI+: 529, 531


416
411
ESI+: 467, 469


417
411
ESI+: 455, 457


418
411
ESI+: 479, 481


419
411
ESI+: 409, 411


420
411
ESI+: 455, 457


421
411
ESI+: 467, 469


422
411
ESI+: 467, 469


423
411
ESI+: 479, 481


424
411
ESI+: 479, 481


425
549
ESI+: 435


426
426
ESI+: 346


427
427
FAB−: 395, 397


428
427
ESI+: 353, 355


429
23
ESI+: 369([M + Na]+)


430
23
ESI+: 347, 369([M + Na]+)


431
23
ESI+: 385([M + Na]+)


432
23
ESI+: 361, 383([M + Na]+)


433
11
ESI+: 439, 441


434
11
NMR-C: 0.44-0.51(2H, m), 0.95(6H, s), 0.97-1.06(2H, m),




1.47(9H, s), 1.58-1.68(1H, m), 2.69-2.78(2H, m), 3.04(2H,




s), 3.06-3.18(4H, m), 3.21(3H, s), 3.29-3.36(2H,




m), 3.46-3.58(4H, m), 4.15-4.22(2H, m), 6.48(1H, s)


435
11
ESI+: 383, 385


436
11
ESI+: 377


437
11
ESI+: 331


438
11
ESI+: 345


439
11
ESI+: 453, 455


440
11
ESI+: 389




















TABLE 93







PEx
Psyn
Dat









441
11
ESI+: 441, 443



442
11
ESI+: 391



443
11
ESI+: 465, 467



444
11
ESI+: 387



445
11
ESI+: 389



446
11
ESI+: 339, 341



447
11
ESI+: 397, 399



448
11
ESI+: 413



449
11
ESI+: 395, 397



450
11
ESI+: 377



451
11
ESI+: 377



452
11
ESI+: 391



453
11
ESI+: 441, 443



454
11
ESI+: 389



455
11
ESI+: 377



456
11
ESI+: 365



457
11
ESI+: 453, 455



458
11
ESI+: 453, 455



459
11
ESI+: 389



460
11
ESI+: 365



461
11
ESI+: 431



462
11
ESI+: 471



463
11
ESI+: 445



464
11
ESI+: 333



465
11
ESI+: 349



466
11
ESI+: 347



467
11
ESI+: 391



468
11
ESI+: 405



469
11
ESI+: 347



470
11
ESI+: 361



471
11
ESI+: 465, 467



472
11
ESI+: 465



473
11
ESI+: 431



474
11
ESI+: 443



475
11
ESI+: 429



476
11
ESI+: 443



477
11
ESI+: 401



478
11
ESI+: 443



479
11
ESI+: 465



480
11
ESI+: 493





















TABLE 94







PEx
Psyn
Dat




















481
11
ESI+: 431



482
11
ESI+: 405



483
11
ESI+: 479



484
11
ESI+: 309([M-Boc]+)



485
11
ESI+: 515



486
11
ESI+: 515



487
11
ESI+: 477



488
11
ESI+: 493



489
11
ESI+: 449



490
11
ESI+: 449



491
11
ESI+: 377



492
11
ESI+: 471



493
11
ESI+: 471



494
11
ESI+: 487, 489



495
495
ESI+: 473, 475



496
495
ESI+: 507, 509



497
495
ESI+: 507, 509



498
495
EI: 491, 493



499
495
ESI+: 492, 493



500
12
ESI+: 429; 431



501
12
ESI+: 425



502
12
ESI+: 413



503
12
ESI+: 420



504
12
ESI+: 463



505
12
ESI+: 409



506
19
ESI+: 303



507
19
ESI+: 473



508
19
ESI+: 405



509
19
ESI+: 501



510
19
ESI+: 495



511
19
ESI+: 361



512
19
ESI+: 347



513
19
ESI+: 433



514
19
ESI+: 393



515
71
ESI+: 345



516
71
ESI+: 319



517
71
ESI+: 331



518
71
ESI+: 319



519
162
ESI+: 437, 439



520
162
ESI+: 435, 437





















TABLE 95







PEx
Psyn
Dat




















521
18
ESI+: 417



522
18
ESI+: 417



523
13
ESI+: 479



524
13
ESI+: 493



525
13
ESI+: 479



526
13
ESI+: 533



527
13
ESI+: 497



528
13
ESI+: 513



529
13
ESI+: 493



530
13
ESI+: 485



531
13
ESI+: 485



532
15
ESI+: 523



533
15
ESI+: 537



534
15
ESI+: 559



535
15
ESI+: 431



536
20
ESI+: 433



537
20
ESI+: 509



538
339
ESI+: 486



539
540
ESI+: 526



540
540
ESI+: 538



541
540
ESI+: 467



542
540
ESI+: 467



543
543
ESI+: 531



544
545
ESI+: 587



545
545
ESI+: 543



546
545
ESI+: 601



547
408
ESI+: 455, 457



548
408
ESI+: 455, 457



549
549
ESI+: 435



550
549
ESI+: 449



551
11
ESI+: 465



552
11
ESI+: 477



553
11
ESI+: 479



554
11
ESI+: 471



555
11
ESI+: 487, 489



556
11
ESI+: 493



557
11
ESI+: 479



558
11
ESI+: 465



559
11
ESI+: 519



560
11
ESI+: 479





















TABLE 96







PEx
Psyn
Dat




















561
11
ESI+: 483



562
11
ESI+: 499, 501



563
11
ESI+: 471



564
11
ESI+: 471



565
565
ESI+: 527



566
565
ESI+: 527



567
565
ESI+: 527



568
565
ESI+: 561, 563



569
565
ESI+: 563



570
565
ESI+: 545



571
19
ESI+: 433



572
19
ESI+: 447



573
20
ESI+: 363



574
15
ESI+: 377




















TABLE 97







Ex
Str









1







 



2 M







 



3 M







 



4







 



5







 



6 H







 



7 M







 



8 M
























TABLE 98







Ex
Str









 9 M







 



10 M







 



11







 



12 M







 



13 H







 



14 M







 



15







 



16
























TABLE 99







Ex
Str









17







 



18







 



19 M







 



20 M







 



21







 



22 H







 



23 H







 



24 M
























TABLE 100







Ex
Str









25 H







 



26 M







 



27 M







 



28 H







 



29







 



30







 



31 M







 



32 M
























TABLE 101







Ex
Str









33 M







 



34 M







 



35 M







 



36







 



37 M







 



38 M







 



39 M







 



40 M






















TABLE 102





Ex
Str







41 M






 


42 M






 


43 M






 


44 M






 


45 M






 


46






 


47 M























TABLE 103







Ex
Str









48 M







 



49 M







 



50







 



51







 



52 M







 



53 M







 



54 M
























TABLE 104







Ex
Str









55 M







 



56







 



57







 



58







 



59 M







 



60







 



61
























TABLE 105







Ex
Str









62 H







 



63 M







 



64







 



65







 



66 M







 



67 M
























TABLE 106







Ex
Str









68 H







 



69 H







 



70 M







 



71 M







 



72 M







 



73 H
























TABLE 107







Ex
Str









74 M







 



75 H







 



76 M







 



77







 



78 M







 



79 M







 



80 M
























TABLE 108







Ex
Str









81 M







 



82 H







 



83 M







 



84 M







 



85 M







 



86
























TABLE 109







Ex
Str









87







 



88 H







 



89 M







 



90 M







 



91 M







 



92 H







 



93 M
























TABLE 110







Ex
Str









94  H







 



95  M







 



96 







 



97  M







 



98  M







 



99  M







 



100
























TABLE 111







Ex
Str









101 M







 



102 M







 



103







 



104 M







 



105







 



106 H
























TABLE 112







Ex
Str









107 M







 



108  M







 



109 M







 



110 M







 



111 







 



112  M
























TABLE 113







Ex
Str









113







 



114  M







 



115 M







 



116 M







 



117 M







 



118  H
























TABLE 114







Ex
Str









119







 



120 M







 



121 H







 



122







 



123







 



124







 



125
























TABLE 115







Ex
Str









126







 



127 M







 



128 M







 



129 M







 



130 M







 



131 M







 



132 M
























TABLE 116







Ex
Str









133







 



134 M







 



135 M







 



136 M







 



137 M







 



138 M
























TABLE 117







Ex
Str









139 M







 



140 M







 



141 H







 



142 H







 



143 H







 



144 M






















TABLE 118





Ex
Str







145 M






 


146 M






 


147 M






 


148 M






 


149






 


150 H





















TABLE 119





Ex
Str







151 M






 


152 H






 


153 H






 


154 H






 


155 M






 


156 M






 


157 M























TABLE 120







Ex
Str









158 M







 



159







 



160 M







 



161 M







 



162 M







 



163 M
























TABLE 121







Ex
Str









164 M







 



165







 



166







 



167







 



168







 



169 M
























TABLE 122







Ex
Str









170 M







 



171 M







 



172 M







 



173 M







 



174 H







 



175
























TABLE 123







Ex
Str









176







 



177 M







 



178 M







 



179 M







 



180 M







 



181 H
























TABLE 124







Ex
Str









182 H







 



183 M







 



184 M







 



185 M







 



186 M






















TABLE 125





Ex
Str







187 M






 


188 H






 


189






 


190






 


191






 


192 H






 


193 H























TABLE 126







Ex
Str









194 H







 



195 M







 



196 M







 



197 M







 



198 M







 



199 M
























TABLE 127







Ex
Str









200H







 



201M







 



202







 



203M







 



204H 







 



205H 
























TABLE 128







Ex
Str









206M







 



207M







 



208H







 



209H







 



210M







 



211M
























TABLE 129







Ex
Str









212M







 



213M







 



214H







 



215







 



216M







 



217H
























TABLE 130







Ex
Str









218H







 



219H







 



220H







 



221M







 



222H







 



223H
























TABLE 131







Ex
Str









224M







 



225







 



226







 



227







 



228H







 



229M







 



230
























TABLE 132







Ex
Str









231







 



232H







 



233H







 



234M







 



235M







 



236M
























TABLE 133







Ex
Str









237M







 



238M







 



239M







 



240M







 



241M







 



242M







 



243M
























TABLE 134







Ex
Str









244M







 



245M







 



246M







 



247M







 



248M







 



249M
























TABLE 135







Ex
Str









250







 



251H







 



252







 



253







 



254S







 



255H
























TABLE 136







Ex
Str









256M







 



257H







 



258M







 



259M







 



260H







 



261
























TABLE 137







Ex
Str









262







 



263H







 



264







 



265H







 



266M







 



267T
























TABLE 138







Ex
Str









268M







 



269H







 



270M







 



271M







 



272M
























TABLE 139







Ex
Str









273M







 



274M







 



275M







 



276M







 



277M
























TABLE 140







Ex
Str









278







 



279







 



280M







 



281M







 



282M







 



283H
























TABLE 141







Ex
Str









284H







 



285H







 



286M







 



287M







 



288M






















TABLE 142





Ex
Str







289 H






 


290 M






 


291 H






 


292 M






 


293 M






 


294 M























TABLE 143







Ex
Str









295 M







 



296 M







 



297 M







 



298 M







 



299 M
























TABLE 144







Ex
Str









300 M







 



301 M







 



302 M







 



303 M







 



304 M






















TABLE 145





Ex
Str







305 M






 


306 M






 


307 M






 


308 M





















TABLE 146





Ex
Str







309 M






 


310 M






 


311 S






 


312 H






 


313 H





















TABLE 147





Ex
Str







314 M






 


315 M






 


316 M






 


317 M






 


318






 


319






















TABLE 148





Ex
Syn
Dat

















1
1
ESI+: 251, 253




NMR: 2.44-2.53(3H, m), 2.72-2.74(4H, m), 2.79-2.85(4H, m), 3.02-3.04(2H, m), 6.93




(1H, s), 9.20(1H, s)




mp: 165-167


2
2
ESI+: 293, 295




NMR: 0.96(6H, d, J = 6.5 Hz), 1.69-1.75(2H, m), 1.98-2.07(1H, m), 2.67-2.70(4H, m),




2.90-2.95(2H, m), 2.97-3.04(6H, m), 3.10-3.65(5H, m), 6.46(2H, s), 6.81(1H, s)




mp: 159-163


3
3
ESI+: 203




NMR: 1.69-1.81(2H, m), 2.57(2H, t, J = 6.2 Hz), 2.75-2.86(4H, m), 2.94-3.06(4H, m),




3.08-3.15(2H, m), 6.23(1H, s), 6.44(2H, s), 6.62(1H, s)


4
4
ESI+: 231




NMR: 2.49-2.56(2H, m), 2.76-2.83(2H, m), 2.98-3.20(8H, m), 3.23(3H, s), 6.97(1H, s),




7.05(1H, s), 9.14(2H, s)


5
5
ESI+: 315




NMR: 0.22-0.32(1H, m), 0.38-0.49(1H, m), 0.97-1.07(2H, m), 1.50-1.70(2H, m), 2.17-




2.30(1H, m), 2.31-2.43(1H, m), 2.51-2.61(1H, m), 2.74-3.18(8H, m), 3.30-3.42(1H, m),




3.34(3H, s), 3.73(1H, d, J = 14.3 Hz), 4.14(1H, d, J = 14.3 Hz), 4.70-4.81(1H, m), 6.85(1H, s)


6
6
ESI+: 275




NMR: 1.23(3H, t, J = 7.1 Hz), 1.78-1.86(2H, m), 2.66(2H, t, J = 6.6 Hz), 2.83-2.91(4H, m),




2.91-2.99(4H, m), 3.61-3.67(2H, m), 4.13(2H, q, J = 7.1 Hz), 6.40(1H, s), 6.88(1H, s),




7.43(1H, s)




mp: 178(decomp.)


7
7
ESI+: 274




NMR: 1.78-1.86(2H, m), 2.65(2H, t, J = 6.7 Hz), 2.76-2.86(10H, m), 2.86-2.94(4H, m),




3.36-3.41(2H, m), 6.39(1H, s), 6.56(1H, s), 6.83(1H, s)




mp: 230(decomp.)


8
8
ESI+: 274




NMR: 1.05(3H, t, J = 7.1 Hz), 1.74-1.82(2H, m), 2.62(2H, t, J = 6.5 Hz), 2.89-2.97(4H, m),




3.01-3.15(6H, m), 3.52(2H, m), 6.45(2H, s), 6.65(1H, t, J = 5.4 Hz), 6.89(1H, s), 7.25(1H, s)




mp: 174-176


9
9
ESI+: 295




NMR: 1.20(3H, t, J = 7.3 Hz), 1.85-1.94(2H, m), 2.73(2H, t, J = 6.7 Hz), 2.91-3.00(4H, m),




3.00-3.10(4H, m), 3.23(2H, q, J = 7.3 Hz), 3.62-3.69(2H, m), 6.45(2H, s), 6.96(1H, s),




7.30(1H, s)




mp: 176(decomp.)


10
2
ESI+: 261




NMR: 1.75-1.83(2H, m), 2.55-2.62(2H, m), 2.78-2.84(2H, m), 2.84-2.90(2H, m), 2.94-




3.06(4H, m), 3.20-3.28(2H, m), 3.26(3H, s), 3.34-3.41(2H, m), 3.44-3.50(2H, m), 6.40




(1H, s), 6.43(2H, s), 6.65(1H, s)


















TABLE 149





Ex
Syn
Dat

















11
5
ESI+: 313




NMR: 0.26-0.33(1H, m), 0.36-0.43(1H, m), 0.82(3H, d, J = 6.6 Hz), 0.92-1.05(2H, m),




1.15(3H, d, J = 6.9 Hz), 1.48-1.70(2H, m), 2.13-2.29(1H, m), 2.32-2.45(1H, m), 2.50-2.59




(1H, m), 2.62-3.13(9H, m), 3.35-3.45(1H, m), 4.67-4.78(1H, m), 6.84(1H, s)


12
2
ESI+: 237, 239




NMR: 1.73-1.79(2H, m), 2.64(2H, t, J = 6.2 Hz), 2.74-4.34(13H, m), 5.40(1H, s),




6.44(2H, s), 6.67(1H, s)


13
2
ESI+: 251, 253




NMR: 1.72-1.78(2H, m), 2.67-2.70(5H, m), 2.85-2.92(6H, m), 2.96-2.99(2H, m), 3.13-




3.76(4H, m), 6.40(1H, s), 6.79(1H, s)


14
2
ESI+: 219




NMR: 2.78(3H, s), 2.81-2.87(2H, m), 2.87-2.93(2H, m), 2.98-3.09(4H, m), 3.13-




3.19(2H, m), 4.15-4.21(2H, m), 6.44(2H, s), 6.50(1H, s), 6.54(1H, s)


15
2
ESI+: 279, 281




NMR: 1.58-3.32(16H, m), 4.05-4.12(0.35H, m), 4.51-4.58(0.65H, m), 7.04(0.35H, s),




7.16(0.65H, s), 9.06-9.18(2H, br)


16
2
ESI+: 265, 267




NMR: 1.19(3H, t, J = 6.9 Hz), 1.68-1.74(2H, m), 2.69(2H, t, J = 6.6 Hz), 2.85(2H, q, J =




6.9 Hz), 2.95-2.98(2H, m), 3.00-3.02(2H, m), 3.13-3.18(4H, m), 3.29-3.32(2H, m), 6.86(1H,




s), 9.01-9.20(2H, br)




mp: 221-223


17
2
ESI+: 219




NMR: 2.96-3.04(4H, m), 3.05-3.14(4H, m), 4.52(2H, s), 6.72(1H, s), 6.82(1H, s), 9.26-




9.42(2H, br), 10.71(1H, s)


18
2
ESI+: 233




NMR: 3.01-3.19(8H, m), 3.25(3H, s), 4.61(2H, s), 6.88(1H, s), 7.05(1H, s), 9.33-




9.47(2H, br)


19
2
FAB+: 233




NMR: 2.04(3H, s), 2.78(3H, s), 2.85-3.09(8H, br), 3.12-3.23(2H, m), 4.17-4.28(2H, m),




6.42(1H, s), 6.44(2H, s)


20
2
FAB+: 205




NMR: 2.75-2.89(4H, br), 2.93-3.08(4H, br), 3.15-3.31(2H, m), 3.99-4.13(2H, m), 5.17-




5.93(0.7H, br), 6.36(1H, s), 6.44(1.8H, s), 6.46(1H, s)




mp: 192-195


21
2
ESI+: 307, 309




NMR: 0.73(3H, d, J = 6.3 Hz), 1.07-1.19(4H, m), 1.54-2.19(2H, m), 2.38-2.75(6H, m),




3.07-3.39(6H, m), 4.14-4.27(0.15H, br), 4.49-4.55(0.85H, br), 7.01-7.20(1H, m), 9.00-




9.27(2H, br)




mp: 245-249


22
2
ESI+: 279, 281




NMR: 0.87(3H, t, J = 7.3 Hz), 1.64-1.73(4H, m), 2.65-2.68(2H, m), 2.72-2.76(2H, m),




2.84-2.91(6H, m), 2.96-2.98(2H, m), 3.02-3.70(4H, m), 6.41(1H, s), 6.77(1H, s)


23
2
ESI+: 295, 297




NMR: 1.69-1.75(2H, m), 2.67(2H, t, J = 6.4 Hz), 2.85-2.91 (6H, m), 2.98(2H, t, J = 6.4 Hz),




3.02-3.04(2H, m), 3.10-3.60(6H, m), 3.67(2H, t, J = 6.4 Hz), 6.41(1H, s), 6.78(1H, s)


















TABLE 150





Ex
Syn
Dat







24
2
ESI+: 217




NMR: 1.79-1.90(2H, m), 2.61(2H, t, J = 6.2 Hz), 2.79(3H, s), 2.74-2.93(4H, m), 2.94-3.07




(4H, m), 3.07-3.15(2H, m), 6.40(1H, s), 6.43(2H, s), 6.67(1H, s)


25
2
FAB+: 219




NMR: 2.02(3H, s), 2.65-2.95(8H, m), 3.15-3.28(2H, m), 4.05-4.14(2H, m), 5.32-




5.54(1H, br), 6.21(1H, s), 6.37(1H, s)


26
2
FAB+: 233




NMR: 1.04(3H, t, J = 7.0 Hz), 2.78-2.94(4H, br), 2.95-3.08(4H, br), 3.15-3.24(2H, m),




3.28(2H, q, J = 7.0 Hz), 4.06-4.18(2H, m), 6.44(2H, s), 6.49(1H, s), 6.55(1H, s)


27
2
FAB+: 283, 285




NMR: 2.81-2.90(2H, m), 2.90-3.00(4H, m), 3.11-3.20(2H, m), 3.29-3.37(2H, m), 4.02-




4.10(2H, m), 5.31-5.39(1H, br), 6.43(1.3H, s), 6.57(1H, s)


28
2
ESI+: 219




NMR: 1.99(3H, s), 2.74-2.83(2H, m), 2.86-2.97(6H, m), 3.24-3.31(2H, m), 3.98-




4.06(2H, m), 4.86-5.09(1H, br), 6.37(1H, s), 6.38(1H, s)


29
2
ESI+: 283




NMR: 2.97-3.06(4H, m), 3.07-3.18(7H, m), 3.74-3.81(2H, m), 4.20-4.28(2H, m), 6.80




(1H, s), 7.40(1H, s), 9.28-9.42(2H, br)


30
2
ESI+: 247




NMR: 1.12(6H, d, J = 6.6 Hz), 2.87-3.14(8H, br), 3.15-3.25(2H, br), 4.02-4.20(3H, m),




6.57(1H, s), 6.75(1H, s), 9.31-9.52(2H, br)


31
2
ESI+: 233




NMR: 2.19(3H, s), 2.56(3H, s), 2.88-2.94(2H, m), 2.95-3.08(8H, m), 4.04-4.11(2H, m),




6.44(2H, s), 6.51(1H, s)


32
2
ESI+: 281, 283




NMR: 1.69-1.80(2H, m), 2.64(2H, t, J = 6.2 Hz), 2.80-2.89(2H, m), 2.89-3.01(4H, m),




3.13-3.21(2H, m), 3.21-3.29(2H, m), 6.42(1.4H, s), 6.69(1H, s)


33
2
ESI+: 245




NMR: 1.78-1.89(2H, m), 2.15(3H, s), 2.64(2H, t, J = 6.6 Hz), 2.88-3.08(8H, m), 3.64(2H,




t, J = 6.2 Hz), 6.44(2H, s), 6.96(1H, s)




mp: 159-162


34
2
ESI+: 231




NMR: 1.03(3H, t, J = 7.0 Hz), 1.78-1.87(2H, m), 2.59(2H, t, J = 6.2 Hz), 2.79-2.84(2H, m),




2.86-2.92(2H, m), 2.96-3.06(4H, m), 3.16(2H, t, J = 5.5 Hz), 3.28(2H, q, J = 7.0 Hz),




6.41(1H, s), 6.43(2H, s), 6.65(1H, s)


35
2
ESI+: 297, 299




NMR: 2.72(3H, s), 2.93-3.12(8H, m), 3.23-3.33(2H, m), 4.08-4.20(2H, m), 6.46(2H, s),




6.72(1H, s)




mp: 200-204


36
2
ESI+: 245




NMR: 0.50-0.64(2H, m), 0.99-1.12(2H, m), 1.57-1.68(1H, m), 2.90-3.01(2H, m), 3.04-




3.17(4H, m), 3.23-3.34(2H, m), 3.36-3.47(2H, m), 4.20-4.33(2H, br), 6.62(1H, s), 9.19-




9.38(2H, br)




mp: 193-197


















TABLE 151





Ex
Syn
Dat







37
2
ESI+: 273




NMR: 1.01(6H, d, J = 6.6 Hz), 1.78-1.90(2H, m), 2.64(2H, t, J = 6.8 Hz), 2.91-3.14(9H, m),




3.64(2H, t, J = 6.2 Hz), 6.46(2H, s), 7.00(1H, s), 7.09-7.24(1H, br)


38
2
ESI+: 259




NMR: 0.89(6H, d, J = 6.5 Hz), 1.76-1.84(2H, m), 1.92-2.04(1H, m), 2.60(2H, t, J = 6.3 Hz),




2.77-2.84(2H, m), 2.85-2.91(2H, m), 2.97(2H, d, J = 7.4 Hz), 2.97-3.06(4H, m), 3.16-




3.25(2H, m), 6.33(1H, s), 6.44(2H, s), 6.65(1H, s)


39
2
ESI+: 305, 307




NMR: 0.52-0.98(4H, m), 1.43-2.77(6H, m), 2.89-4.33(11H,), 4.42-4.54(1H, m), 6.48(2H,




s), 6.97-7.11(1H, m)


40
2
ESI+: 319, 321




NMR: 1.39-4.80(24H, m), 6.48(2H, s), 6.99(0.4H, s), 7.08(0.6H, s)


41
2
ESI+: 291, 293




NMR: 0.17-0.20(2H, m), 0.47-0.52(2H, m), 1.04-1.15(1H, m), 1.69-1.75(2H, m), 2.67




(2H, t, J = 6.7 Hz), 2.74(2H, d, J = 6.4 Hz), 2.85-2.91(6H, m), 3.05-3.80(6H, m), 6.41(1H,




s), 6.78(1H, s)


42
2
ESI+: 305, 307




NMR: 1.69-1.92(6H, m), 1.99-2.05(2H, m), 2.65-2.75(3H, m), 2.82-3.95(15H, m), 6.46




(2H, s), 6.80(1H, s)




mp: 141-143


43
2
ESI+: 333, 335




NMR: 1.18-2.12(10H, m), 2.32-2.75(4H, m), 2.92-4.18(11H, m), 4.18-4.29(0.25H, br),




4.48-4.59(0.75H, br), 6.48(2H, s), 6.99(0.25H, s), 7.11(0.75H, s)


44
2
ESI+: 341, 343




NMR: 11.68-1.83(1H, br), 2.64-2.82(2H, m), 2.82-4.02(14H, m), 6.48(2H, s), 7.08(1H,




s), 7.14-7.71(5H, br)


45
2
ESI+: 319, 321




NMR: 1.30-1.38(2H, m), 1.47-1.63(4H, m), 1.70-1.77(4H, m), 2.28(1H, quint, J = 7.5 Hz),




2.68(2H, t, J = 6.7 Hz), 2.82(2H, d, J = 7.3 Hz), 2.91-2.94(2H, m), 2.99-3.05(6H, m),




3.11-3.71(5H, m), 6.46(2H, s), 6.81(1H, s)




mp: 151-153


46
2
ESI+: 327, 329




NMR: 1.72-1.78(2H, m), 2.74(2H, t, J = 6.6 Hz), 2.81-2.84(2H, m), 3.05-3.07(2H, m),




3.15-3.20(4H, m), 3.32-3.35(2H, m), 4.09(2H, s), 6.93(1H, s), 7.28(1H, t, J = 7.4 Hz),




7.37(2H, t, J = 7.4 Hz), 7.54(2H, d, J = 7.4 Hz), 9.0-9.30(2H, br)


47
2
ESI+: 347, 348




NMR: 0.73-3.85(26H, m), 4.13-4.24(0.2H, br), 4.46-4.55(0.8H, br), 6.45(1H, s), 6.93-




7.00(0.2H, br), 7.08(0.8H, s)


48
2
ESI+: 333, 335




NMR: 0.94-1.04(2H, m), 1.13-1.27(3H, m), 1.62-1.75(6H, m), 1.83(2H, d, J = 12.8 Hz),




2.66-2.72(4H,m), 2.91-2.94(2H, m), 2.99-3.03(6H, m), 3.11-3.74(5H, m), 6.46(2H, s),




6.81(1H, s)


49
2
ESI+: 217




NMR: 1.69-1.79(2H, m), 1.95(3H, s), 2.61(2H, t, J = 6.2 Hz), 2.79-2.87(2H, m), 2.93-3.05




(6H, m), 3.21(2H, t, J = 5.3 Hz), 6.44(2H, s), 6.54(1H, s)


















TABLE 152





Ex
Syn
Dat







50
2
ESI+: 219




NMR: 1.33(3H, d, J = 6.4 Hz), 2.91-3.22(9H, m), 3.44-3.54(1H, m), 4.26-4.37(1H, m),




6.75(1H, s), 6.87(1H, s), 9.36-9.58(2H, br)




mp: 193-194


51
2
ESI+: 279




NMR: 1.79-1.97(2H, m), 2.58-2.69(2H, m), 2.69-2.80(2H, m), 2.93-3.08(4H, m), 3.08-




3.23(4H, m), 6.95(1H, s), 7.15-7.29(2H, m), 7.37-7.56(3H, m), 9.11-9.33(2H, m)


52
2
FAB+; 231




NMR: 1.67-1.79(2H, m), 2.18(3H, s), 2.53(3H, s), 2.66(2H, t, J = 6.6 Hz), 2.85-2.93(2H,




m), 2.93-3.06(8H, m), 6.43(2H, s), 6.67(1H, s)


53
2
ESI+: 263




NMR: 2.80-2.94(4H, m), 2.96-3.09(4H, m), 3.26(3H, s), 3.29-3.34(2H, m), 3.38(2H, t, J =




5.4 Hz), 3.50(2H, t, J = 5.4 Hz), 4.04-4.12(2H, m), 6.44(1.8H, s), 6.50(1H, s), 6.54(1H, s)


54
2
ESI+: 233




NMR-A: 1.26(3H, d, J = 6.3 Hz), 2.74-2.98(8H, m), 3.06-3.18(4H, br), 3.19-3.26(1H, m),




4.18-4.28(1H, m), 6.54(1H, s), 6.56(1H, s), 6.64(1H, s), 8.65-8.98(2H, br)


55
2
ESI+: 261




NMR: 1.05(3H, d, J = 6.5 Hz), 1.12(3H, d, J = 6.5 Hz), 1.26(3H, d, J = 6.2 Hz), 2.63-2.73(1H,




m), 2.76-3.12(8H, m), 3.19-3.30(1H, m), 3.98-4.13(2H, m), 6.44(1.7H, s), 6.50(1H,




s), 6.62(1H, s)


56
2
ESI+: 259




NMR: 0.18-0.32(2H, m), 0.41-0.57(2H, m), 0.92-1.08(1H, m), 2.83-3.22(10H, m), 3.30-




3.48(2H, m), 4.10-4.24(2H, m), 6.57(1H, s), 6.73(1H, s), 9.27-9.55(2H, br)




mp: 179-182


57
2
ESI+: 275




NMR: 1.06(6H, d, J = 6.6 Hz), 2.94-3.04(4H, m), 3.08-3.19(5H, m), 3.80-3.90(2H, m),




4.16-4.28(2H, m), 6.76(1H, s), 7.25-7.86(1H, br), 9.10-9.36(2H, br)


58
2
ESI+: 261




NMR: 0.90(6H, d, J = 6.7 Hz), 1.91-2.05(1H, m), 2.82-2.99(6H, m), 3.05-3.15(4H, br),




3.24-3.30(2H, m), 4.07-4.12(2H, m), 6.50(1H, s), 6.52(1H, s), 8.80-8.96(2H, br)




mp: 157


59
2
ESI+: 277




NMR: 1.68-1.80(2H, m), 2.77-2.92(4H, m), 2.96-3.09(4H, m), 3.17-3.30(7H, m), 3.36




(2H, t, J = 6.1 Hz), 4.05-4.15(2H, m), 6.44(2H, s), 6.49(1H, s), 6.51(1H, s)




mp: 141-145


60
1
ESI+: 337




NMR: 1.70-1.80(2H, m), 2.36-2.42(2H, m), 2.66-2.80(4H, m), 2.86-2.93(2H, m), 2.97-




3.07(4H, m), 3.02(3H, s), 3.11-3.17(2H, m), 3.21-3.28(2H, m), 6.82(1H, s), 7.07-7.13(2H,




m), 7.28-7.34(1H, m), 7.36-7.42(2H, m)


61
2
ESI+: 261




NMR: 0.92(3H, t, J = 7.3 Hz), 1.26-1.40(2H, m), 1.45-1.58(2H, m), 2.85-3.14(8H, m),




3.16-3.34(4H, m), 4.08-4.23(2H, m), 6.54(1H, s), 6.60(1H, s), 9.30-9.54(2H, br)


62
2
ESI+: 295




NMR: 2.70-2.97(8H, m), 3.22-3.31(2H, m), 4.10-4.20(2H, m), 4.42(2H, s), 6.39(1H, s),




6.51(1H, s), 6.55(1H, s), 7.21-7.40(5H, m)


















TABLE 153





Ex
Syn
Dat







63
2
ESI+: 277




NMR: 1.10(3H, t, J = 6.9 Hz), 2.78-2.95(4H, m), 2.97-3.10(4H, m), 3.29-3.48(6H, m), 3.53




(2H, t, J = 5.7 Hz), 4.04-4.12(2H, m), 6.44(1.8H, s), 6.50(1H, s), 6.55(1H, s)


64
2
ESI+: 303




NMR: 1.17-1.32(2H, m), 1.52-1.64(2H, br), 1.85-2.00(1H, m), 2.81-3.18(10H, m), 3.21-




3.36(4H, m), 3.79-3.92(2H, m), 4.02-4.17(2H, m), 6.51(1H, s), 6.54(1H, s), 9.30-9.52(2H, br)


65
2
ESI+: 281




NMR: 2.59-2.70(2H, m), 2.90-3.17(6H, m), 3.20-3.32(2H, m), 4.14-4.24(2H, m), 6.73(1H,




s), 7.19-7.30(2H, m), 7.39-7.54(3H, m), 9.29-9.49(2H, br)


66
2
ESI+: 309




NMR: 1.66-1.78(2H, m), 2.51-2.58(2H, m), 2.61-2.70(2H, m), 2.82-2.95(4H, m), 2.97-




3.12(4H, m), 3.76(3H, s), 6.43(2H, s), 6.65(1H, d, J = 2.0 Hz), 6.67(1H, d, J = 7.7 Hz),




6.72(1H, s), 6.94(1H, dd, J = 2.0, 7.8 Hz), 7.38(1H, dd, J = 7.7, 7.8 Hz)


67
2
ESI+: 313, 315




NMR: 1.64-1.80(2H, m), 2.46-2.56(2H, m), 2.66(2H, t, J = 6.2 Hz), 2.79-2.93(3H, m), 2.94-




3.02(2H, m), 3.03-3.13(2H, m), 3.88-3.99(1H, br), 6.40(1.5H, s), 6.73(1H, s), 7.03-7.10




(1H, m), 7.12-7.16(1H, m), 7.40-7.46(1H, m), 7.49(1H, dd, J = 7.6, 7.9 Hz)




mp: 159-162


68
2
ESI+: 347, 349




NMR: 1.66-1.78(2H, m), 2.41-2.47(2H, m), 2.65(2H, t, J = 6.2 Hz), 2.72-2.84(4H, m), 2.84-




2.94(2H, m), 3.01-3.11(2H, m), 4.08-4.15(1H, br), 6.37(1H, s), 6.71(1H, s), 7.07(1H, dd, J =




1.8, 8.2 Hz), 7.32(1H, d, J = 1.8 Hz), 7.68(1H, d, J = 8.2 Hz)


69
2
ESI+: 371, 373




NMR: 1.62-1.73(2H, m), 2.38-2.45(2H, m), 2.52-2.65(4H, m), 2.66-2.73(2H, m), 2.74-




2.83(2H, m), 2.84-2.99(6H, m), 2.95(3H, s), 6.38(1H, s), 6.84(1H, s), 7.07-7.12(1H, m),




7.17-7.21(1H, m), 7.38-7.50(2H, m)


70
2
ESI+: 405, 407




NMR: 1.61-1.73(2H, m), 2.39-2.74(8H, m), 2.77-2.99(8H, m), 2.96(3H, s), 6.40(0.8H, s),




6.87(1H, s), 7.13(1H, dd), 7.41(1H, d, J = 1.8 Hz), 7.70(1H, d, J = 8.2 Hz)


71
2
ESI+: 275




NMR: 2.47-2.53(2H, m), 2.71-2.80(2H, m), 2.88-3.08(8H, m), 3.24(3H, s), 3.48(2H, t, J =




6.1 Hz), 4.02(2H, t, J = 6.1 Hz), 6.44(1.7H, s), 6.99(1H, s), 7.01(1H, s)




mp: 164-166


72
2
ESI+: 365




NMR: 0.34(3H, d, J = 6.8 Hz), 0.35(3H, d, J = 6.8 Hz), 1.13-1.29(1H, m), 1.58-1.78(2H, m),




2.18-2.36(2H, m), 2.56-2.66(2H, m), 2.71(2H, t, J = 6.6 Hz), 2.81-3.09(8H, m), 3.74(3H, s),




6.42(2H, s), 6.63-6.73(2H, m), 6.85(1H, s), 6.88(1H, dd, J = 1.8, 7.8 Hz), 7.30(1H, dd, J = 7.7,




7.8 Hz)


73
2
ESI+: 367




NMR: 1.61-1.73(2H, m), 2.30-2.50(4H, m), 2.53-2.60(2H, m), 2.60-2.73(4H, m), 2.73-2.81(2H,




m), 2.82-2.97(4H, m), 2.93(3H, s), 3.75(3H, s), 6.37(1H, s), 6.66-6.70(2H, m), 6.80




(1H, s), 6.88-6.93(1H, m), 7.33(1H, dd, J = 7.9, 8.2 Hz)


74
2
ESI+: 243




NMR: 0.23-0.33(2H, m), 0.98-1.08(2H, m), 1.29-1.39(1H, m), 1.70-1.81(2H, m), 2.60(2H,




t, J = 6.2 Hz), 2.76-2.85(2H, m), 2.92-3.08(4H, m), 3.13-3.23(2H, m), 3.23-3.29(2H, m),




4.97(1H, s), 6.42(2H, s), 6.57(1H, s)


















TABLE 154





Ex
Syn
Dat







75
2
ESI+: 355




NMR: 1.70-1.81(2H, m), 2.47-2.53(2H, m), 2.61-2.66(2H, m), 2.66-2.74(2H, m), 2.79




(2H, t, J = 6.6 Hz), 2.82-2.89(2H, m), 2.90-3.05(6H, m), 3.04(3H, s), 6.47(1H, s), 6.92(1H,




s), 7.01-7.10(2H, m), 7.21-7.31(1H, m), 7.51-7.60(1H, dd, J = 7.1, 14.4 Hz)


76
2
ESI+: 291




NMR: 1.07(6H, d, J = 6.1 Hz), 2.79-2.94(4H, m), 2.96-3.10(4H, m), 3.28-3.41(4H, m), 3.48-




3.59(3H, m), 4.04-4.13(2H, m), 6.44(1.8H, s), 6.50(1H, s), 6.54(1H, s)




mp: 135


77
2
ESI+: 289




NMR: 1.51-1.64(1H, m), 1.92-2.04(1H, m), 2.54-2.65(1H, m), 2.84-3.35(12H, m), 3.38-




3.49(1H, m), 3.58-3.68(1H, m), 3.69-3.84(2H, m), 4.06-4.15(2H, m), 6.53(1H, s), 6.59(1H,




s), 9.28-9.54(2H, br)


78
2
ESI+: 353




NMR: 2.34(3H, s), 2.39-2.48(2H, m), 2.54-2.65(4H, m), 2.77-3.09(11H, m), 3.96-4.08




(2H, m), 6.40(1.5H, s), 6.67(1H, s), 6.93(1H, d, J = 7.6 Hz), 6.98(1H, s), 7.18(1H, d,




J = 7.6 Hz), 7.33(1H, t, J = 7.6 Hz)




mp: 173-176


79
2
ESI+: 295




NMR: 2.35(3H, s), 2.52-2.61(2H, m), 2.81-2.97(4H, m), 2.97-3.12(2H, m), 3.12-3.25(2H,




m), 3.92-4.12(3H, m), 6.42(1.8H, s), 6.57(1H, s), 6.92(1H, d, J = 7.7 Hz), 6.95(1H, s),




7.19(1H, d, J = 7.7 Hz), 7.36(1H, t, J = 7.7 Hz)


80
2
ESI+: 299




NMR: 0.29-0.38(2H, m), 0.81(6H, d, J = 6.7 Hz), 0.89-1.00(2H, m), 1.54-1.66(1H, m), 1.66-




1.77(2H, m), 1.84-1.99(1H, m), 2.58(2H, t, J = 6.3 Hz), 2.78-2.85(2H, m), 2.92(2H, d, J =




7.3 Hz), 2.94-3.05(4H, m), 3.07-3.17(2H, m), 3.17-3.25(2H, m), 6.40(1H, s), 6.62(1H, s)


81
2
ESI+: 301




NMR: 0.30-0.42(2H, m), 0.93-1.04(2H, m), 1.57-1.74(3H, m), 2.61(2H, t, J = 6.4 Hz), 2.83-




2.94(2H, m), 2.98-3.32(13H, m), 3.56(2H, t, J = 6.2 Hz), 6.43(2H, s), 6.65(1H, s)


82
2
ESI+: 291




NMR: 1.29(3H, d, J = 7.3 Hz), 2.73(1H, dd, J = 12.0, 7.3 Hz), 2.80-3.00(5H, m), 3.11-3.18




(1H, m), 3.25(3H, s), 3.53(2H, t, J = 5.6 Hz), 4.01-4.12(2H, m), 4.58(2H, s), 6.44(1H, s),




6.79(1H, s), 7.04(1H, s)


83
2
ESI+: 305




NMR: 1.32(3H, d, J = 7.4 Hz), 1.79(2H, quint, J = 6.6 Hz), 2.80(1H, dd, J = 13.0, 7.4 Hz),




2.85-3.09(5H, m), 3.20-3.28(4H, m), 3.36(2H, t, J = 6.6 Hz), 3.94(2H, t, J = 6.6 Hz), 4.57(2H,




s), 6.48(2H, s), 6.83(1H, s), 6.96(1H, s)


84
2
ESI+: 277




NMR: 1.27(3H, d, J = 7.2 Hz), 2.77-2.88(4H, m), 3.02-3.14(3H, m), 3.26(3H, s), 3.31-




3.33(2H, m), 3.38-3.41(2H, m), 3.51(2H, t, J = 5.5 Hz), 4.07-4.09(2H, m), 6.45(2H, s), 6.48(1H,




s), 6.51(1H, s)


85
2
ESI+: 291




NMR: 1.28(3H, d, J = 7.2 Hz), 1.74(2H, quint, J = 6.3 Hz), 2.76-2.89(4H, m), 3.04-3.16(3H,




m), 3.22-3.29(7H, m), 3.37(2H, t, J = 6.3 Hz), 4.10-4.12(2H, m), 6.45(2H, s), 6.48(1H,




s), 6.50(1H, s)


















TABLE 155





Ex
Syn
Dat







86
2
ESI+: 289




NMR: 1.53-1.62(2H, br), 1.62-1.77(2H, m), 2.84-3.15(8H, m), 3.16-3.26(2H, m), 3.45




(2H, t, J = 11.2 Hz), 3.80-3.97(3H, m), 4.05-4.14(2H, m), 6.54(1H, s), 6.75(1H, s), 9.24-




9.48(1.8H, br)


87
2
ESI+: 245




NMR: 1.31(6H, d, J = 7.1 Hz), 1.83-1.95(2H, m), 2.68-2.80(2H, m), 2.97-3.27(8H, m),




3.27-3.45(3H, m), 6.94(1H, s), 9.27(2H, s)


88
2
ESI+: 303




NMR: 0.41-0.48(2H, m), 0.96-1.03(2H, m), 1.56-1.64(1H, m), 2.75-2.85(2H, m), 2.85-




2.97(4H, m), 3.08-3.18(6H, m), 3.25(3H, s), 3.62(2H, t, J = 6.0 Hz), 3.97-4.03(2H, m),




6.38(1H, s), 6.47(1H, s)


89
2
ESI+: 303




NMR: 1.23(6H, d, J = 7.1 Hz), 1.65-1.81(2H, m), 2.63-2.70(2H, m), 2.76-2.91(4H, m),




2.93-3.15(8H, m), 3.29(3H, s), 3.58(2H, t, J = 6.2 Hz), 3.85-3.99(1H, m), 6.43(2H, s),




6.68(1H, s)


90
2
ESI+: 277




NMR: 2.18(3H, s), 2.80-2.86(2H, m), 2.87-2.93(2H, m), 2.94-3.10(8H, m), 3.30(3H, s),




3.61(2H, t, J = 5.8 Hz), 4.02-4.08(2H, m), 6.42(1.7H, s), 6.49(1H, s)




mp: 166-170


91
2
ESI+: 273




NMR: 1.46-1.84(8H, m), 2.79-2.94(4H, m), 2.95-3.07(4H, m), 3.12-3.19(2H, m), 4.08-




4.22(3H, m), 6.43(1.7H, s), 6.49(1H, s), 6.67(1H, s)


92
2
ESI+: 281




NMR: 2.66-2.74(2H, m), 2.77-2.97(6H, m), 3.60-3.70(2H, m), 4.15-4.22(2H, m), 6.38




(1H, s), 6.62-6.66(2H, br), 7.02-7.09(1H, m), 7.18-7.25(2H, m), 7.31-7.39(2H, m)




mp: 220-222


93
2
ESI+: 317




NMR: 0.43-0.49(1H, m), 0.61-0.66(1H, m), 0.98-1.05(2H, m), 1.28(3H, d, J = 7.4 Hz), 1.60-




1.67(1H, m), 2.61-2.67(2H, m), 2.90-2.93(1H, m), 3.04-3.25(8H, m), 3.32(2H, dd, J =




13.2, 4.8 Hz), 3.62(2H, t, J = 5.9 Hz), 3.97-4.03(2H, m), 4.14-4.20(1H, m), 6.44-6.46(3H, m)


94
2
ESI+: 275




NMR: 1.67-1.73(2H, m), 2.15(3H, s), 2.64(2H, t, J = 6.7 Hz), 2.79-2.84(4H, m), 2.88-2.93




(6H, m), 3.02-3.04(2H, m), 3.28(3H, s), 3.59(2H, t, J = 6.2 Hz), 6.37(1H, s), 6.62(1H, s)


95
2
ESI+: 261




NMR: 1.67-1.73(2H, m), 2.17(3H, s), 2.65(2H, t, J = 6.7 Hz), 2.72(2H, t, J = 6.7 Hz), 2.89-




2.91(2H, m), 2.99-3.04(8H, m), 3.66(2H, t, J = 6.7 Hz), 6.43(2H, s), 6.66(1H, s)


96
2
ESI+: 231




NMR: 1.08(3H, t, J = 7.3 Hz), 1.88-1.98(2H, m), 2.62-2.79(4H, m), 2.98-3.18(8H, m),




3.27-3.37(2H, m), 6.92(1H, s), 9.33(2H, s)


97
2
ESI+: 289




NMR: 1.03(3H, t, J = 7.4 Hz), 1.68-1.78(2H, m), 2.66(2H, t, J = 6.9 Hz), 2.72(2H, q, J =




7.4 Hz), 2.86(2H, t, J = 6.3 Hz), 2.90-2.95(2H, m), 2.95-3.05(4H, m), 3.06-3.13(4H, m),




3.30(3H, s), 3.59(2H, t, J = 6.3 Hz), 6.52(2H, s), 6.69(1H, s)


















TABLE 156





Ex
Syn
Dat

















98
2
ESI+: 291




NMR: 1.04(3H, t, J = 7.4 Hz), 2.71(2H, q, J = 7.4 Hz), 2.84-2.93(4H, m), 2.94-3.08(8H, m),




3.31(3H, s), 3.61(2H, t, J = 5.9 Hz), 4.06-4.12(2H, m), 6.44(2H, s), 6.50(1H, s)




mp: 159-163


99
2
ESI+: 277




NMR: 1.07(3H, d, J = 6.7 Hz), 2.79-2.94(4H, m), 2.97-3.09(4H, m), 3.14-3.22(2H, m),




3.24(3H, s), 3.32-3.39(1H, m), 3.41-3.48(1H, m), 4.01-4.11(3H, m), 6.44(2H, s), 6.50(1H,




s), 6.63(1H, s)


100
2
ESI+: 259




NMR: 0.88(6H, d, J = 6.6 Hz), 1.77-1.98(3H, m), 2.54-2.78(4H, m), 2.91-3.17(8H, m),




3.26-3.33(2H, m), 6.88(1H, s), 9.34(2H, s)


101
2
ESI+: 305




NMR: 1.24(6H, d, J = 7.4 Hz), 2.80-2.92(4H, m), 2.98-3.13(8H, m), 3.30(3H, s), 3.60(2H,




t, J = 5.9 Hz), 3.80-3.97(1H, m), 4.04-4.12(2H, m), 6.43(1.8H, s), 6.51(1H, s)


102
2
ESI+: 319




NMR: 1.01(3H, t, J = 7.2 Hz), 1.62-1.87(2H, m), 2.62-2.82(6H, m), 2.85-3.07(8H, m), 3.16-




3.28(2H, m), 3.26(3H, s), 3.30(2H, d, J = 5.5 Hz), 3.91-3.99(1H, m), 6.43(2H, s), 6.67(1H, s)


103
2
ESI+: 265




NMR: 1.83-1.98(2H, m), 2.85-3.00(4H, m), 3.01-3.14(4H, br), 3.22-3.29(2H, m), 3.29-




3.37(2H, m), 4.09-4.18(2H, m), 4.53(2H, dt, J = 47.4, 5.8 Hz), 6.54(1H, s), 6.57(1H, s),




9.30-9.46(2H, br)


104
2
ESI+: 317




NMR: 0.40-0.50(2H, m), 0.96-1.05(2H, m), 1.10(3H, t, J = 7.0 Hz), 1.58-1.67(1H, m),




2.84-2.92(2H, m), 2.99-3.18(8H, m), 3.18-3.27(2H, m), 3.43(2H, q, J = 7.0 Hz), 3.65(2H,




t, J = 6.0 Hz), 3.98-4.05(2H, m), 6.44(1.8H, s), 6.52(1H, s)




mp: 140-145


105
2
ESI+: 343




NMR: 0.35-0.56(6H, m), 0.97-1.08(2H, m), 1.64-1.75(1H, m), 2.90-2.98(2H, m), 3.00-




3.36(15H, m), 4.04-4.13(2H, m), 6.54(1H, s), 9.24-9.38(1.8H, br)




mp: 166-167


106
2
ESI+: 317




NMR: 0.39-0.47(2H, m), 0.95-1.03(2H, m), 1.56-1.65(1H, m), 1.82-1.92(2H, m), 2.78-




2.85(2H, m), 2.87-3.00(6H, m), 3.02-3.08(2H, m), 3.13-3.23(5H, m), 3.34(2H, t, J =




6.2 Hz), 3.95-4.01(2H, m), 6.37(1H, s), 6.48(1H, s)




mp: 169-171


107
2
ESI+: 351




NMR: 1.29(3H, d, J = 7.2 Hz), 1.84(2H, quint, J = 6.3 Hz), 2.70(2H, t, J = 6.3 Hz), 2.72-2.88




(3H, m), 2.97-3.23(4H, m), 3.69(2H, t, J = 6.3 Hz), 5.17(2H, s), 6.47(2H, s), 6.92(1H, s),




7.31-7.42(5H, m), 7.45(1H, s)


108
2
ESI+: 289




NMR: 1.06-1.23(3H, br), 161-1.74(1H, br), 1.96-2.08(4H, br), 2.62-2.70(1H, m), 2.91-




3.13(7H, m), 3.16-3.27(2H, m), 3.52-4.29(7H, m), 6.87(1H, s)




mp: 185-186


















TABLE 157





Ex
Syn
Dat

















109
2
ESI+: 288




NMR: 0.98(3H, t, J = 7.1 Hz), 1.73-1.84(2H, br), 2.05(3H, s), 2.56(2H, t, J = 6.8 Hz), 2.99-




3.08(6H, m), 3.11-3.18(4H, m), 3.29-4.63(5H, br), 5.88-6.09(1H, br), 6.87(1H, s)




mp: 170-171


110
112
ESI+: 293




NMR: 1.82-1.95(2H, m), 2.61-2.71(2H, m), 2.74-2.87(4H, m), 2.91-3.07(4H, m), 3.22-




3.32(2H, m), 4.45(2H, s), 6.36(1H, s), 6.42(2H, s), 6.70(1H, s), 7.17-7.37(5H, m)




mp: 148(decomp.)


111
112
ESI+: 325




NMR: 2.85-2.94(4H, m), 3.00-3.12(4H, m), 3.24-3.28(2H, m), 3.73(3H, s), 4.12-4.19(2H,




m), 4.41(2H, s), 6.56(1H, s), 6.60(1H, s), 6.79-6.89(3H, m), 7.22-7.28(1H, m), 9.23-




9.44(2H, br)


112
112
ESI+: 329, 331




NMR: 2.78-2.88(4H, m), 2.96-3.08(4H, m), 3.27-3.34(2H, m), 4.12-4.21(2H, m), 4.44




(2H, s), 6.47(2H, s), 6.54(1H, s), 6.56(1H, s), 7.23-7.42(4H, m)




mp: 151(decomp.)


113
112
ESI+: 325




NMR: 2.85-2.96(4H, m), 3.01-3.11(4H, m), 3.20-3.27(2H, m), 3.73(3H, s), 4.11-4.17(2H,




m), 4.36(2H, s), 6.55(1H, s), 6.66(1H, s), 6.87-6.92(2H, m), 7.20-7.27(2H, m), 9.30-




9.49(2H, br)


114
112
ESI+: 329, 331




NMR: 2.28(4H, s), 2.72-2.82(4H, m), 2.92-3.04(4H, m), 3.24-3.33(2H, m), 4.10-4.20(2H,




m), 4.42(2H, s), 6.52(1H, s), 6.54(1H, s), 7.29-7.35(2H, m), 7.37-7.42(2H, m)




mp: 178(decomp.)


115
112
ESI+: 325




NMR: 2.28(4H, s), 2.73-2.88(4H, m), 2.94-3.05(4H, m), 3.37-3.46(2H, m), 3.63(2H, t, J =




5.6 Hz), 4.07-4.18(4H, m), 6.51(1H, s), 6.61(1H, s), 6.89-6.98(3H, m), 7.23-7.33(2H, m)




mp: 132-134


116
112
ESI+: 296




NMR: 2.73-2.86(4H, m), 2.90-3.04(4H, m), 3.40-3.48(2H, m), 4.14-4.22(2H, m), 4.52




(2H, s), 6.43(2H, s), 6.46(1H, s), 6.54(1H, s), 7.23-7.35(2H, m), 7.70-7.79(1H, m), 8.50-




8.57(1H, m)


117
112
ESI+: 302




NMR: 2.78-2.90(4H, m), 2.95-3.06(4H, m), 3.38-3.45(2H, m), 4.11-4.17(2H, m), 4.57




(2H, s), 6.44(2H, s), 6.51(1H, s), 6.66(1H, s), 7.53(1H, d, J = 2 Hz), 9.06(1H, d, J = 2 Hz)




mp: 134-138


118
2
ESI+: 339




NMR-A: 2.41-2.47(2H, m), 2.54-2.67(4H, m), 2.94(3H, s), 2.96-3.03(6H, m), 3.13-3.20




(2H, m), 4.00-4.07(2H, m), 6.63(1H, s), 6.74(1H, s), 7.15-7.21(2H, m), 7.36-7.42(1H,




m), 7.44-7.50(2H, m)




mp: 199-201


















TABLE 158





Ex
Syn
Dat







119
2
ESI+: 249




NMR: 2.85-2.98(4H, m), 3.03-3.12(4H, m), 3.29(2H, t, J = 6.1 Hz), 3.32-3.38(2H, m), 3.57(2H,




t, J = 6.1 Hz), 4.02-4.17(2H, m), 5.33-5.89(2H, br), 6.52(1H, s), 6.56(1H, s), 9.17-




9.42(2H, br)


120
2
ESI+: 303




NMR: 0.35-0.39(2H, m), 0.97-1.01(2H, m), 1.59-1.72(3H, m), 1.90-2.03(2H, m), 2.27




(4H, s), 2.61(2H, t, J = 6.4 Hz), 2.82-2.84(2H, m), 3.00-3.03(2H, m), 3.05-3.09(6H, m),




3.19-3.22(2H, m), 4.40(1H, t, J = 5.8 Hz), 4.52(1H, t, J = 5.8 Hz), 6.66(1H, s)


121
2
ESI+: 353, 355




NMR: 2.42-2.48(2H, m), 2.69-2.76(2H, m), 2.92-3.01(6H, m), 3.03(3H, s), 3.23-3.35(4H,




m), 4.19(2H, t, J = 5.4 Hz), 6.42(1H, s), 7.09(m, s)




mp: 99-104


122
2
ESI+: 337




NMR: 1.78-1.88(2H, m), 2.67(2H, t, J = 6.5 Hz), 2.95-3.05(4H, m), 3.08-3.17(4H, m), 3.66-




3.73(2H, m), 5.17(2H, s), 6.95(1H, s), 7.28-7.44(5H, m), 7.50(1H, s), 9.20-9.43(2H, br)




mp: 185-188


123
2
ESI+: 303




NMR: 0.92(6H, d, J = 6.8 Hz), 1.77-1.97(3H, m), 2.68(2H, t, J = 6.5 Hz), 2.95-3.04(4H, m),




3.10-3.18(4H, m), 3.63-3.70(2H, m), 3.90(2H, d, J = 6.4 Hz), 6.96(1H, s), 7.48(1H, s), 9.06-




9.26(2H, br)




mp: 202-207


124
2
ESI+: 245




NMR: 1.12(3H, t, J = 7.0 Hz), 2.46-2.52(2H, m), 2.72-2.82(2H, m), 3.00-3.24(8H, m),




3.88(2H, q, J = 7.0 Hz), 6.99(1H, s), 7.04(1H, s), 9.26-9.50(2H, br)




mp: 241(decomp.)


125
2
ESI+: 259




NMR: 0.87(3H, t, J = 7.4 Hz), 1.47-1.61(2H, m), 2.46-2.52(2H, m), 2.73-2.82(2H, m), 3.00-




3.21(8H, m), 3.81(2H, t, J = 7.5 Hz), 6.98(1H, s), 7.04(1H, s), 9.23-9.49(2H, br)




mp: 125-129


126
2
ESI+: 307




NMR: 2.61-2.70(2H, m), 2.82-3.16(10H, m), 5.11(2H, s), 6.83(1H, s), 7.06(1H, s), 7.18-




7.35(5H, m), 9.21-9.40(2H, br)




mp: 177-180


127
2
ESI+: 273




NMR: 0.83(6H, d, J = 6.7 Hz), 1.84-1.97(1H, m), 2.30(4H, s), 2.45-2.54(2H, m), 2.73-




2.81(2H, m), 2.86-3.07(8H, m), 3.72-3.80(2H, m), 6.96(1H, s), 7.01(1H, s)




mp: 142-144


















TABLE 159





Ex
Syn
Dat







128
2
ESI+: 289




NMR: 1.24(6H, d, J = 6.2 Hz), 1.78-1.84(2H, m), 2.29(4H, s), 2.66(2H, t, J = 6.5 Hz), 2.87-




2.89(4H, br), 2.99-3.01(4H, br), 3.61-3.64(2H, m), 4.87(1H, quint, J = 6.2 Hz), 6.90(1H,




s), 7.44(1H, s)


129
2
ESI+: 367, 369




NMR: 1.52-1.67(2H, m), 2.38-2.47(2H, m), 2.71-2.82(2H, m), 3.01-3.10(9H, m), 3.15




(2H, t, J = 6 Hz), 3.30-3.39(2H, m), 4.06(2H, t, J = 7.1 Hz), 6.47(2H, s), 7.13(1H, s)




mp: 153-155


130
2
ESI+: 331




NMR: 2.93-3.10(10H, m), 3.13-3.21(2H, m), 3.24(3H, s), 3.58(2H, t, J = 5.9 Hz),




4.12(2H, t, J = 4.4 Hz), 6.46(2H, s), 6.91(1H, s)




mp: 180(decomp.)


131
2
ESI+: 329




NMR: 1.66-1.81(2H, m), 2.68(2H, t, J = 6.4 Hz), 2.90-3.18(12H, m), 3.20(3H, s), 3.52(2H,




t, J = 6.0 Hz), 6.45(2H, s), 7.02(1H, s)




mp: 175(decomp.)


132
2
ESI+: 261




NMR: 0.88(3H, t, J = 7.4 Hz), 1.49-1.63(2H, m), 2.86-3.07(8H, m), 3.77-3.88(2H, m), 4.57(2H,




s), 6.43(2H, s), 6.84(1H, s), 7.03(1H, s)




mp: 183(decomp.)


133
2
ESI+: 309




NMR: 2.89-3.18(8H, m), 3.32(3H, s), 4.75(2H, s), 5.12(2H, s), 6.90(1H, s), 6.94(1H, s),




7.21-7.36(5H, m), 9.19-9.37(2H, br)




mp: 233(decomp.)


134
2
ESI+: 351




NMR: 1.74-1.80(2H, m), 2.30(4H, s), 2.64(2H, t, J = 6.6 Hz), 2.76-2.79(2H, br), 2.84-2.87(2H,




br), 2.93-2.99(6H, m), 3.57-3.60(2H, m), 4.33(2H, t, J = 6.6 Hz), 6.88(1H, s), 7.21-




7.33(6H, m)


135
2
ESI+: 341, 343




NMR-A: 2.98-3.05(4H, m), 3.07-3.13(2H, m), 3.14-3.23(4H, m), 3.28-3.35(5H, m), 3.74(2H,




t, J = 6.18 Hz), 4.10-4.16(2H, m), 6.64(2H, s), 6.77(1H, s), 8.89(2H, s)




mp: 183(decomp.)


136
2
ESI+: 337, 339




NMR: 0.70(3H, t, J = 7.4 Hz), 1.29-1.45(2H, m), 2.41-2.48(2H, m), 2.72-2.80(2H, m), 3.00-




3.11(6H, m), 3.28-3.40(2H, m), 3.98(2H, t, J = 7.3 Hz), 6.47(2H, s), 6.98(1H, s)




mp: 187(decomp.)


137
2
ESI+: 335




NMR: 0.46(3H, t, J = 7.4 Hz), 0.91-1.03(2H, m), 2.30(4H, s), 2.45-2.52(2H, m), 2.71-2.84




(6H, m), 2.89-3.11(6H, m), 7.13(1H, s), 7.16-7.23(2H, m), 7.38-7.52(3H, m)




mp: 196-200


















TABLE 160





Ex
Syn
Dat







138
2
ESI+: 339




NMR: 2.28(3H, s), 2.74-2.96(8H, m), 3.72(3H, s), 4.73(2H, s), 5.08(2H, s), 6.79-




6.89(5H, m), 7.18-7.29(1H, m)




mp: 188-189


139
2
ESI+: 343, 345




NMR: 2.29(3H, s), 2.74-2.98(8H, m), 4.75(2H, s), 5.12(2H, s), 6.83-6.89(2H, m),




7.21-7.26(1H, m), 7.30-7.40(3H, m)




mp: 192-194


140
2
ESI+: 299




NMR: 0.25-0.36(2H, m), 0.66(3H, t, J = 7.4 Hz), 0.95-1.04(2H, m), 1.24-1.36(2H, m),




1.81-1.99(1H, m), 2.27-2.45(8H, m), 2.60-2.74(2H, m), 2.87-3.87(8H, m), 6.94(1H, s)




mp: 170-171


141
2
ESI+: 305




NMR: 0.37-0.50(2H, m), 0.95-1.04(2H, m), 1.57-1.67(1H, m), 1.95-2.11(2H, m), 2.78-




2.85(2H, m), 2.86-3.03(6H, m), 3.03-3.10(2H, m), 3.11-3.21(2H, m), 3.99(2H, t, J =




4.3 Hz), 4.50(2H, dt, J = 47.5, 5.8 Hz), 6.37(1H, s), 6.49(1H, s)




mp: 144-147


142
2
ESI+: 245




NMR: 0.33-0.42(2H, m), 0.81-0.95(2H, m), 1.38-1.48(1H, m), 2.70-2.79(2H, m), 2.84-




2.98(4H, m), 3.05-3.15(2H, m), 3.17-3.26(2H, m), 4.03-4.11(2H, m), 5.32-5.62(1H, br),




6.24(1H, s), 6.36(1H, s)


143
2
ESI+: 286




NMR: 1.71-1.77(2H, m), 2.29(2H, s), 2.64(2H, t, J = 6.4 Hz), 2.79-2.85(4H, m), 2.90-2.92




(2H, m), 3.04-3.07(2H, m), 3.14-3.17(2H, m), 3.27(3H, s), 3.38(2H, t, J = 6.3 Hz),




3.69(2H, t, J = 6.3 Hz), 7.02(1H, s)


144
2
ESI+: 339




NMR: 2.30(4H, s), 2.78-2.99(8H, m), 3.71(3H, s), 4.71(2H, m), 5.04(2H, s), 6.84(1H, s),




6.85-6.91(2H, m), 6.92(1H, s), 7.19-7.24(2H, m)




mp: 173-176


145
2
ESI+: 343, 345




NMR: 2.81-3.03(8H, m), 4.74(2H, s), 5.11(2H, s), 6.44(2H, s), 6.86(IH, s), 6.88(1H, s),




7.27-7.34(2H, m), 7.36-7.43(2H, m)




mp: 207(decomp.)


146
2
ESI+: 343, 345




NMR: 2.28(3H, s), 2.71-2.96(8H, m), 4.77(2H, s), 5.11(2H, s), 6.86(1H, s), 6.88(1H, s),




7.04-7.09(1H, m), 7.24-7.35(2H, m), 7.50-7.54(1H, m)




mp: 119-127


















TABLE 161





Ex
Syn
Dat







147
2
ESI+: 385, 387




NMR: 1.74-1.80(2H, m), 2.30(4H, s), 2.64(2H, t, J = 6.5 Hz), 2.78-2.81(2H, br), 2.85-




2.87(2H, br), 2.96-2.99(4H, br), 3.09(2H, t, J = 6.5 Hz), 3.57-3.60(2H, m), 4.36(2H, t, J = 6.5 Hz),




6.88(1H, s), 7.26-7.33(3H, m), 7.39-7.46(2H, m)




mp: 187-188


148
2
ESI+: 337




NMR: 1.78-1.94(2H, m), 2.65(2H, t, J = 7.6 Hz), 2.89-3.12(8H, m), 3.87(2H, t, J = 7.5 Hz),




4.58(2H, s), 6.46(2H, s), 6.85(1H, s), 6.87(1H, s), 7.15-7.35(5H, m)




mp: 218(decomp.)


149
2
ESI+: 339




NMR: 2.97-3.20(8H, m), 4.12-4.32(4H, m), 4.62(2H, s), 6.83-6.98(4H, m), 7.18-7.34(3H,




m), 9.22-9.41(2H, br)




mp: 246(decomp.)


150
2
ESI+: 291




NMR: 1.39(3H, d, J = 6.7 Hz), 2.83-3.07(8H, m), 3.24(3H, s), 3.46-3.55(2H, m), 3.97-




4.10(2H, m), 4.63(1H, q, J = 6.7 Hz), 6.41(1H, s), 6.82(1H, s), 7.06(1H, s)




mp: 189(decomp.)


151
2
ESI+: 273




NMR: 0.42-0.50(2H, m), 0.96-1.05(2H, m), 1.17(3H, t, J = 7.0 Hz), 1.61-1.70(1H, m),




2.85-2.99(4H, m), 3.00-3.13(6H, m), 3.19-3.28(2H, m), 3.94-4.01(2H, m), 6.45(2H, s), 6.53(1H, s)




mp: 174-177


152
2
ESI+: 287




NMR: 0.41-0.48(2H, m), 0.86(3H, t, J = 7.4 Hz), 0.95-1.03(2H, m), 1.57-1.72(3H, m), 2.76-




2.88(4H, m), 2.88-2.98(4H, m), 3.02-3.09(2H, m), 3.11-3.20(2H, m), 3.95-4.01(2H,




m), 6.37(1H, s), 6.47(1H, s)




mp: 138-141


153
2
ESI+: 289




NMR: 0.39-0.47(2H, m), 0.94-1.03(2H, m), 1.55-1.65(1H, m), 2.77-2.84(2H, m), 2.87-




2.99(4H, m), 3.03(2H, t, J = 6.5 Hz), 3.10-3.20(4H, m), 3.69(2H, t, J = 6.5 Hz), 3.97-




4.05(2H, m), 6.37(1H, s), 6.47(1H, s)




mp: 146-150


154
2
ESI+: 277




NMR: 1.23(3H, d, J = 6.3 Hz), 2.75-2.81(2H, m), 2.81-2.87(2H, m), 2.90-3.03(5H, m),




3.25(3H, s), 3.28-3.37(2H, m), 3.38-3.55(3H, m), 4.02-4.12(1H, m), 6.39(1H, s),




6.48(1H, s), 6.51(1H, s)




mp: 170(decomp.)


155
2
ESI+: 329, 331




NMR: 2.75-2.87(4H, m), 2.91-3.06(4H, m), 3.30-3.38(2H, m), 4.16-4.24(2H, m), 4.48




(2H, s), 6.36(1H, s), 6.43(2H, s), 6.57(1H, s), 7.26-7.35(3H, m), 7.45-7.52(1H, m)




mp: 184(decomp.)


















TABLE 162





Ex
Syn
Dat







156
2
ESI+: 317




NMR: 0.17-0.26(1H, m), 0.59-0.69(1H, m), 0.93-1.07(2H, m), 1.23(3H, d, J = 6.1 Hz),




1.58-1.69(1H, m), 2.52-2.58(1H, m), 2.75-2.87(1H, m), 2.89-3.05(3H, m), 3.05-3.21(5H,




m), 3.25(3H, s), 3.29-3.43(2H, m), 3.54-3.67(2H, m), 3.96-4.07(1H, m), 6.44(2H, s), 6.51(1H, s)




mp: 102-103


157
2
ESI+: 259




NMR: 0.49-0.56(2H, m), 0.96-1.05(2H, m), 1.62-1.71(1H, m), 2.77(3H, s), 2.85-2.93(2H,




m), 2.99-3.12(6H, m), 320-3.28(2H, m), 3.97-4.03(2H, m), 6.43(2H, s), 6.53(1H, s)




mp: 211(decomp.)


158
2
ESI+: 353, 355




NMR: 1.07-1.29(3H, br), 1.62-1.77(1H, br), 1.95-2.11(1H, br), 2.63-2.77(2H, br), 2.86-




3.42(9H, m), 3.94-4.27(3H, m), 7.08(1H, s)




mp: 187-189


159
2
ESI+: 231




NMR: 1.27(6H, s), 1.84-1.91(2H, m), 3.05-3.20(8H, m), 3.26-3.32(2H, m), 6.99(1H, s),




7.37(1H, s), 9.36-9.59(1.9H, br)




mp: 288-290


160
2
ESI+: 429, 431




NMR: 1.60-2.08(2H, m), 2.65-3.38(12H, m), 3.93-4.41(4H, m), 6.94-7.39(6H, m)




mp: 176-177


161
2
ESI+: 245




NMR: 1.19(6H, s), 1.64-1.70(2H, m), 2.81(3H, s), 2.86-2.94(4H, m), 2.99-3.15(6H, m),




6.39(1H, s), 6.44(1.8H, s), 6.93(1H, s)




mp: 197-200


162
2
ESI+: 385, 387




NMR: 1.74-1.81(2H, m), 2.64(2H, t, J = 6.6 Hz), 2.81-2.83(2H, br), 2.88-2.90(2H, br), 2.95-




3.01(6H, m), 3.57-3.60(2H, m), 4.34(2H, t, J = 6.4 Hz), 6.45(2H, s), 6.89(1H, s), 7.23-7.36(5H, m)




mp: 201(decomp.)


163
2
ESI+: 381




NMR: 1.74-1.81(2H, m), 2.64(2H, t, J = 6.6 Hz), 2.82-2.84(2H, br), 2.89-2.94(4H, m), 2.98-




3.02(4H, br), 3.57-3.60(2H, m), 3.78(3H, s), 4.28(2H, t, J = 6.6 Hz), 6.45(2H, s), 6.86-6.90(2H,




m), 6.98(1H, d, J = 7.9 Hz), 7.16-7.19(1H, m), 7.21-7.25(1H, m), 7.30(1H, br)




mp: 190(decomp.)


164
2
ESI+: 381




MMR: 1.75-1.81(2H, m), 2.64(2H, t, J = 6.6 Hz), 2.81-2.83(2H, br), 2.89-2.93(4H, m),




2.98-3.02(4H, br), 3.58-3.61(2H, m), 3.72(3H, s), 4.33(2H, t, J = 6.5 Hz), 6.45(2H, s),




6.79-6.84(3H, m), 6.89(1H, s), 7.22(1H, t, J = 8.1 Hz), 7.26(1H, br)




mp: 196(decomp.)


















TABLE 163





Ex
Syn
Dat







165
2
ESI+: 325




NMR: 2.81-2.94(4H, m), 2.97-3.11(4H, m), 3.28-3.37(2H, m), 3.83(3H, s), 4.09-4.20(2H,




m), 4.37(2H, s), 6.45(1H, s), 6.56(1H, s), 6.85-6.93(1H, m), 7.00-7.06(1H, m), 7.11-7.16(1H,




m), 7.21-7.30(1H, m), 9.12-9.41(2H, br).


166
2
ESI+: 313




NMR: 2.81-2.94(4H, m), 2.98-3.15(4H, m), 3.22-3.38(2H, m), 4.09-4.24(2H, m), 4.46




(2H, s), 6.55(1H, s), 6.57(1H, s), 7.01-7.20(3H, m), 7.32-7.45(1H, m), 9.13-9.41(2H, br)


167
2
ESI+: 309




NMR: 2.29(3H, s), 2.84-2.95(4H, m), 2.99-3.11(4H, m), 3.23-3.31(2H, m), 4.11-4.19(2H,




m), 4.39(2H, s), 6.56(1H, s), 6.60(1H, s), 7.05-7.14(3H, m), 7.22(1H, t, J = 7.5 Hz),




9.28-9.54(2H, br)


168
2
ESI+: 320




NMR: 2.83-2.95(4H, m), 2.99-3.13(4H, m), 3.28-3.37(2H, m), 4.14-4.24(2H, m), 4.49




(2H, s), 6.54(1H, s), 6.58(1H, s), 7.52-7.60(1H, m), 7.63-7.69(1H, m), 7.71-7.80(2H, m),




9.17-9.53(2H, br)


169
2
ESI+: 363




NMR: 2.76-2.88(4H, m), 2.94-3.07(4H, m), 3.2-3.34(2H, m), 4.13-4.21(2H, m),




4.53(2H, s), 6.44(2H, s), 6.56(1H, s), 6.58(1H, s), 7.54-7.70(4H, m)




mp: 141-146


170
2
ESI+: 289




NMR: 1.18(6H, s), 1.58-1.64(2H, m), 2.85-2.93(4H, m), 3.00-3.10(4H, m), 3.24-3.30(5H,




m), 3.37-3.45(2H, m), 3.46-3.52(2H, m), 6.40(1H, s), 6.44(2H, s), 6.92(1H, s)




mp: 172-175


171
2
ESI+: 385, 387




NMR: 1.74-1.81(2H, m), 2.64(2H, t, J = 6.5 Hz), 2.81-2.83(2H, br), 2.89-2.92(2H, br), 2.95(2H,




t, J = 6.4 Hz), 2.99-3.03(4H, br), 3.57-3.60(2H, m), 4.33(2H, t, J = 6.4 Hz), 6.45(2H,




s), 6.89(1H, s), 7.22(1H, br), 7.30(2H, d, J = 8.5 Hz), 7.37(2H, d, J = 8.5 Hz)


172
2
ESI+: 353




NMR: 2.29(4H, s), 2.73-2.75(2H, br), 2.81-2.83(2H, m), 2.93-2.98(6H, m), 3.74(2H, t, J =




4.5 Hz), 4.14(2H, t, J = 4.5 Hz), 4.37(2H, t, J = 6.5 Hz), 6.67(1H, s), 7.21-7.34(5H, m),




7.36-7.44(1H, br)




mp: 185-187


173
2
ESl+: 387, 389




NMR: 2.30(4H, s), 2.73-2.75(2H, br), 2.82-2.84(2H, br), 2.94-2.98(6H, m), 3.73(2H, t, J =




4.5 Hz), 4.14(2H, t, J = 4.5 Hz), 4.37(2H, t, J = 6.4 Hz), 6.67(1H, s), 7.30-7.38(5H, m)




mp: 186(decomp.)


174
2
ESI+: 357




NMR: 2.52-3.04(17H, m), 3.97-4.12(2H, m), 6.36(1H, s), 6.71(1H, s), 7.16-7.24(1H,




m), 7.26-7.34(2H, m), 7.41-7.50(1H, m)




mp: 179-182


















TABLE 164





Ex
Syn
Dat







175
2
ESI+: 355, 357




NMR: 3.13-3.21(6H, m), 3.23(3H, s), 3.30-3.37(2H, m), 3.52(2H, t, J = 5.7 Hz), 4.09(2H,




t, J = 5.7 Hz), 4.73(2H, s), 7.22(1H, s), 9.19-9.38(2H, br)




mp: 244(decomp.)


176
2
ESI+: 341, 343




NMR: 3.00-3.06(2H, m), 3.07-3.15(4H, m), 3.21-3.27(5H, m), 3.35-3.40(2H, m), 3.42-




3.53(4H, m), 4.10-4.24(2H, m), 6.64(1H, s), 9.20-9.42(2H, br)




mp: 107-110


177
2
ESI+: 387, 389




NMR: 2.30(4H, s), 2.75-2.77(2H, br), 2.81-2.83(2H, br), 2.93-2.97(4H, br), 3.11(2H, t, J =




6.4 Hz), 3.74(2H, t, J = 4.5 Hz), 4.14(2H, t, J = 4.5 Hz), 4.40(2H, t, J = 6.4 Hz), 6.67(1H, s),




7.26-7.33(2H, m), 7.41-7.46(3H, m)




mp: 169-170


178
2
ESI+: 387, 389




NMR: 2.30(4H, s), 2.74-2.76(2H, br), 2.81-2.84(2H, br), 2.93-3.00(6H, m), 3.74(2H, t, J =




4.5 Hz), 4.14(2H, t, J = 4.5 Hz), 4.39(2H, t, J = 6.4 Hz), 6.67(1H, s), 7.25-7.38(5H, m)




mp: 160-162


179
2
ESI+: 383




NMR: 2.30(4H, s), 2.75-2.77(2H, br), 2.81-2.84(2H, br), 2.92-2.98(6H, m), 3.73(2H, t, J =




4.5 Hz), 3.78(3H, s), 4.14(2H, t, J = 4.5 Hz), 4.32(2H, t, J = 6.6 Hz), 6.67(1H, s), 6.87-6.90




(1H, m), 6.97-6.99(1H, m), 7.18-7.25(2H, m), 7.39-7.51(1H, br)




mp: 158-160


180
2
ESI+: 383




NMR: 2.30(4H, s), 2.73-2.75(2H, br), 2.81-2.84(2H, br), 2.92-2.98(6H, m), 3.72(3H, s),




3.74(2H, t, J = 4.5 Hz), 4.14(2H, t, J = 4.5 Hz), 4.37(2H, t, J = 6.5 Hz), 6.67(1H, s), 6.79-6.82




(1H, m), 6.84-6.86(2H, m), 7.22(1H, t, J = 8.1 Hz), 7.35-7.44(1H, br)




mp: 134-136


181
2
ESI+: 317




NMR: 1.41(3H, s), 1.88(3H, s), 2.61-3.16(12H, m), 3.25(3H, s), 3.37-3.52(2H; m), 3.92-




4.09(2H, m), 5.06(1H, s), 6.38(1H, s), 6.55(1H, s)




mp: 173-176


182
2
ESI+: 367




NMR: 2.57-2.68(2H, m), 2.83-3.10(14H, m), 3.26(3H, s), 3.58(2H, t, J = 5.8 Hz), 4.11-




4.14(2H, m), 6.44(1H, s), 6.54(1H, s), 7.15-7.34(5H, m)


183
2
ESI+: 305




NMR: 0.96(3H, t, J = 7.7 Hz), 1.28-1.45(2H, m), 2.58-2.68(2H, m), 2.78-3.09(12H, m),




3.31(3H, s), 3.61(2H, t, J = 6.3 Hz), 4.03-4.21(2H, m), 6.40(1H, s), 6.48(1H, s)


184
2
ESI+: 339




NMR: 2.52-2.60(2H, m), 2.85-2.99(4H, m), 3.03-3.10(2H, m), 3.28(3H, s), 3.29-3.35(2H,




m), 3.41-3.58(4H, m), 3.92-4.01(2H, m), 6.42(2H, s), 6.62(1H, s), 7.05-7.14(2H, m),




7.27-7.33(1H, m), 7.35-7.41(2H, m)




mp: 169(decomp.)


















TABLE 165





Ex
Syn
Dat







185
2
ESI+: 371




NMR: 2.30(4H, s), 2.75-2.77(2H, br), 2.81-2.84(2H, br), 2.94-2.98(4H, br), 3.01(2H, t, J =




6.4 Hz), 3.73(2H, t, J = 4.5 Hz), 4.14(2H, t, J = 4.5 Hz), 4.37(2H, t, J = 6.4 Hz), 6.67(1H, s),




7.14-7.20(2H, m), 7.27-7.33(1H, m), 7.36-7.47(2H, m)




mp: 186-187


186
2
ESI+: 371




NMR: 2.30(4H, s), 2.73-2.75(2H, br), 2.81-2.83(2H, br), 2.93-2.98(4H, br), 3.00(2H, t, J =




6.4 Hz), 3.73(2H, t, J = 4.5 Hz), 4.14(2H, t, J = 4.5 Hz), 4.39(2H, t, J = 6.4 Hz), 6.67(1H, s),




7.03-7.08(1H, m), 7.12-7.17(2H, m), 7.32-7.43(2H, m)




mp: 162-164


187
2
ESI+: 371




NMR: 2.30(4H, s), 2.74-2.76(2H, br), 2.82-2.84(2H, br), 2.94-2.98(6H, m), 3.74(2H, t, J =




4.5 Hz), 4.14(2H, t, J = 4.5 Hz), 4.36(2H, t, J = 6.5 Hz), 6.67(1H, s), 7.10-7.16(2H, m),




7.29-7.35(2H, m), 7.35-7.44(1H, br)




mp: 179-181


188
2
ESI+: 305




NMR: 1.36(6H, s), 2.81-3.02(8H, m), 3.24(3H, s), 3.50(2H, t, J = 6.0 Hz), 4.04(2H, t, J =




5.9 Hz), 6.40(1H, s), 6.78(1H, s), 7.02(1H, s)




mp: 175-176


189
2
ESI+: 287




NMR: 2.85-3.00(4H, m), 3.04-3.15(4H, m), 3.37-3.48(2H, m), 4.03-4.20(4H, m), 6.59




(1H, s), 6.73(1H, s), 9.09-9.33(2H, br)




mp: 221-222


190
2
ESR: 365, 367




NMR: 3.04-3.19(8H, m), 3.33-3.39(2H, m), 3.72(2H, q, J = 9.3 Hz), 4.20-4.27(2H, m),




6.81(1H, s), 9.17-9.38(2H, br)




mp: 214-215


191
2
ESI+: 365, 367




NMR: 2.99-3.17(6H, m), 3.21-3.29(2H, m), 3.46(2H, t, J = 4.2 Hz), 4.13-4.26(4H, m),




6.83(1H, s), 9.10-9.33(2H, br)




mp: 216-221


192
2
ESI+: 345




NMR-A: 2.57-2.68(6H, m), 2.95-3.22(11H, m), 4.00-4.08(2H, m), 6.63(1H, s), 6.72(1H,




s), 6.98(1H, dd, J = 4.9, 1.2 Hz), 7.33(1H, dd, J = 2.8, 1.2 Hz), 7.66(1H, dd, J = 4.9, 2.8 Hz)




mp: 200(decomp.)


193
2
ESI+: 345




NMR: 2.65-2.79(6H, m), 2.94-3.22(11H, m), 4.02-4.10(2H, m), 6.64(1H, s), 6.78(1H, s),




6.97(1H, dd, J = 3.5, 1.2 Hz), 7.18(1H, dd, J = 5.3, 3.5 Hz), 7.69(1H, dd, J = 5.3, 1.2 Hz)




mp: 200(decomp.)


















TABLE 166





Ex
Syn
Dat







194
2
ESI+: 327




NMR: 0.35-0.43(2H, m), 0.86-0.96(2H, m), 1.40-1.52(1H, m), 2.77-2.86(2H, m), 2.86-




2.98(4H, m), 3.05-3.18(2H, m), 3.36-3.42(2H, m), 4.00-4.16(4H, m), 6.37(1H, s), 6.57




(1H, s)




mp: 177(decomp.)


195
2
ESI+: 289




NMR: 1.16(6H, s), 1.66(2H, t, J = 6.6 Hz), 2.61(2H,t, J = 6.6 Hz), 2.81-2.95(4H, m), 2.98-




3.10(4H, m), 3.30(3H, s), 3.31-3.37(2H, m), 3.38-3.44(2H, m), 6.35(1H, s), 6.44(1.8H, s),




6.71(1H, s)




mp: 156-158


196
2
ESI+: 367




NMR: 1.26(3H, d, J = 7.0 Hz), 2.30(4H, s), 2.71-2.72(2H, br), 2.81-2.83(2H, m), 2.93-




2.97(4H, m), 3.10-3.19(1H, m), 3.69-3.71(2H, m), 4.09-4.12(2H, m), 4.26(2H, d, J = 7.1 Hz),




6.66(1H, s), 7.21-7.35(6H, m)




mp: 177-179


197
2
ESI+: 367




NMR: 1.26(3H, d, J = 6.3 Hz), 2.29(4H, s), 2.80-2.85(4H, m), 2.91(2H, d, J = 6.4 Hz), 2.96-




2.98(4H, m), 3.64-3.69(1H, m), 3.77-3.83(1H, m), 3.99-4.04(1H, m), 4.12-4.17(1H, m),




5.00-5.08(1H, m), 6.67(1H, s), 7.19-7.23(3H, m), 7.27-7.31(2H, m), 7.48(1H, brs)




mp: 85-87


198
2
ESI+: 431, 433




NMR: 2.31(4H, s), 2.79-2.82(2H, m), 2.91-2.99(6H, m), 3.15-3.18(2H, m), 3.76(2H, t, J =




4.4 Hz), 4.26(2H, t, J = 4.4 Hz), 4.39(2H, t, J = 6.5 Hz), 7.21-7.33(5H, m), 7.39-7.45(1H, br)




mp: 142-143


199
2
ESI+: 297, 299




NMR: 2.29(4H, s), 2.85-2.88(2H, m), 2.95-2.99(4H, m), 3.02-3.05(2H, m), 3.25(3H, s),




3.35-3.38(2H, m), 3.41-3.44(2H, m), 3.49-3.51(2H, m), 4.16-4.18(2H, m), 6.56(1H, s)




mp: 139-141


200
2
ESI+: 311, 313




NMR: 1.26(3H, t, J = 7.1 Hz), 2.28(2H, s), 2.86-2.91(6H, m), 3.08-3.11(2H, m), 3.82-3.84




(2H, m), 4.18(2H, q, J = 7.1 Hz), 4.29-4.31(2H, m), 7.61(1H, brs);




mp: 145-147


201
2
ESI+: 393




NMR: 0.38-0.43(2H, m), 0.92-0.97(2H, m), 1.46-1.53(1H, m), 2.28(4H, s), 2.74-2.77(2H,




m), 2.94-2.97(4H, m), 3.01-3.03(2H, m), 3.17-3.19(2H, m), 3.70-3.72(2H, m), 4.16-




4.18(2H, m), 4.36(2H, t, J = 6.5 Hz), 7.21-7.34(6H, m)




mp: 142-144


















TABLE 167





Ex
Syn
Dat







202
2
ESI+: 313




NMR: 2.84-2.99(4H, m), 3.02-3.15(4H, m), 3.34-3.40(5H, m), 3.56-3.76(4H, m), 4.03-




4.14(2H, m), 6.57(1H, s), 6.63(1H, s), 9.06-9.25(2H, br)




mp: 172-173


203
2
ESI+: 353




NMR: 0.35-0.46(2H, m), 0.97-1.06(2H, m), 1.59-1.70(1H, m), 2.83-2.91(2H, m), 2.96-




3.10(4H, m), 3.16-3.23(5H, m), 3.24-3.31(2H, m), 3.51(2H, t, J = 13.3 Hz), 3.70(2H, t, J =




16 Hz), 4.08-4.16(2H, m), 6.43(2H, s), 6.52(1H, s)




mp: 163-165


204
2
ESI+: 291




NMR: 1.20(6H, s), 2.71-2.77(2H, m), 2.78-2.84(2H, m), 2.87-2.96(4H, m), 3.05(2H, s),




3.25(3H, s), 3.39-3.45(2H, m), 3.47-3.53(2H, m), 6.37(1H, s), 6.44(1H, s), 6.50(1H, s)




mp: 194(decomp.)


205
2
ESI+: 283




NMR-A: 1.81-2.00(2H, m), 2.46-2.63(3H, br), 2.75-2.90(4H, m), 2.97-3.26(8H, m), 6.48-




6.59(1H, br), 6.63(1H, s), 6.98-7.13(1H, br), 7.63-7.78(1H, br), 7.82-7.94(1H, br)




mp: 203(decomp.)


206
2
ESI+: 277




NMR: 1.07(3H, d, J = 6.5 Hz), 2.79-2.91(4H, m), 2.98-3.07(4H, m), 3.25-3.34(4H, m),




3.40-3.54(4H, m), 3.86(1H, dd, J = 10.4, 2.3 Hz), 3.93(1H, dd, J = 10.4, 3.1 Hz), 6.43(1.8H,




s), 6.50(1H, s), 6.53(1H, s)




mp: 133-136


207
2
ESI+: 277




NMR: 1.07(3H, d, J = 6.5 Hz), 2.79-2.93(4H, m), 2.98-3.07(4H, m), 3.25-3.34(4H, m),




3.39-3.54(4H, m), 3.86(1H, dd, J = 10.4, 2.3 Hz), 3.93(1H, dd, J = 10.4, 3.0 Hz), 6.44(1.8H,




s), 6.50(1H, s), 6.53(1H, s)




mp. 131-134


208
2
ESI+: 429




NMR: 2.26(2H, s), 2.49-2.53(2H, m), 2.77-2.79(4H, m), 2.89-2.91(2H, m), 2.98(2H, t, J =




6.5 Hz), 3.70-3.72(2H, m), 4.01-4.03(2H, m), 4.39(2H, t, J = 6.5 Hz), 7.08-7.11(2H, m),




7.22-7.35(6H, m), 7.37-7.41(3H, m)




mp: 169-171


209
2
ESI+: 283




NMR: 1.68-1.83(2H, m), 2.03(3H, s), 2.33-2.42(2H, m), 2.71(2H, t, J = 6.4 Hz), 2.93-3.10




(6H, m), 3.11-3.24(2H, m), 6.50(1H, t, J = 2.1 Hz), 6.63(1H, s), 7.00(1H, s), 8.65-8.95(2H, m)




mp: 206(decomp.)


















TABLE 168





Ex
Syn
Dat







210
2
ESI+: 285




NMR: 2.33(3H, s), 2.82-2.89(2H, m), 2.95-3.12(6H, m), 3.12-3.22(2H, m), 4.07-4.13(2H,




m), 6.51-6.52(1H, m), 6.64(1H, s), 6.75(1H, s), 7.63-7.65(1H, m), 7.81(1H, t, J = 1.7 Hz),




8.66-8.91(2H, br)




mp: 226(decomp.)


211
2
ESI+: 327




NMR: 0.35-0.48(2H, m), 0.97-1.08(2H, m), 1.64-1.78(1H, m), 2.84-2.94(2H, m), 2.98-




3.11(4H, m), 3.17-3.30(4H, m), 3.93(2H, q, J = 10 Hz), 4.12(2H, t, J = 4.5 Hz), 6.44(2H, s),




6.55(1H, s)




mp: 174(decomp.)


212
2
ESI+: 395




NMR: 0.90(3H, t, J = 7.3 Hz), 1.30-1.39(2H, m), 2.53-2.57(2H, m), 2.80-2.82(2H, m), 2.95-




3.01(8H, m), 3.71-3.73(2H, m), 4.16-4.18(2H, m), 4.37(2H, t, J = 6.5 Hz), 6.45(2H, s),




7.21-7.34(6H, m)




mp: 134-136


213
2
ESI+: 401




NMR: 0.87-0.97(5H, m), 1.10-1.25(3H, m), 1.31-1.41(3H, m), 1.53(2H, q, J = 6.6 Hz), 1.59-




1.71(5H, m), 2.55-2.59(2H, m), 2.88-2.91(2H, m), 2.95-3.02(6H, m), 3.76-3.78(2H,




m), 4.16(2H, t, J = 6.6 Hz), 4.20-4.22(2H, m), 6.44(2H, s), 7.46(1H, brs)




mp: 139-141


214
2
ESI+: 435




NMR: 2.63-2.66(2H, m), 2.77-2.82(4H, m), 2.88-2.91(2H, m), 2.96-2.99(2H, m), 3.71-




3.73(2H, m), 4.07-4.09(2H, m), 4.39(2H, t, J = 6.5 Hz), 6.40(1H, s), 6.84(1H, dd, J = 3.4, 1.1




Hz), 7.10(1H, dd, J = 5.2, 3.4 Hz), 7.21-7.34(5H, m), 7.40-7.47(1H, br), 7.59(1H, dd, J = 5.2,




1.1 Hz)




mp: 215-216


215
2
ESI+: 329




NMR: 0.32-0.39(1H, m), 0.54-0.62(1H, m), 0.96-1.07(2H, m), 1.33-1.44(1H, m), 1.58-




1.67(1H, m), 1.69-1.85(2H, m), 1.91-2.01(1H, m), 2.86-3.38(11H, m), 3.46-3.55(1H,




m), 3.60-3.69(1H, m), 3.72-3.80(1H, m), 3.94-4.18(3H, m), 6.53(1H, s), 9.18-9.44(2H, br)




mp: 154-156


216
2
ESI+: 317




NMR: 0.32-0.41(1H, m), 0.48-0.57(1H, m), 0.96-1.10(5H, m), 1.55-1.65(1H, m), 2.81-




3.30(14H, m), 3.34-3.42(1H, m), 3.64-3.73(1H, m), 3.96-4.08(2H, m), 6.43(2H, s), 6.50




(1H, s)




mp: 135-138


217
2
ESI+: 305




NMR: 0.31-0.41(1H, m), 0.46-0.57(1H, m), 0.95-1.04(2H, m), 1.27(3H, dd, J = 23.9, 6.3




Hz), 1.55-1.65(1H, m), 2.74-3.02(6H, m), 3.04-3.31(6H, m), 3.97-4.09(2H, m), 4.96-




5.22(1H, m), 6.37(1H, s), 6.49(1H, s)




mp: 171-173


















TABLE 169





Ex
Syn
Dat







218
2
ESI+: 301




NMR-A: 2.24(3H, s), 2.76-2.85(2H, m), 2.93-3.11(6H, m), 3.12-3.23(2H, br), 4.03-




4.11(2H, m), 6.63(1H, s), 6.79(1H, s), 6.98(1H, dd, J = 3.4, 1.1 Hz), 7.16(1H, dd, J = 5.1, 3.5 Hz),




7.68(1H, dd, J = 5.1, 1.1 Hz), 8.71-8.96(2H, br)




mp: 248-252


219
2
ESI+: 295




NMR-A: 2.09(3H, s), 2.63-2.71(2H, m), 2.95-3.09(6H, m), 3.14-3.23(2H, br), 4.04-




4.11(2H, m), 6.64(1H, s), 6.76(1H, s), 7.19-7.24(2H, m), 7.34-7.40(1H, m), 7.43-7.49(2H,




m), 6.80(2H, s)




mp: 250(decomp.)


220
2
ESI+: 341, 343




NMR: 1.69-1.75(2H, m), 2.04-2.17(2H, m), 2.27(2H, s), 2.70(2H, t, J = 6.7 Hz), 2.85-2.91




(8H, m), 2.96-2.99(2H, m), 3.20-3.22(2H, m), 4.46(1H, t, J = 5.9 Hz), 4.58(1H, t, J = 5.9 Hz),




6.83(1H, s)


221
2
ESI+: 317




NMR: 0.29-0.35(2H, br), 0.98-1.05(2H, br), 1.62-1.75(2H, m), 1.86-1.93(1H, m), 2.29




(4H, s), 2.36-2.39(2H, m), 2.65-2.69(2H, m), 2.90-2.94(2H, br), 3.01-3.10(4H, br), 3.21-




3.28(2H, br), 4.06-4.29(2H, br), 4.23(1H, t, J = 5.8 Hz), 4.34(1H, t, J = 5.8 Hz), 6.94(1H, s)




mp: 182(decomp.)


222
2
ESI+: 283




NMR-A: 1.76-1.88(2H, m), 2.38(3H, s), 2.61-2.68(2H, m), 2.73(2H, t, J = 6.4 Hz), 2.95-




3.22(8H, m), 6.44(1H, d, J = 2.9 Hz), 6.60-6.65(2H, m), 7.02(1H, s), 7.78-7.84(1H, m)




mp: 180(decomp.)


223
2
ESI+: 353, 355




NMR: 1.12(3H, d, J = 6.3 Hz), 1.60-1.68(1H, m), 1.76-1.86(1H, m), 2.66-2.70(2H, m),




2.81(1H, dd, J = 14.1, 3.4 Hz), 2.86-2.96(7H, m), 3.22-3.25(2H, m), 3.27(3H, s), 3.36-3.41




(2H, m), 3.81-3.89(1H, m), 6.41(2H, s), 6.82(1H, s)




mp: 161(decomp.)


224
2
ESI+: 315




NMR: 0.28-0.35(1H, m), 0.38-0.44(1H, m), 0.95-1.00(5H, m), 1.55-1.62(1H, m), 1.65-




1.76(2H, m), 2.57-2.60(2H, m), 2.83-2.85(2H, m), 2.99-3.13(8H, m), 3.17(3H, s), 3.19-




3.23(2H, m), 3.52-3.59(1H, m), 6.41(2H, s), 6.63(1H, s)


225
2
ESI+: 261




NMR: 1.00(3H, t, J = 7.2 Hz), 1.33-1.47(2H, m), 2.62-2.73(2H, m), 2.81(3H, s), 2.94-3.15




(8H, m), 3.16-3.31(2H, br), 4.21-4.35(2H, br), 6.64(1H, s), 9.42(2H, s)




mp: 151-152


226
2
ESI+: 247




NMR: 1.09(3H, t, J = 7.4 Hz), 2.70-2.95(5H, m), 2.97-3.17(8H, m), 3.18-3.39(2H, br), 4.23-




4.39(2H, m), 6.67(1H, s), 9.48(2H, s)




mp: 184-185


















TABLE 170





Ex
Syn
Dat







227
2
ESI+: 329




NMR: 0.30-0.40(1H, m), 0.54-0.64(1H, m), 0.96-1.06(2H, m), 1.33-1.45(1H, m), 1.58-




1.67(1H, m), 1.70-1.85(2H, m), 1.92-2.01(1H, m), 2.85-3.37(11H, m), 3.46-3.55(1H,




m), 3.61-3.69(1H, m), 3.72-3.80(1H, m), 3.95-4.03(1H, m), 4.05-4.18(2H, m), 6.53(1H,




s), 9.19-9.37(2H, br)




mp: 156-158


228
2
ESI+: 305




NMR: 0.32-0.41(1H, m), 0.48-0.55(1H, m), 0.95-1.04(2H, m), 1.27(3H, dd, J = 23.9, 6.3




Hz), 1.56-1.65(1H, m), 2.72-3.01(6H, m), 3.04-3.31(6H, m), 3.97-4.09(2H:, m), 4.97-




5.01(1H, m), 6.38(1H, s), 6.48(1H, s)




mp: 117(decomp.)


229
2
ESI+: 331




NMR: 0.41-0.48(2H, m), 0.97-1.04(2H, m), 1.07(6H, d, J = 6.1 Hz), 1.58-1.66(1H, m),




2.85-2.92(2H, m), 2.99-3.18(8H, m), 3.18-3.27(2H, m), 3.47-3.57(1H, m), 3.63(2H, t, J =




5.9 Hz), 3.99-4.05(2H, m), 6.43(2H, s), 6.51(1H, s)




mp: 117(decomp.)


230
2
ESI+: 331




NMR: 0.37-0.44(2H, m), 0.96-1.03(2H, m), 1.11(6H, s), 1.63-1.72(1H, m), 2.87-2.94(2H,




m), 3.04-3.16(9H, m), 3.21-3.33(4H, m), 4.10-4.17(2H, m), 6.51(1H, s), 8.99-9.17(2H, br)




mp: 155-156


231
2
ESI+: 345




NMR: 0.33-0.41(2H, m), 0.90(6H, s), 0.96-1.03(2H, m), 1.65-1.74(1H, m), 2.88-2.95(2H,




m), 3.00(2H, s), 3.03-3.17(9H, m), 3.22-3.30(4H, m), 4.09-4.16(2H, m), 6.50(1H, s),




9.22-9.35(2H, br)




mp: 141-145


232
2
ESI+: 371




NMR: 0.39-0.46(2H, m), 0.97-1.04(2H, m), 1.57-1.66(1H, m), 2.76-2.82(2H, m), 2.84-




2.97(4H, m), 3.07-3.19(6H, m), 3.88(2H, t, J = 6.0 Hz), 3.99-4.12(4H, m), 6.37(1H, s),




6.48(1H, s)




mp: 187(decomp.)


233
2
ESI+: 345




NMR: 0.29-0.38(1H, m), 0.51-0.60(1H, m), 0.93-1.05(2H, m), 1.57-1.66(1H, m), 2.72-




3.25(12H, m), 3.32-3.47(2H, m), 3.55-3.74(4H, m), 3.85-3.93(1H, m), 3.95-4.08(2H,




m), 6.38(1H, s), 6.47(1H, s)




mp: 204(decomp.)


234
2
ESI+: 233




NMR: 0.96(3H, t, J = 7.6 Hz), 1.48-1.66(2H, m), 2.76-2.86(4H, m), 2.89(1H, dd, J = 11.8,




7.7 Hz), 2.94-3.09(4H, m), 3.27(1H, dd, J = 11.8, 2.4 Hz), 3.77-3.86(1H, m), 5.32-5.87(1H,




br), 6.37(1H, s), 6.43(2H, s), 6.48(1H, s)




mp: 193(decomp.)


















TABLE 171





Ex
Syn
Dat







235
2
ESI+: 249




NMR: 2.76-2.87(4H, m), 2.94-3.07(5H, m), 3.25(1H, dd, J = 11.9, 2.6 Hz), 3.30(3H, s),




3.41-3.52(2H, m), 4.07-4.14(1H, m), 5.40-5.83(1H, br), 6.38(1H, s), 6.43(2H, s), 6.50(1H, s)


236
2
ESI+: 247




NMR: 0.87-0.97(3H, m), 1.32-1.63(4H, m), 2.75-2.86(4H, m), 2.90(1H, dd, J = 11.8, 7.7




Hz), 2.94-3.09(4H, m), 3.26(1H, dd, J = 11.8, 2.4 Hz), 3.86-3.94(1H, m), 5.31-5.86(1H, br),




6.36(1H, s), 6.43(2H, s), 6.47(1H, s)




mp: 191(decomp.)


237
2
ESI+: 347




NMR: 0.33-0.41(1H, m), 0.46-0.54(1H, m), 0.97-1.08(2H, m), 1.54-1.62(1H, m), 2.84-




2.98(3H, m), 2.98-3.12(5H, m), 3.14-3.25(6H, m), 3.27-3.41(6H, m), 3.61-3.70(1H, m),




3.96-4.08(2H, m), 6.43(2H, s), 6.51(1H, s)




mp: 150-154


238
2
ESI+: 291




NMR: 0.96(3H, t, J = 7.5 Hz), 1.48-1.64(2H, m), 2.79-2.93(4H, m), 2.97-3.10(5H, m),




3.25(3H, s), 3.27-3.39(2H, m), 3.40-3.55(3H, m), 3.80-3.89(1H, m), 6.44(2H, s), 6.52(1H,




s), 6.53(1H, s)




mp: 147(decomp.)


239
2
ESI+: 305




NMR: 0.88-0.96(3H, m), 1.34-1.60(4H, m), 2.79-2.93(4H, m), 2.95-3.10(5H, m), 3.25




(3H, s), 3.29-3.38(2H, m), 3.39-3.55(3H, m), 3.89-3.97(1H, m), 6.44(2H, s), 6.51(1H, s),




6.53(1H, s)




mp: 151(decomp.)


240
2
ESI+: 247




NMR: 0.97(3H, t, J = 7.5 Hz), 1.50-1.67(2H, m), 2.78(3H, s), 2.80-2.92(5H, m), 2.97-3.07




(4H, m), 3.22(1H, dd, J = 11.6, 2.4 Hz), 3.97-4.05(1H, m), 6.43(2H, s), 6.51(1H, s), 6.53(1H, s)




mp: 166(decomp.)


241
2
ESI+: 261




NMR: 0.88-0.97(3H, m), 1.33-1.63(4H, m), 2.78(3H, s), 2.80-2.93(5H, m), 2.96-3.09(4H,




m), 3.21(1H, dd, J = 11.6, 2.3 Hz), 4.04-4.14(1H, m), 6.44(2H, s), 6.50(1H, s), 6.53(1H, s)




mp: 152-153


242
2
ESI+: 347




NMR: 0.31-0.42(1H, m), 0.44-0.57(1H, m), 0.95-1.11(2H, m), 1.53-1.64(1H, m), 2.80-




2.97(3H, m), 2.98-3.13(5H, m), 3.13-3.26(6H, m), 3.27-3.42(6H, m), 3.62-3.70(1H, m),




3.96-4.09(2H, m), 6.43(2H, s), 6.51(1H, s)




mp: 156-158


















TABLE 172





Ex
Syn
Dat







243
2
ESI+: 317




NMR: 0.30-0.42(1H, m), 0.46-0.59(1H, m), 0.95-1.09(5H, m), 1.55-1.67(1H, m), 2.80-




3.30(14H, m), 3.33-3.43(1H, m), 3.62-3.75(1H, m), 3.95-4.09(2H, m), 6.42(2H, s), 6.50




(1H, s)




mp: 133-136


244
2
ESI+: 247




NMR: 1.17(3H, t, J = 7.3 Hz), 2.16(3H, s), 2.66(2H, q, J = 7.3 Hz), 2.87-3.09(10H, m), 3.98-




4.04(2H, m), 6.44(2H, s), 6.50(1H, s)




mp: 200(decomp.)


245
2
ESI+: 291




NMR: 1.82-1.92(2H, m), 2.15(3H, s), 2.63-2.71(2H, m), 2.79-3.03(10H, m), 3.23(3H,




s), 3.40(2H, t, J = 5.2 Hz), 3.99-4.06(2H, m), 6.37(1H, s), 6.46(1H, s)




mp: 160-163


246
2
ESI+: 291




NMR: 1.13(3H, t, J = 6.9 Hz), 2.19(3H, s), 2.83(2H, t, J = 6.2 Hz), 2.87-3.12(10H, m), 3.48




(2H, q, J = 6.9 Hz), 3.65(2H, t, J = 6.2 Hz), 3.99-4.09(2H, m), 6.44(2H, s), 6.50(1H, s)




mp: 152-155


247
2
ESI+: 279




NMR: 1.94-2.11 (2H, m), 2.16(3H, s), 2.69-2.79(2H, m), 2.88-3.10(10H, m), 4.01-4.08




(2H, m), 4.55(2H, dt, J = 48.1, 6.9 Hz), 6.44(2H, s), 6.51(1H, s)




mp: 187-190


248
2
ESI+: 327




NMR: 0.28-0.32(1H, m), 0.44-0.48(1H, m), 0.97-0.99(2H, m), 1.30-1.39(1H, m), 1.56-




1.79(5H, m), 1.87-1.94(1H, m), 2.58-2.61(2H, m), 2.85-2.86(2H, m), 2.99-3.08(6H, m),




3.17-3.47(4H, m), 3.58-3.64(1H, m), 3.70-3.76(1H, m), 4.02-4.09(1H, m), 6.42(2H, s),




6.64(1H, s)


249
2
ESI+: 327




NMR: 0.28-0.32(1H, m), 0.44-0.48(1H, m), 0.97-0.99(2H, m), 1.30-1.39(1H, m), 1.56-




1.79(5H, m), 1.87-1.94(1H, m), 2.58-2.61(2H, m), 2.85-2.87(2H, m), 2.99-3.08(6H, m),




3.17-3.47(4H, m), 3.58-3.64(1H, m), 3.70-3.76(1H, m), 4.02-4.09(1H, m), 6.42(2H, s),




6.64(1H, s)


250
2
ESI+: 343




NMR: 0.36-0.50(2H, m), 0.97-1.06(2H, m), 1.13-1.29(2H, m), 1.56-1.74(3H, m), 1.90-




2.06(1H, m), 2.84(2H, d, J = 7.3 Hz), 2.89-2.98(2H, m), 3.03-3.18(6H, m), 3.23-3.35(4H,




m), 3.79-3.87(2H, m), 4.00-4.08(2H, m), 6.53(1H, s), 9.13-9.41(2H, br)




mp: 153-155


















TABLE 173





Ex
Syn
Dat







251
2
ESI+: 343




NMR: 0.28-0.40(1H, m), 0.50-0.62(1H, m), 0.94-1.03(2H, m), 1.10-1.25(1H, m), 1.33-




1.62(5H, m), 1.71-1.80(1H, m), 2.24(2H, s), 2.70-3.10(10H, m), 3.10-3.21(1H, m),




3.30-3.48(2H, m), 3.63-3.70(1H, m), 3.82-3.89(1H, m), 3.93-4.07(2H, m), 6.46(1H, s)




mp: 171(decomp.)


252
2
ESI+: 303




NMR: 1.43-1.54(1H, m), 1.73-1.90(2H, m), 2.00-2.06(1H, m), 2.25(3H, s), 2.83-3.23(11H,




m), 3.35-3.45(1H, m), 3.66-3.84(2H, m), 4.10-4.30(3H, m), 6.57(1H, s), 9.57(2H, br)


253
2
ESI+: 303




NMR: 1.41-1.53(1H, m), 1.70-1.88(2H, m), 1.94-2.05(1H, m), 2.23(3H, s), 1.77-2.85(2H,




m), 2.93-3.16(9H, m), 3.31-3.42(1H, m), 3.65-3.89(2H, m), 4.06-4.25(3H, m), 6.54(1H,




s), 9.40(2H, s)


254
2
ESI+: 331




NMR: 0.34-0.49(2H, m), 0.92(3H, d, J = 6.7 Hz), 0.96-1.03(2H, m), 1.57-1.69(1H, m), 2.08-




2.23(1H, m), 2.80(1H, dd, J = 13.4, 7.8 Hz), 2.86-2.99(3H, m), 3.02-3.14(6H, m), 3.14-




3.21(4H, m), 3.21-3.26(2H, m), 3.30(1H, dd, J = 9.2, 5.0 Hz), 3.95-4.08(2H, m), 6.48(3H,




s), 6.52(1H, s)


255
2
ESI+: 329




NMR: 0.37-0.50(2H, m), 0.93-1.05(2H, m), 1.50-1.68(2H, m), 1.92-2.04(1H, m), 2.53-




2.65(1H, m), 2.76-2.85(2H, m), 2.86-3.22(10H, m), 3.37-3.47(1H, m), 3.57-3.79(3H,




m), 3.97-4.09(2H, m), 6.37(1H, s), 6.48(1H, s)




mp: 117-118


256
2
ESI+: 279




NMR: 1.31(3H, dd, J = 5.87, 24.2 Hz), 2.19(3H, s), 2.70-3.17(12H, m), 4.03-4.12(2H, m),




4.96-5.19(1H, m), 6.44(2H, s), 6.51(1H, s)




mp: 165-168


257
2
ESI+: 335




NMR: 0.46-0.62(2H, m), 0.89-1.01(2H, m), 1.64-1.76(1H, m), 2.25(2H, s), 2.75-2.85(2H, m),




2.88-3.02(6H, m), 3.11-3.22(2H, m), 3.86-3.98(2H, m), 4.19(2H, s), 6.54(1H,




s), 7.24-7.31(1H, m), 7.33-7.40(2H, m), 7.42-7.49(2H, m)




mp: 107-110


258
2
ESI+: 369, 371




NMR: 0.47-0.62(2H, m), 0.87-1.00(2H, m), 1.65-1.78(1H, m), 2.28(4H, s), 2.82-2.92(2H,




m), 2.94-3.13(6H, m), 3.17-3.29(2H, m), 3.90-4.01(2H, m), 4.20(2H, s), 6.58(1H, s),




7.32-7.45(3H, m), 7.50-7.54(1H, m)




mp: 139-141


















TABLE 174





Ex
Syn
Dat







259
2
ESI+: 369, 371




0.41-0.56(2H, m), 0.72-0.85(2H, m), 1.52-1.63(1H, m), 2.28(4H, s), 2.81-2.93(2H, m),




2.98-3.12(6H, m), 3.16-3.27(2H, m), 3.94-4.04(2H, m), 4.23(2H, s), 6.60(1H, s), 7.33(1H,




dt, J = 1.61, 7.48 Hz), 7.40-7.49(2H, m), 7.80-7.88(1H, m)




mp: 106-109


260
2
ESI+: 353




0.47-0.63(2H, m), 0.83-1.00(2H, m), 1.60-1.74(1H, m), 2.25(4H, s), 2.76-2.85(2H, m),




2.88-3.05(6H, m), 3.11-3.26(2H, m), 3.87-3.99(2H, m), 4.21(2H, s), 6.55(1H, s), 7.07-




7.14(1H, m), 7.24-7.32(2H, m), 7.38-7.45(1H, m)




mp: 102-105


261
2
ESI+: 301




NMR: 1.85-2.01(1H, m), 2.80(3H, s), 2.94-3.26(11H, m), 3.74-3.92(2H, m), 4.10-4.31




(4H, m), 5.66(1H, s), 6.69(1H, s), 9.38-9.62(2H, br)


262
2
ESI+: 301




NMR: 0.37-0.51(2H, m), 0.91(6H, d, J = 6.6 Hz), 0.96-1.04(2H, m), 1.58-1.71(1H, m),




1.92-2.08(1H, m), 2.72-2.83(2H, m), 2.89-2.99(2H, m), 3.03-3.19(6H, m), 3.23-3.34(2H,




m), 3.99-4.07(2H, m), 6.53(1H, s), 9.24-9.42(2H, br)




mp: 160-162


263
2
ESI+: 343




NMR: 0.30-0.49(2H, m), 0.90-1.05(2H, m), 1.12-1.27(1H, m), 1.41-1.67(3H, m), 1.73-




1.85(1H, m), 1.91-2.05(1H, m), 2.66-2.99(8H, m), 3.00-3.21(5H, m), 3.22-3.32(1H, m),




3.71-3.78(1H, m), 3.82-3.90(1H, m), 3.96-4.08(2H, m), 6.37(1H, s), 6.47(1H, s)




mp: 186-189


264
2
ESI+: 293




NMR: 1.07(3H, t, J = 7.3 Hz), 1.95-2.15(2H, m), 2.68(2H, q, J = 7.3 Hz), 2.80-2.92(2H, m),




2.93-3.18(10H, m), 4.07-4.19(2H, m), 4.56(2H, dt, J = 47.4, 5.7 Hz), 6.55(1H, s), 9.24-




9.52(2H, br)




mp: 153-154


265
2
ESI+: 353




NMR: 0.46-0.57(2H, m), 0.84-0.96(2H, m), 1.64-1.74(1H, m), 2.80-3.07(8H, m), 3.14-




3.25(2H, m), 3.88-3.97(2H, m), 4.24(2H, s), 6.38(1H, s), 6.54(1H, s), 7.13-7.28(2H, m),




7.30-7.39(1H, m), 7.66(1H, dt, J = 1.66, 7.68 Hz)




mp: 133-136


266
2
ESI+: 331




NMR: 0.37-0.52(2H, m), 0.95-1.06(2H, m), 1.43-1.55(2H, m), 1.58-1.74(3H, m), 2.82-




2.95(4H, m), 2.98-3.12(6H, m), 3.16-3.27(5H, m), 3.33(2H, t, J = 6.4 Hz), 3.94-4.02(2H,




m), 6.43(2H, s), 6.51(1H, s)


















TABLE 175





Ex
Syn
Dat







267
2
ESI+: 393




NMR: 0.28-0.43(1H, m), 0.44-0.58(1H, m), 0.94-1.10(2H, m), 1.52-1.64(1H, m), 2.81-




3.09(6H, m), 3.09-3.25(3H, m), 3.25-3.34(2H, m), 3.34-3.46(1H, m), 3.94-4.17(3H, m),




4.29(1H, dd, J = 11.5, 2.4 Hz), 4.53-4.63(1H, m), 6.42(1.5H, s), 6.52(1H, s), 6.69-




6.76(1H, m), 6.77-6.87(3H, m)




mp: 179-182


268
2
ESI+: 365




NMR: 0.40-0.52(2H, m), 0.98-1.10(2H, m), 1.61-1.71(1H, m), 2.85-2.93(2H, m), 2.98-




3.12(4H, m), 3.17-3.29(4H, m), 3.33-3.41(2H, m), 4.02-4.10(2H, m), 4.25(2H, t, J =




5.9 Hz), 6.44(2H, s), 6.53(1H, s), 6.90-6.97(3H, m), 7.24-7.32(2H, m)


269
2
ESI+: 305




NMR: 1.04(3H, t, J = 7.4 Hz), 1.14(3H, t, J = 7.0 Hz), 2.71(2H, q, J = 7.4 Hz), 2.76-




2.95(10H, m), 2.98-3.07(2H, m), 3.49(2H, q, J = 7.0 Hz), 3.64(2H, t, J = 5.9 Hz), 4.04-




4.11(2H, m), 6.38(1H, s), 6.45(1H, s)




mp: 179-181


270
2
ESI+: 379




NMR: 0.46-0.57(2H, m), 0.84-0.97(2H, m), 1.25(3H, t, J = 7.09 Hz), 1.60-1.72(1H, m),




2.87-2.95(2H, m), 2.97-3.15(6H, m), 3.20-3.33(2H, m), 3.85-3.93(2H, m), 3.97(2H, q, J =




7.09 Hz), 4.16(2H, s), 6.45(2H, s), 6.56(1H, s), 6.93-6.00(2H, m), 7.24(1H, dt, J = 1.42,




7.34 Hz), 7.55(1H, dd, J = 1.42.8.22 Hz)




mp: 215(decomp.)


271
2
ESI+: 309




NMR: 0.38-0.49(2H, m), 1.01-1.15(2H, m), 1.62-1.75(1H, m), 2.87-2.94(2H, m), 2.99-




3.10(4H, m), 3.11-3.17(2H, m), 3.20-3.27(2H, m), 3.35(2H, dt, J = 4.3, 15.2 Hz), 4.04-




4.12(2H, m), 6.22-6.40(1H, m), 6.44(2H, s), 6.55(1H, s)




mp: 198-201


272
2
ESI+: 415




NMR: 0.48-0.59(2H, m), 0.88-0.98(2H, m), 1.69-1.80(1H, m), 2.89-2.97(2H, m), 3.01-




3.17(6H, m), 3.23-3.32(2H, m), 3.91-4.00(2H, m), 4.30(2H, s), 6.48(2H, s), 6.58(1H, s),




7.22-7.27(1H, m), 7.30-7.35(1H, m), 7.38-7.42(1H, m)




mp: 200(decomp.)


273
2
ESI+: 415




NMR: 0.48-0.64(2H, m), 0.91-1.01(2H, m), 1.64-1.80(1H, m), 2.86-3.17(8H, m), 3.21-




3.33(2H, m), 3.88-3.99(2H, m), 4.21(2H, s), 6.45(2H, s), 6.59(1H, s), 7.28(1H, dd, J =




1.22, 8.36 Hz), 7.41(1H, d, J = 8.36 Hz), 7.46(1H, d, J = 1.22 Hz)




mp: 161-164


274
2
ESI+: 377




NMR: 0.46-0.64(2H, m), 0.93-1.10(2H, m), 1.67-1.81(1H, m), 2.87-3.00(4H, m), 3.01-




3.35(8H, m), 3.88-3.99(2H, m), 4.09(2H, s), 4.46-4.59(2H, m), 6.45(2H, s), 6.57(1H, s),




6.73(1H, d, J = 8: 17 Hz), 7.11-7.16(1H, m), 7.29(1H, s)




mp: 215(decomp.)


















TABLE 176





Ex
Syn
Dat

















275
2
ESI+: 393




NMR: 0.40-0.63(2H, m), 0.78-1.00(2H, m), 1.56-1.77(1H, m), 2.83-2.96(2H, m), 2.99-




3.17(6H, m), 3.20-3.34(2H, m), 3.84-3.93(2H, m), 4.14(2H, s), 4.17-4.25(4H, m), 6.44




(2H, s), 6.56(1H, s), 6.76(1H, dd, J = 1.37, 8.27 Hz), 6.84(1H, t, J = 8.27 Hz),




7.10(1H, dd, J = 1.37, 8.27 Hz)




mp: 184-187


276
2
ESI+: 349




NMR: 0.45-0.58(2H, m), 0.75-0.88(2H, m), 1.55-1.66(1H, m), 2.17(3H, s), 2.84-2.96(2H,




m), 2.99-3.14(6H, m), 3.19-3.29(2H, m), 3.93-4.01(2H, m), 4.14(2H, s), 6.42(2H, s),




6.59(1H, s), 7.14-7.17(2H, m), 7.21-7.28(1H, m), 7.68-7.75(1H, m)




mp: 163-166


277
2
ESI+: 349




NMR: 0.50-0.63(2H, m), 0.92-1.03(2H, m), 1.67-1.78(1H, m), 2.31(3H, s), 2.88-2.99(4H,




m), 3.03-3.15(4H, m), 3.24-3.33(2H, m), 3.91-3.99(2H, m), 4.16(2H, s), 6.45(2H, s),




6.58(1H, s), 7.05-7.11(1H, m), 7.22-7.29(3H, m)




mp: 192-195


278
4
ESI+: 245




NMR: 1.20(6H, s), 2.31(2H, s), 2.95-3.18(8H, m), 6.69(1H, s), 7.12(1H, s), 9.24-9.38(1.8H,




br), 10.12(1H, s)




mp: 270-272


279
4
ESI+: 231




NMR: 1.32(6H, s), 1.78-1.89(2H, m), 2.72-2.81(2H, m), 3.00-3.21(8H, m), 6.90-7.16(2H, m),




9.29-9.48(2H, br)




mp: 270-273


280
282
ESI+: 353, 355




NMR: 1.27(3H, d, J = 7.2 Hz), 1.69-1.79(2H, m), 2.61-2.77(4H, m), 2.93-3.46(9H, m),




3.28(3H, s), 3.72(2H, t, J = 6.5 Hz), 6.47(2H, s), 6.85(1H, s)




mp: 188(decomp.)


281
282
ESI+: 315




NMR: 0.32-0.43(2H, m), 0.97-1.01(2H, m), 1.27(3H, d, J = 7.2 Hz), 1.59-1.77(3H, m), 2.62-




2.70(2H, m), 2.77-2.84(1H, br), 3.03-3.28(8H, m), 3.23(3H, s), 3.43-3.58(2H, m), 3.56(2H,




t, J = 6.3 Hz), 6.43(2H, s), 6.67(1H, s)




mp: 195(decomp.)


282
282
ESI+: 353, 355




NMR: 1.24(3H, d, J = 7.4 Hz), 1.69-1.76(2H, m), 2.62-2.75(4H, m), 2.90-3.31(8H, m),




3.28(3H, s), 3.72(2H, t, J = 6.5 Hz), 3.84-3.89(1H, m), 6.49(2H, s), 6.79(1H, s)




mp: 184(decomp.)


283
2
ESI+: 371




NMR: 0.46-0.60(2H, m), 0.81-0.95(2H, m), 1.61-1.75(1H, m), 2.78-2.89(2H, m), 2.91-




3.01(4H, m), 3.01-3.08(2H, m), 3.14-3.25(2H, m), 3.91-3.99(2H, m), 4.22(2H, s), 6.40




(1H, s), 6.55(1H, s), 7.12-7.30(2H, m), 7.41-7.52(1H, m)




mp: 195(decomp.)


















TABLE 177





Ex
Syn
Dat







284
2
ESI+: 371




NMR: 0.46-0.55(2H, m), 0.84-0.94(2H, m), 1.64-1.75(1H, m), 2.81-3.09(8H, m), 3.14-




3.25(2H, m), 3.88-3.99(2H, m), 4.28(2H, s), 6.38(1H, s), 6.55(1H, s), 7.20-7.29(1H, m),




7.30-7.40(1H, m), 7.44-7.52(1H, m)




mp: 157-159


285
2
ESI+: 387, 389




NMR: 0.41-0.56(2H, m), 0.79-0.93(2H, m), 1.61-1.75(1H, m), 2.78-3.09(8H, m), 3.15-




3.24(2H, m), 3.92-3.98(2H, m), 4.27(2H, s), 6.39(1H, s),




6.55(1H, s), 7.25-7.32(1H, m), 7.47-7.55(1H, m), 7.62-7.70(1H, m)




mp: 181-184


286
2
ESI+: 377




NMR: 0.44-0.62(2H, m), 0.85-1.02(2H, m), 1.62-1.79(1H, m), 2.83-3.38(12H, m), 3.83-




3.99(2H, m), 4.10(2H, s), 4.49(2H, t, J = 8.51 Hz), 6.47(2H, s), 6.57(1H, s), 6.81-




6.90(1H, m), 7.14(1H, d, J = 6.8 Hz), 7.30(1H, d, J = 8.1 Hz)




mp: 190(decomp.)


287
2
ESI+: 335




NMR: 0.29-0.43(1H, m), 0.43-0.57(1H, m), 0.92-1.10(2H, m), 1.56-1.68(1H, m), 2.82-




2.92(2H, m), 2.95-3.39(13H, m), 3.69-3.86(1H, m), 3.96-4.11(2H, m), 4.32-4.65(2H,




m), 6.43(2H, s), 6.52(1H, s)


288
2
ESI+: 379




NMR: 0.54-0.62(2H, m), 0.94-1.04(2H, m), 1.68-1.79(1H, m), 2.90-3.17(8H, m), 3.24-




3.34(5H, m), 3.90-3.98(2H, m), 4.20(2H, s), 4.41(2H, s), 6.44(2H, s), 6.58(1H, s),




7.15-7.24(1H, m), 7.29-7.42(3H, m)




mp: 190-193


289
2
ESI+: 371




NMR: 0.44-0.56(2H, m), 0.85-0.96(2H, m), 1.65-1.75(1H, m), 2.80-3.08(8H, m), 3.14-




3.26(2H, m), 3.88-3.98(2H, m), 4.20(2H, s), 6.38(1H, s), 6.54(1H, s), 7.13(1H, dt,




J = 2.5, 8.5 Hz), 7.18-7.26(1H, m), 7.64-7.72(1H, m)




mp: 220(decomp.)


290
2
ESI+: 387, 389




NMR: 0.44-0.58(2H, m), 0.82-0.96(2H, m), 1.64-1.75(1H, m), 2.89-2.97(2H, m), 3.00-




3.16(6H, m), 3.21-3.32(2H, m), 3.90-4.01(2H, m), 4.22(2H, s), 6.45(2H, s), 6.58(1H, s),




7.22-7.29(1H, m), 7.38-7.44(1H, m), 7.69(1H, dd, J = 6.7, 3.0 Hz)




mp: 165-168


291
2
ESI+: 393




NMR: 0.47-0.60(2H, m), 0.92-1.02(2H, m), 1.65-1.76(1H, m), 2.81-3.04(8H, m), 3.17-




3.27(2H, m), 3.86-3.95(2H, m), 4.06(2H, s), 4.22(4H, s), 6.38(1H, s), 6.54(1H, s),




6.79-6.89(2H, m), 6.91-6.95(1H, m)




mp: 165-168


















TABLE 178





Ex
Syn
Dat







292
2
ESI+: 317




NMR: 0.14-0.25(1H, m), 0.58-0.68(1H, m), 0.91(3H, d, J = 6.9 Hz), 0.97-1.09(2H, m), 1.55-




1.68(1H, m), 2.75-3.19(8H, m), 3.25(3H, s), 3.28-3.48(3H, m), 3.61(2H, t, J = 6.1 Hz),




3.86(1H, dd, J = 10.5, 1.6 Hz), 3.92(1H, dd, J = 10.6, 2.3 Hz), 6.43(2H, s), 6.52(1H, s)




mp: 183(decomp.)


293
2
ESI+: 379




NMR: 0.43-0.55(2H, m), 0.76-0.87(2H, m), 1.53-1.65(1H, m), 2.86-3.12(8H, m), 3.18-




3.29(5H, m), 3.88-3.97(2H, m), 4.23(2H, s), 4.36(2H, s), 6.44(2H, s), 6.60(1H, s), 7.20-




7.29(1H, m), 7.31-7.43(2H, m), 7.82(1H, d, J = 7.8 Hz)




mp: 180(decomp.)


294
2
ESI+: 335




NMR: 0.31-0.43(1H, m), 0.44-0.54(1H, m), 0.94-1.10(2H, m), 1.55-1.67(1H, m), 2.82-




2.93(2H, m), 2.95-3.40(13H, m), 3.68-3.86(1H, m), 3.97-4.12(2H, m), 4.33-4.65(2H,




m), 6.43(2H, s), 6.52(1H, s)


295
2
ESI+: 367




NMR: 0.43-0.46(2H, m), 1.00-1.06(2H, m), 1.60-1.67(1H, m), 2.82-2.85(2H, m), 2.98-




3.03(4H, m), 3.15-3.17(2H, m), 3.20-3.23(2H, m), 3.38-3.41(2H, m), 4.05-4.07(2H, m),




4.60(2H, t, J = 6.1 Hz), 6.42(2H, s), 6.51(1H, s), 8.20(2H, s), 8.22(1H, s)




mp: 170(decomp.)


296
2
ESI+: 438




NMR: 0.44-0.48(2H, m), 1.05-1.10(2H, m), 1.63-1.70(1H, m), 2.84-2.86(2H, m), 2.98-




3.04(4H, m), 3.18-3.23(4H, m), 3.41-3.44(2H, m), 3.94(3H, s), 4.06-4.09(2H, m), 4.46-




4.49(2H, m), 6.42(2H, s), 6.52(1H, s), 6.99(1H, d, J = 7.1 Hz), 7.71(1H, d, J = 10.9 Hz)




mp: 125-128


297
2
ESI+: 426




NMR: 0.42-0.46(2H, m), 0.97-1.02(2H, m), 1.57-1.64(1H, m), 2.83-2.85(2H, m), 2.98-




3.03(4H, m), 3.16-3.21(4H, m), 3.34-3.37(2H, m), 4.05-4.07(2H, m), 4.56-4.59(2H, m),




6.41(2H, s), 6.52(1H, s), 7.82-7.90(2H, m)




mp: 178(decomp.)


298
2
ESI+: 365




NMR: 0.42-0.56(2H, m), 0.78-0.91(2H, m), 1.57-1.68(1H, m), 2.83-3.14(8H, m), 3.21-




3.33(2H, m), 3.72(3H, s), 3.85-3.96(2H, m), 4.15(2H, s), 6.45(2H, s), 6.57(1H, s),




6.93-7.04(2H, m), 7.22-7.30(1H, m), 7.53-7.61(1H, m)




mp: 195(decomp.)


299
2
ESI+: 365




NMR: 0.51-0.64(2H, m), 0.93-1.03(2H, m), 1.68-1.78(1H, m), 2.84-3.15(8H, m), 3.22-




3.33(2H, m), 3.74(3H, s), 3.86-3.97(2H, m), 4.18(2H, s), 6.44(2H, s), 6.57(1H, s),




6.81-6.88(1H, m), 6.96-7.04(2H, m), 7.24-7.31(1H, m)




mp: 220(decomp.)


















TABLE 179





Ex
Syn
Dat







300
2
ESI+: 419




NMR: 0.44-0.58(2H, m), 0.78-0.91(2H, m), 1.55-1.67(1H, m), 2.87-3.15(8H, m), 3.21-




3.33(2H, m), 3.87-3.98(2H, m), 4.27(2H, s), 6.45(2H, s), 6.66(1H, s), 7.33-7.39(1H, m),




7.41-7.52(2H, m), 7.84-7.91(1H, m)




mp: 210(decomp.)


301
2
ESI+: 379




NMR: 0.45-0.56(2H, m), 0.82-0.95(2H, m), 1.58-1.69(1H, m), 2.27(3H, s), 2.86-3.15(8H,




m), 3.22-3.32(2H, m), 3.68(3H, s), 3.78-3.96(2H, m), 4.10(2H, s), 6.45(2H, s), 6.56(1H,




s), 6.86(1H, d, J = 8.3 Hz), 7.05(1H, dd, J = 1.8, 8.3 Hz), 7.38(1H, d, J = 1.8 Hz)




mp: 205(decomp.)


302
2
ESI+: 383




NMR: 0.44-0.60(2H, m), 0.76-0.89(2H, m), 1.55-1.66(1H, m), 2.89-2.96(2H, m), 3.00-




3.12(6H, m), 3.21-3.30(2H, m), 3.72(3H, s), 3.91-3.97(2H, m), 4.11(2H, s), 6.45(2H, s),




6.58(1H, s), 6.95-7.01(1H, m), 7.04-7.11(1H, m), 7.35-7.42(1H, m)




mp: 189-192


303
2
ESI+: 399, 401




NMR: 0.39-0.57(2H, m), 0.74-0.89(2H, m), 1.53-1.68(1H, m), 2.81-3.15(8H, m), 3.20-




3.32(2H, m), 3.73(3H, s), 3.88-3.99(2H, m), 4.10(2H, s), 6.45(2H, s), 6.58(1H, s), 7.01(1H,




d, J = 8.7 Hz), 7.31(1H, dd, J = 2.6, 8.7 Hz), 7.59(1H, d, J = 2.59 Hz)




mp: 193-196


304
2
ESI+: 427




NMR: 0.34-0.50(2H, m), 0.97-1.07(2H, m), 1.60-1.67(1H, m), 2.82-2.85(2H, m), 2.96-




3.05(4H, m), 3.09-3.46(6H, m), 3.22(3H, s), 3.46-3.53(2H, m), 4.03-4.05(2H, m), 4.83-




4.86(1H, m), 6.42(2H, s), 6.47(1H, s), 6.92-6.97(1H, m), 7.08-7.22(3H, m)




mp: 132-133


305
2
ESI+: 427




NMR: 0.34-0.49(2H, m), 0.99-1.11(2H, m), 1.61-1.68(1H, m), 2.82-2.86(2H, m), 2.89-




3.43(10H, m), 3.22(3H, s), 3.44-3.52(2H, m), 3.97-4.06(2H, m), 4.81-4.87(1H, m), 6.42




(2H, s), 6.45(1H, s), 6.73-6.78(3H, m), 7.25-7.31(1H, m)




mp: 174(decomp.)


306
2
ESI+: 427




NMR: 0.35-0.51(2H, m), 0.97-1.09(2H, m), 1.60-1.67(1H, m), 2.80-3.51(14H, m), 3.21




(3H, s), 3.97-4.06(2H, m), 4.71-4.76(1H, m), 6.43(2H, s), 6.47(1H, s), 6.91-6.95(2H, m),




7.07-7.11(2H, m)




mp: 138-140


307
2
ESI+: 445




NMR: 0.35-0.50(2H, m), 0.97-1.08(2H, m), 1.59-1.66(1H, m), 2.79-2.86(2H, m), 2.89-




3.43(10H, m), 3.21(3H, s), 3.44-3.52(2H, m), 4.03-4.05(2H, m), 4.75-4.80(1H, m), 6.43




(2H, s), 6.47(1H, s), 6.95-7.00(1H, m), 7.17(1H, td, J = 9.3, 5.6 Hz), 7.26(1H, ddd,




J = 11.5, 8.7, 2.9 Hz)




mp: 150-151


















TABLE 180





Ex
Syn
Dat







308
2
ESI+: 463




NMR: 0.35-0.46(2H, m), 0.97-1.12(2H, m), 1.61-1.68(1H, m), 2.78-3.58(14H, m), 3.21




(3H, s), 3.96-4.05(2H, m), 4.77-4.82(1H, m), 6.43(3H, s), 6.84-6.88(2H, m)




mp: 155(decomp.)


309
2
ESI+: 461, 463




NMR: 0.34-0.39(1H, m), 0.46-0.51(1H, m), 0.98-1.10(2H, m), 1.61-1.68(1H, m), 2.80-




3.42(12H, m), 3.21(3H, s), 3.45-3.53(2H, m), 4.02-4.07(2H, m), 4.83-4.88(1H, m), 6.43




(2H, s), 6.48(1H, s), 7.12-7.21(2H, m), 7.41(1H, dd, J = 8.3, 3.0 Hz)




mp: 149(decomp.)


310
2
ESI+: 367




NMR: 0.43-0.47(2H, m), 1.03-1.07(2H, m), 1.63-1.70(1H, m), 2.83-2.86(2H, m), 2.99-




3.05(4H, m), 3.18-3.22(4H, m), 3.35-3.38(2H, m), 4.05-4.07(2H, m), 4.58(2H, t, J = 6.1 Hz),




6.42(2H, s), 6.52(1H, s), 7.14(1H, t, J = 4.8 Hz), 8.60(2H, d, J = 4.8 Hz)




mp: 188(decomp.)


311
2
ESI+: 386




NMR: 0.42-0.46(2H, m), 1.01(6H, d, J = 6.3 Hz), 1.60-1.69(3H, m), 2.57-2.61(2H, m),




2.71-2.74(2H, m), 2.88-2.90(2H, m), 3.03-3.11(8H, m), 3.23-3.24(2H, m), 3.41-3.50(4H,




m), 4.01-4.03(2H, m), 6.48(3H, s), 6.52(1H, s)




mp: 129(decomp.)


312
2
ESI+: 371




NMR: 0.49-0.60(2H, m), 0.85-1.00(2H, m), 1.61-1.74(1H, m), 2.78-3.07(8H, m), 3.13-




3.27(2H, m), 3.87-4.00(2H, m), 4.17(2H, s), 6.38(1H, s), 6.55(1H, s), 7.25-7.51(3H, m)




mp: 230(decomp.)


313
2
ESI+: 371




NMR: 0.49-0.60(2H, m), 0.85-0.95(2H, m), 1.62-1.72(1H, m), 2.81-3.06(8H, m), 3.17-




3.25(2H, m), 3.92-4.01(2H, m), 4.21(2H, s), 6.38(1H, s), 6.56(1H, s), 7.09-7.22(3H, m)




mp: 191-194


314
2
ESI+: 459




NMR: 0.43-0.47(2H, m), 0.95-1.00(2H, m), 1.15(3H, t, J = 7.0 Hz), 1.53-1.60(1H, m), 2.85-




2.87(2H, m), 3.00-3.05(4H, m), 3.17-3.22(4H, m), 3.31-3.34(2H, m), 3.47(2H, q, J = 7.0 Hz),




4.05-4.07(2H, m), 4.38-4.40(4H, m), 6.42(2H, s), 6.53(1H, s), 7.06-7.12(2H, m)




mp: 138-139


315
2
ESI+: 331




NMR: 0.30-0.42(1H, m), 0.46-0.59(1H, m), 0.93-1.12(8H, m), 1.53-1.65(1H, m), 2.79-




3.58(14H, m), 3.71-3.83(1H, m), 3.94-4.12(2H, m), 6.42(2H, s), 6.50(1H, s)




mp: 157-160


316
2
ESI+: 317




NMR: 0.14-0.27(1H, m), 0.57-0.68(1H, m), 0.91(3H, d, J = 6.9 Hz), 0.96-1.09(2H, m), 1.55-




1.68(1H, m), 2.76-3.19(9H, m), 3.25(3H, s), 3.28-3.48(2H, m), 3.61(2H, t, J = 6.1 Hz),




3.80-3.97(2H, m), 6.43(2H, s), 6.52(1H, s)




mp: 186(decomp)


















TABLE 181





Ex
Syn
Dat







317
2
ESI+: 349




NMR: 0.32-0.43(1H, m), 0.44-0.55(1H, m), 0.93-1.15(5H, m), 1.55-




1.67(1H, m), 2.82-2.92(2H, m), 2.94-3.30(9H, m), 3.33-3.48(2H, m), 3.57-




3.67(1H, m), 3.79-3.94(1H, m), 3.98-4.13(2H, m), 4.31-




4.60(2H, m), 6.43(2H, s), 6.52(1H, s)


318
2
ESI+: 291




NMR: 0.91(3H, d, J = 6.8 Hz), 2.01-2.15(1H, m), 2.83-3.31(17H, m), 4.05-




4.14(2H, m), 6.51(1H, s), 6.52(1H, s), 9.24-9.50(2H, br)




mp: 129-132


319
2
ESI+: 277




NMR: 1.1(3H, t, J = 6.2 Hz), 2.85-2.93(2H, m), 2.93-3.00(2H, m), 3.01-




3.12(4H, m), 3.12-3.46(7H, m), 3.53-3.64(1H, m), 4.02-




4.13(2H, m), 6.52(1H, s), 6.54(1H, s), 9.32-9.48(2H, br)
















TABLE 182













 








 








 








 








 








 








 








 








 






















TABLE 183













 








 








 








 








 








 








 








 








 






















TABLE 184













 








 








 








 








 








 








 








 








 






















TABLE 185













 








 








 








 








 








 








 








 








 






















TABLE 186













 








 








 








 








 








 








 








 








 








 








 






















TABLE 187













 








 








 








 








 








 








 








 








 








 








 






















TABLE 188













 








 








 








 








 








 








 








 








 








 








 






















TABLE 189













 








 








 








 








 








 








 








 








 








 








 








 








 






















TABLE 190













 








 








 















INDUSTRIAL APPLICABILITY
The compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof has a 5-HT2C receptor agonist activity and can be used as an agent for preventing or treating 5-HT2C receptor-related diseases.
Here, examples of the 5-HT2C receptor-related diseases include incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

## Claims

1. A compound or a salt thereof, which is
11-cyclopropyl-1-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline,
4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-[(2R)-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-[(2S)-3-fluoro-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, or
5-cyclopropyl-4-(3-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, or a salt thereof.

2. A pharmaceutical composition comprising a compound or a salt thereof of claim 1 and a pharmaceutically acceptable excipient.

3. A method for treating stress urinary incontinence and mixed urinary incontinence, comprising administering to a subject an effective amount of a compound or a salt thereof of claim 1.

4. A compound or a salt thereof of claim 1, which is
11-cyclopropyl-1-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline, or a salt thereof.

5. A compound or a salt thereof of claim 1, which is
4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, or a salt thereof.

6. A compound or a salt thereof of claim 1, which is
5-cyclopropyl-4-[(2R)-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, or a salt thereof.

7. A compound or a salt thereof of claim 1, which is
5-cyclopropyl-4-[(2S)-3-fluoro-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, or a salt thereof.

8. A compound or a salt thereof of claim 1, which is
5-cyclopropyl-4-(3-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, or a salt thereof.